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Abstract 
Poliomyelitis is a seriously debilitating human disease, caused by poliovirus. Since the 
initiation of the World Health Organisation (WHO) and the Pan American Health 
Organisation (PAHO) poliomyelitis eradication program, mass immunisation of the 
worldwide population and better monitoring of acute flaccid paralysis (AFP) cases enabled 
the reduction in the number of poliomyelitis cases worldwide and the eradication of 
circulating wild-type polioviruses in a large number of countries. The oral live-attenuated 
poliovirus vaccine (OPV) and inactivated poliovirus vaccine (IPV) have been used 
extensively as a tool for achieving poliomyelitis eradication. Since the introduction of 
OPV, neurovirulent revertant poliovirus vaccine strains have been reported to cause rare 
cases of paralysis in vaccinees and/or contacts of vaccinees. However, recent reports of 
vaccine-associated acute paralysis (VAAP) outbreaks, caused by newly emerging 
circulating vaccine-derived polioviruses (cVDPVs), in Hispaniola and Madagascar have 
raised the existing concerns about the potential of poliovirus vaccine strains to recombine 
with human enteroviruses (HEV). The original aim of the project was to determine whether 
a non-poliovirus HEV could evolve to use the poliovirus receptor (PVR). A variety of 
methods were used to exploit aspects of the evolutionary capacity of viruses to achieve this 
goal. Although the aim was not attained, the investigation of recombinants between 
different HEVs yielded interesting results, which were pursued further. Two approaches 
were developed: in vitro generation of recombinant viruses and phenotypic analysis of 
such chimeras and the selection for recombinant viruses in vivo. 
In vitro generation of reciprocal recombinants between the structural and the non-structural 
coding region of coxsackievirus A21 (CVA21) and poliovirus type 3 (PV3) was initiated. 
Transfected and passaged chimeras did not produce infectious virions. 
iv 
Immunofluorescence analysis of VP1 protein expression suggested that the recombinants 
were not acytopathic. A series of assays were then carried out to investigate the nature of 
the defect. HeLa S10 translation/transcription reactions of the in vitro generated 
recombinants expressed the correct protein-processing pattern suggesting efficient 
processing occurred in vitro. Replication assays demonstrated that the chimeras were 
replication competent. Trans-encapsidation experiments were then carried out and 
preliminary results strongly suggested that the defect could lie at the packaging level. 
Additional studies are required. 
Selection of recombinants in vivo, without predetermining the crossover sites, was also 
conducted. Under the conditions used, recombination between CVA21 and PV3 impaired 
genomes and echovirus 7 (EV7) and PV3 impaired genomes proved to be unsuccessful. 
This could have been due to both genomes localising to separate replication compartments 
rendering replication-dependent recombination impossible. This needs to be verified. 
Characterisation of the impaired parental genomes used for the experiment needs to be 
carried out. However, recent reports of recombinants between Sabin polioviruses and 
HEV-C confirm the possibility of such a recombination event occurring and emphasize 
concerns regarding the success of the polio eradication program. 
RNA viruses are also subjected to polymerase error rate, another evolutionary mechanism. 
Ribavirin, a random mutagen, was used to increase the error rate of CVA2 1, a HEV-C, to 
investigate whether this particular HEV-C could evolve to use an alternative receptor for 
attachment and entry. However, no novel tropic viruses were recovered under the 
experimental conditions applied. 
V 
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Messenger RNA 
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Non-translated region 
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Discrepencies observed in CVA21 related plasmid names were due to a recent change in 
the nomenclature and conservation of the original plasmid names in the laboratory 
database (see table of plasmids and appendix 2). 
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1 Introduction 
1.1 Picomaviruses 
Picornaviruses are some of the smallest RNA viruses: Pico (very small unit of 
measurement 10"12) ma (RNA) viruses. The Picornaviridae family comprises some of the 
oldest known viruses such as the foot and mouth disease virus (FMDV), one of the first 
viruses to be recognised (Loeffler & Frosch, 1898), and poliomyelitis, which has been 
prevalent since at least the 18th Egyptian dynasty (1550-1333 BC) as is shown in an 
illustration of a doorkeeper on a funeral stone (Melnick, 1982). 
1.2 Classification of the Picornaviridae family 
The Picornaviridae family is composed of over 200 serotypes. The original taxonomy was 
based on physical properties (particle density and pH-sensitivity) and serological 
relatedness. However, picornavirus classification was recently revised based on nucleotide 
sequences and divided into 9 genera: Aphthoviruses, Cardioviruses, Enteroviruses, 
Erboviruses, Hepatoviruses, Kobuviruses, Parechoviruses, Rhinoviruses and Teschoviruses 
(see table 1.1). The nine genera include pathogens that cause a wide range of mild to acute 
diseases. 
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Genus Species Serotypes 
Aphthovirus Foot and Mouth Disease Virus FMDV-0, A, C, Asia 1, SAT1-3 
Equine Rhinitis A virus ERAV 
Cardiovirus Encephalomycarditis Virus EMCV 
Theileovirus TMEV, VHEV 
Enterovirus Poliovirus PV 1-3 
Human Enterovirus A CVA 2-8,10,12,14,16, EV71 
Human Enterovirus B CVB 1-6, CVA9, E1-33, 
EV69-73 
Human Enterovirus C CVA 1,11,13,15,17-24 
Human Enterovirus D EV-68, EV- 70 
Bovine Enterovirus BEV-1, BEV-2 
Porcine Enterovirus A PEV-8 
Porcine Enterovirus B PEV-9, PEV 10 
Simian Enterovirus A SEV-A 
Erbovirus Equine Rhinitis virus ERBV 1 and 2 
Hepatovirus Hepatitis A virus HAV 
Avian Encephalomyelitis Virus AEV 
Kobuvirus Aichi virus AN 
Bovine Kobuvirus BKV 
Parechovirus Human Parechovirus HpeV-1 and 2 
Ljungan Virus LV 
Rhinovirus Human Rhinovirus A HRV 1,2,7,8,9 -13 etc 
Human Rhinovirus B HRV 3-6,14,17,26 etc 
Teschovirus Porcine Teschovirus PTV 1-11 
Table 1.1: Classification of members of the Picornaviridae. 
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1.3 Pathogenesis within a host 
Pathogenesis is defined by the broad spectrum of symptoms triggered by viral infection 
and the host range or tissues susceptible to infection by specific viruses. Because of the 
nature of this project, emphasis and detailed analysis of the human enterovirus (HEV) 
pathogenesis and life cycle, and not that of other genera of the Picornaviridae family, is 
contained in this chapter. The majority of HEV infections cause asymptomatic or mild 
syndromes (see table 1.2). However, HEVs have also been involved in cardiac and central 
nervous system (CNS) syndromes. Invasion of the CNS is characteristic of poliovirus, the 
prototype picomavirus, resulting in acute flaccid paralysis (AFP). However, 
Coxsackieviruses A have also been shown to cause AFP. In fact recent studies carried out 
in ICAM-1 transgenic mice have shown that CVA21 could cause identical symptoms to 
those seen in poliovirus infected PVR-transgenic mice (Dufresne et al., 2004). 
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Clinical diseases associated with Infection 
Enteroviruses 
Poliovirus type 1,2 Paralytic poliomyelitis and mild febrile illness 
and 3 
Coxsackievirus A Aseptic meningitis 
Hand, foot and mouth disease 
Common cold 
Coxsackievirus B Aseptic meningitis 
Myocarditis, pleurodynia, severe systemic disease in infants 
Upper respiratory tract illness, pneumonia 
and post-viral fatigue syndrome 
Echoviruses Aseptic meningitis 
Paralysis 
Respiratory disease 
Myocarditis 
Epidemic myalagia 
Hepatic disturbances 
Enterovirus 68 Pneumonia 
Enterovirus 70 Acute haemorrhagic conjunctivitis 
Enterovirus 71 Hand, foot and mouth disease 
Rhinoviruses 
Major receptor group Common cold 
rhinoviruses 
Minor receptor group Common cold 
rhinoviruses 
Parechoviruses 
Echoviruses types 22 Respiratory disease 
and 23 Encephalitis 
He atoviruses Hepatitis 
A hthoviruses Foot-and-mouth disease 
Cardioviruses 
Encephalomyocarditis Encephalitis and myocarditis 
virus and Mengovirus 
Theiler's murine Encephalomyelitis (in mice) 
encephalomyocarditis 
virus 
Table 1.2: Clinical diseases associated with picornavirus infection and exacerbation. 
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1.3.1 Poliovirus pathogenesis and life cycle within a human host 
Poliovirus is the prototype HEV and has been extensively studied since it was first 
identified as the etiologic agent of poliomyelitis in 1909 (Landsteiner & Popper, 1909). 
Infection with poliovirus causes mild or asymptomatic syndromes in 90% of cases and 
infection only progresses to poliomyelitic paralysis in 1% of cases (Melnick et al., 1996 a). 
Poliovirus infects cells of the digestive tract (oropharyngeal cells and intestinal cells), 
multiplies locally at the initial sites of virus ingestion (tonsils, Peyer's patch) and virions 
are shed into the environment through faeces (see figure 1.3). The translocation of 
poliovirus particles across M-like cells, which are found in the epithelial sheet of the 
Peyers patches (Ouzilou et al., 2002) enables the virus to come in contact with cells from 
the immune system, which are then thought to favour spread to cervical and mesenteric 
lymph nodes. These events lead to a primary viraemia during which poliovirus can 
replicate in peripheral blood mononuclear cells (Freidstadt & Eberle, 1996). Once inside 
the bloodstream the infectious virus particles spread to other susceptible tissues such as 
other lymph nodes, brown fat, muscle, and the central nervous system (CNS). Poliovirus 
has been shown to cross the blood-brain barrier in mice (Yang et al., 1997). Invasion of the 
CNS is primarily thought to occur by means of peripheral or cranial nerve retrograde 
axonal transport, stimulated by skeletal muscle injury (Gromeier & Wimmer 1998), and 
leads to the development of poliomyelitis. The fast retrograde axonal transport pathway of 
poliovirus from the axon to the neuronal cell body occurs in a PVR-dependent manner by 
the PVR interaction with the dynein-motor complex component Tctex-1 (Mueller et al., 
2002). Poliovirus is then able to attach, enter, infect and destroy motor neurons, in 
particular neurons of the anterior horn of the spinal cord leading to paralytic poliomyelitis 
Small intestine: 
Invasion 
Multiplication 
Mesenteric lymph nodes: 
M Iltiplication 
Initial antibody 
appearance 
CNS: 
Invasion 
Multiplication 
Intraneural spread 
12 Excretion in faeces 
Figure 1.3: Poliovirus pathogenesis 
This schematic illustration represents a longstanding view of the pathogenesis of 
poliovirus. Note that additional data emphasize the importance of retrograde axonal flow 
of virus into the central nervous system. Virus enters by way of the alimentary tract and 
multiplies locally at the initial sites of virus implantation (tonsils, Peyer's patch) or the 
lymph nodes that drain these tissues, and virus begins to appear in the throat and in the 
feces-leading to virus shedding into the environment. At this time, it is possible that 
virus may spread to the CNS by peripheral or cranial nerve axonal flow. Secondary virus 
spread occurs by way of the bloodstream to other susceptible tissues-namely, other 
lymph nodes, brown fat, muscle, and the CNS. Virus can then also spread into the CNS at 
this time by means of peripheral or cranial nerve retrograde axonal flow-for example, 
from muscle. If a high level of virus replication occurs within the CNS, motor neurons die 
and paralysis ensues. (Diagram and legends taken from Melnick et al., 1996a) 
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in humans, primates and PVR transgenic mice (Ren et al., 1990). The following 
description of the virus life cycle focuses on poliovirus unless otherwise specified. 
1.3.2 Host cell infection and poliovirus life cycle 
1.3.2.1 Overview (see figure 1.4) 
The complete life cycle of poliovirus within a host cell occurs in approximately 5 to 
10 hours and is initiated by the attachment of the virus to its receptor: PVR (CD 155) 
(Hogle et al., 1985). Conformational changes induced by receptor attachment lead to the 
uncoating and release of the viral genomic RNA into the host cell cytoplasm (Belnap et al., 
2000), in which the entirety of the reproductive life cycle of poliovirus occurs. Once the 
genomic RNA has entered the cell, the 5' covalently-linked VPg is cleaved off by a 
cellular enzyme, releasing the RNA for translation into a single polyprotein (Pelletier et al., 
1988). The translated polyprotein undergoes a cascade of autocatalytic events known as 
proteolytic processing, generating functional viral proteins (Schechter et al., 1967; 
Ypma-Wong et al., 1988). Once the non-structural proteins are generated, the host cell 
endoplasmic reticulum membranes are altered and re-arranged to form replication 
complexes where initiation of the negative-sense strand synthesis occurs (Bienz et al., 
1987; Beinz et al., 1990). The negative-sense strands are then used as a template for the 
positive-sense strand synthesis. The newly synthesised positive-sense strand progeny RNA 
molecules are translated, enhancing the number of replication complexes formed and 
amplification of the viral genome (Jarvis et al., 1992). The VPg-linked progeny RNA 
genomes are then packaged into the virus capsid proteins VP I, VP3 and VPO, resulting 
from the polyprotein processing (Arnold et al., 1987). Encapsidation leads to the final 
maturation of the immature virions into infectious icosahedral particles, which are then 
released into the intercellular environment (Hellen et al., 1992). Poliovirus infection can be 
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lytic or non-lytic depending on the host cell type (Lopez-Guerrero et al., 2000), the state of 
differentiation of a particular cell type, the genetic make-up of the virus and the conditions 
of infection (Agol et al., 1998, Tolskaya et al., 1995). 
1.3.2.2 Attachment 
The recognition and the attachment to the PVR cellular receptor, a membrane-anchored 
immunoglobulin-like glycoprotein recognised by all three serotypes of poliovirus, is the 
first step of the poliovirus replication life cycle. 
1.3.2.2.1 Virus structure and receptor attachment 
Poliovirus is a non-enveloped virus that has an RNA genome packaged inside an 
icosahedral capsid of approximately 25nm in diameter, composed of 60 copies of the VP1, 
VP2, VP3 and VP4 viral capsid proteins. The poliovirus three-dimensional structure has a 
deep and narrow 20 A-surface depression around the 5-fold axes, also known as the 
"canyon", formed by the assembled VP 1, VP2 and VP3 proteins (see figure 1.5). 
Rossmann first developed the "canyon" hypothesis in his three-dimensional analysis of the 
human rhinovirus 14 (Rossmann et al., 1985). The "canyon" is lined by conserved residues 
(Rossmann et al., 1988; Rossmann et al., 1989), encircling each of the twelve 5-fold axes, 
and forms a docking site for the PVR attachment (He et al., 2000). The membrane-distal 
N-terminal domain of PVR binds to the viral canyon (He et al., 2003). Under the floor of 
the canyon, in the VP1 capsid protein lays a hydrophobic pocket, which contains a 
sphingosine or palmitate-like molecule (Rossmann et al., 1994) or "pocket factor". The 
"pocket factor" is of cellular origin and is thought to play a regulatory role in viral 
assembly and uncoating (Filman et al., 1989) as well as stabilising the virions during the 
transit phase from infected cells to non-infected cells. Binding of the PVR to the canyon 
depression of the poliovirion destabilises the "pocket factor", which triggers a 
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conformational change in the virus particle leading to the uncoating and release of the viral 
genomic RNA into the host cell cytoplasm (Rossmann et al., 1994). 
1.3.2.3 Viral uncoating and genome delivery 
The interaction of a mature poliovirus particle, with a sendimentation coefficient of 160S, 
with the cognate receptor PVR (He et al., 2003) has been demonstrated to cause 
conformational changes including the extrusion of the internal VP4 and of the N-terminus 
of VPl (Fricks & Hogle, 1990; Hogle et al., 2002) generating A-particles. A model for 
virus entry was proposed by Belnap in 2000 (see figure 1.6. A and 1.6. B) (Belnap et al., 
2000) whereby myristylated VP4 and VP1 N-terminus were extruded and embedded in the 
cell plasma membrane leading to the formation of a pore and triggering a change in the 
location of VP3, which acts as a plug to prevent leakage of the viral RNA genome from 
infectious particles. This conformational change is confirmed by the previous observations 
of a 10% size expansion of poliovirus particles on attachment to host cell surface 
(Incardona et al., 1964). These events are followed by RNA genome entry into the cell 
cytoplasm through the newly formed pore (see figure 1.6 B), confirmed by recent VP4 
mutagenesis studies (Danthi et al., 2003). The RNA genome delivery to the host cell 
cytoplasm leads to a decrease in the extracellular particle sedimentation coefficient to 80S. 
Because of the unstable nature of the A-particle 135S intermediates, up to 50-90% of virus 
particles are eluted or unable to deliver their RNA molecule. This contributes to the very 
high particle to infectivity ratio of 1000 to 1 (Fenwick & Cooper, 1962). Alternative 
uncoating and entry pathways have been thought to exist. Indeed studies of various 
rhinovirus serotypes demonstrated the virus entry to be dependent on a receptor-mediated 
endocytosis pathway (Nurani et al., 2003; Kronenberger et al., 1998). Alternative 
uncoating pathways are not discussed in this thesis. 
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1.3.2.4 Genome and translation 
All picomaviruses have a similar genome organisation (see figure 1.7). The poliovirus 
genome is described here. The infectious poliovirus genome is a positive-sense single 
stranded -7.5 kilobase-long RNA molecule (Holland et al., 1960a; Holland et al., 1960b) 
that is covalently linked to a small virus specific protein VPg via a phosphodiester bond at 
its 5'end (Flanegan et al., 1977; Lee et al., 1977, Lee et al., 1976), and is polyadenylated at 
its 3'end (Yogo et al., 1972). The genome is divided into three regions, the 5'untranslated 
region or non-coding region (5'UTR: Agol et al., 1991), the coding region and the 3'UTR. 
The UTR regions contain RNA structures involved in the regulation of translation and 
RNA synthesis. The RNA genome has one functional open reading frame, which directs 
synthesis of a single polyprotein (Warner et al., 1963). The polyprotein then undergoes 
proteolytic processing generating four structural proteins (VP I, VP3, VP2 and VP4: 
Maizel et al., 1963) and ten non-structural proteins (2A, 2B, 2C, 2BC, 3A, 3B, 3AB, 3C, 
3D, 3CD: Summers et al., 1965), which are involved in RNA replication, virion assembly 
and progeny release from the infected host cell. 
Once inside the cell, translation of the genome is initiated by a cap-independent 
mechanism involving a 5'UTR internal ribosome entry site structure, known as the IRES 
(Jang et al., 1988, Pelletier et al., 1988; Trono et al., 1988). The IRES is a cis-acting 
element with a tertiary structure that interacts with RNA-binding proteins to generate a 
functional `ribosome-landing site' (Palmenberg et al., 1997). The IRES structure binds the 
40S subunit of the ribosome in a specific orientation and forms a productive translation 
complex with the template limited RNA segment `starting window' (Pilipenko et al., 
1994). Other cis-acting elements such as the 5' cloverleaf structure are known to play a 
role in RNA replication and there is evidence of its role in the viral translation initiation 
process (Gamarnik et al., 1998; Simoes et al., 1991). 
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3B 
The overall genome structure of the different genera is similar and is summarised in this 
figure. 
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Other proteins such as PTB (pyrimidine tract binding protein: Hellen et al., 1994; Hellen et 
al., 1993; Niepmann et at., 1997), PCBP-2 (poly C-binding protein 2: Blyn et al., 1996; 
Blyn et at., 1997; Herman et al., 1998), autoantigen La (Meerovitch et al., 1993; Shiroki et 
at., 1999; Svitkin et at., 1994) and unr (Hunt et al., 1999) are important nuclear 
RNA-binding proteins also involved in efficient translation of the viral RNA genome 
(Gosert et al., 2000). Certain translation factors can act as chaperones or bridges between 
the IRES and the ribosome (Pilipenko et al., 2000). 2A has been shown to stimulate 
translation (Roberts et al., 1998; Hambidge et at., 1992) whereas 3CD has been shown to 
inhibit the process (Gamarnik et al., 1998). 
1.3.2.5 Polyprotein processing 
The poliovirus polyprotein precursor undergoes proteolytic processing, co-translationally, 
driven by viral proteases (see figure 1.8). There are three viral proteinases involved in the 
proteolytic cleavage events and the generation of mature viral proteins: the 2A, 3C and 
3CD proteases. The primary cleavage event is autocatalytic occurring both in cis or trans 
and is directed by the 2A protease cleaving the tyrosine-glycine (Y-G) amino acid 
sequence at the junction between the P1 structural protein precursor and the P2/P3 
non-structural protein precursors thereby separating the structural proteins from the 
non-structural proteins (Schechter et al., 1967). The 3C and the 3CD proteases 
preferentially cleave glutamine-glycine (Q-G) residues leading to the generation of the 
remainder of the viral proteins (Luke et al., 2001). In poliovirus only 9 of the 13 Q-G 
residues are cleaved (Hanecak et al., 1982; Kitamura et al., 1981). The lack of conservation 
of residues surrounding the Q-G amino acid sequences indicates that processing is not only 
sequence-dependent but that preferential processing must occur (Kusov et al., 1999). 
Studies demonstrating enhanced activity of 3CD protease over 3C protease (Parsley et al., 
1999) and complete P1 processing solely achieved by 3CD protease confirms that the 
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amino acid sequence cannot alone account for proteolytic activity of 3C and 3CD proteases 
and that structural conformations are also involved in specific protease activity (Harris et 
al., 1992; Ypma-Wong et al., 1988). The 3C and the 3CD proteases process the P1 
precursor into VPO, VP3 and VP1 structural proteins and the non-structural protein 
precursors P2 and P3 into 2A, 2B, 2C, 2BC, 3A, 3B, 3AB, 3C, 3D and 3CD. 
1.3.2.5.1 Capsid proteins 
The capsid proteins VPO, VP3 and VP 1 assemble to form empty virus capsids, a process 
discussed further in section 1.3.2.7.1. 
1.3.2.5.2 Non-structural proteins 
The P2 and P3 protein precursors contain most of the proteins important for the replication 
of the virus. P1 deletion mutants have been shown to replicate in tissue culture (Percy et 
al., 1992; Collis et al., 1992; Kaplan et al., 1988). The non-structural proteins have a 
variety of functions in the poliovirus life cycle within an infected host cell such as protease 
activity, membrane rearrangements, RNA replication and regulation of host cell functions. 
1.3.2.5.3 The viral proteins and their cellular targets 
Viral proteases are capable of hijacking host proteins, employing them for viral functions 
and shutting down the key cellular functions such as translation and transcription leading 
to cell cycle arrest and cell death. 
1.3.2.5.3.1 Translation 
Upon virus infection the host cell translation machinery shuts off. This mechanism is 
regulated by cellular and viral proteins. The poliovirus 2A protease exerts its proteolytic 
activity on host cell proteins by cleaving eIF4G (Etchison et al., 1982; Krausslich et al., 
1987; Sommergruber et al., 1994), a cellular translation initiation factor, and more 
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specifically eIF4G-I (Haghighat et at., 1996) and eIF4G-II (Svitkin et al., 1999; Gradi et 
al., 1998), essential components of the host cell cap-dependent translation initiation 
complex. Moreover, the cleavage of the poly (A)-binding protein (PABP) by the poliovirus 
2A and 3C proteases contributes to host cell translation shut off (Joachims et al., 1999). 
Once complete host cell protein synthesis shut off has occurred, 2 to 4 hours post infection, 
eIF4G is used for the viral cap-independent IRES-mediated translation (Ohlmann et al., 
1996). 
1.3.2.5.3.2 Transcription 
Similarly, viral proteases regulate both the viral and the cellular transcription machineries. 
The poliovirus 3C and 3CD proteases bind viral RNA secondary structures such as the 
5'cloverleaf of the positive-sense RNA molecule (Andino et al., 1993; Leong et al., 1993) 
and the poly(rC)-binding protein (PCBP: Parsley et al., 1997) thereby forming a complex 
required for poliovirus replication. 3CD has been suggested to be involved in genome 
circularisation as it bridges the 5'cloverleaf structure-PCBP complex with polyA-binding 
protein (PABP), bound to the 3' poly-A tail of the RNA molecule (Herold et al., 2001). 
The 3C and 2A proteases are also involved in the regulation of the host cell transcription 
and apoptotic pathways upon viral infection, by exerting a proteolytic activity on a variety 
of host cell proteins such as TATA-binding proteins (Clark et al., 1993; Yalamanchili et 
al., 1997), the cAMP-responsive element (Deitz et al., 2000), the transcriptional activator 
Oct-1 (Yalamanchili et al., 1997), the PABP (Joachims et al., 1999; Kerekatte et al., 1999), 
and anti-apoptosis and PKR phosphorylation pathways (Black et al., 1993). 
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13.2.5.3.3 Membrane re-arrangement and replication compartments 
1.3.2.5.3.3.1 P2 proteins 
P2 proteins are involved in membrane rearrangements within a host cell, disrupting cellular 
functions and creating replication compartments for the generation of progeny viral RNA. 
2B is thought to be involved in alteration of intracellular membrane permeability, 
facilitating the release of progeny virus (van Kuppeveld et al., 1997), inhibition of cellular 
exocytosis, dissociation of Golgi complexes and viral RNA amplification (Aldabe et al., 
1996; Barco et al., 1998; Doedens et al., 1995; Sandoval et al., 1997; van Kuppeveld et al., 
1995; van Kuppeveld et al., 1997; Johnson et al., 1991). 
2B and 2BC proteins play a role in the formation of viral replication vesicles (Bienz et al., 
1987; Bienz et al., 1983; Aldabe et al., 1995; Cho et al., 1994; Suhy et al., 2000; 
Teterina et al., 1997) and results showing that 2C is involved in positive strand synthesis 
give further evidence of the role taken by 2C during viral replication (Barton et al., 1997; 
Molla et al., 1991). 
1.3.2.5.3.3.2 P3 Proteins 
3A and 3AB proteins have also been shown to be associated with intracellular membranes 
(Datta et al., 1994; Semler et al., 1982; Towner et al., 1996). Indeed, 3AB, which delivers 
3B, known as VPg, (Kusov et al., 1999) and the 3D polymerase (Hope et al., 1997; Xiang 
et al., 1998) to replication compartments, is involved in rearrangement of intracellular 
membranes into replication vesicles (Doedens et al., 1997; Doedens et al., 1995; Lama et 
al., 1992). 
3D is the essential RNA-dependent RNA-polymerase that catalyses the positive-sense and 
the negative-sense strand synthesis RNA elongation during the replication process. 
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1.3.2.5.3.4 Immune evasion and immune response interference 
Some poliovirus proteins have been shown to interfere with the host immune response, 
probably indicating that poliovirus has evolved to evade the immune response induced 
following viral infection. The poliovirus proteins 2BC and 3A modulate the host immune 
response by interfering with exocytotic pathways (Barco et al., 1995), secretion of antiviral 
cytokines (ß-IFN, IL-6, IL-8) (Dodd et al., 2001), and antigen presentation via major 
histocompatibility complex class I (MHC-I) molecules (Doedens et al., 1995; Deitz et al., 
2000). 
1.3.2.6 RNA replication 
1.3.2.6.1 Replication complex formation and membrane rearrangement 
Genomic RNA replication is driven by the virally encoded RdRp and occurs in rearranged 
cellular membrane vesicles also known as replication complexes. The use of membranous 
replication compartments enables the localisation and concentration of proteins required 
for replication and assembly, provides protection from degradation by any cellular factors 
or proteins (Ahlquist et al., 2002) and could be a means of hiding the presence of double 
stranded RNA thereby avoiding the induction of a dsRNA activated immune response such 
as the protein kinase R (PKR) response and RNA silencing (Ahlquist et al., 2002). 
Poliovirus replication complexes have been shown to contain viral and cellular proteins, 
replicative-intermediate RNA and newly synthesised progeny RNA (Bienz et al., 1994, 
Bienz et al., 1992; Egger et al., 1996; Troxler et al., 1992; Egger et al., 2002) and are 
assembled on membrane vesicles (Bienz et al., 1987; Bienz et al., 1990). In fact it has been 
demonstrated that HeLa S 10 nuclear extracts contained cellular proteins inducing the 
formation of replication complexes (Jurgen et al., 2003). During poliovirus infection, 
COP II-coated vesicles derived from the anterograde membrane transport pathway form on 
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the ER but unlike other vesicles from that particular pathway, they are unable to fuse with 
the Golgi system or the ER-Golgi intermediate compartment (Rust et al., 2001). The 
involvement of the COP Il-dependent pathway was supported by inhibition studies 
(Sandoval et al., 1997). However, replication complex formation is not solely dependent on 
COP II-mediated pathways and studies using Brefeldin A (BFA) demonstrated 
COP I-dependent poliovirus replication inhibition (Cuconati et al., 1998; Irurzun et al., 
1992; Maynell et al., 1992). 
1.3.2.6.2 Cis-acting replication elements 
The viral RNA genome possesses signals, cis-acting elements, that allow the polymerase to 
differentiate between viral and cellular RNAs. The 5'UTR and 3'UTR cis-acting elements 
as well as elements within the genome-coding region have been identified to be involved in 
replication. The 5'UTR IRES ensures the formation of a pre-initiation template/ribosome 
complex. The 5'UTR cloverleaf stemloop d has been shown to interact with the 3CDP`° and 
PCBP has been shown to interact with the stem loop b of the cloverleaf thereby forming a 
ternary ribonucleoprotein complex (Andino et at., 1990a; Andino et al., 1990b). The 
cloverleaf structure has also been involved in the switch between translation and 
replication, as the two processes are mutually incompatible on a single template (Barton et 
at., 1999). 
The CRE, a secondary RNA structure, initially identified in the P 1-coding region of 
HRV 14 (McKnight et al., 1998), is involved in replication. Subsequent studies identified 
the presence of similar structures in the P1-coding region of cardioviruses (Lobert et al., 
1999) and in the 2C-coding region of poliovirus (Goodfellow et al., 2000). These structures 
contain a conserved GXYXAAAXXXXXXA motif (Yang et al., 2002), where the first two 
A residues of the AAA triplet template addition of pUpU onto VPg. The uridylylated VPg 
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(VPg-pUpU) (Paul et al., 2000; Rieder et al., 2000) is then used as a primer for the 
initiation of the positive-sense strand synthesis but not negative-sense strand synthesis 
(Goodfellow et al., 2003; Morasco et al., 2003; Murray et al., 2003). 
As opposed to the 5'UTR, the 3'UTR has not been studied extensively and the precise role 
of the latter in replication of picomaviruses is still unclear. The 3'UTR is not essential for 
viability of picornaviruses and mutagenesis and deletion of the 3'UTR did not prevent 
viability, though a reduction in viral fitness was observed (Meredith et al., 1999; Todd et 
al., 1997). The 3'UTR of enteroviruses has been identified to have two or three stem loops 
(Pilipenko et al., 1992), supported by thermodynamic studies (Jacobson et al., 1993; 
Melchers et al., 1997) and phylogenetic studies (Pilipenko et al., 1992). The 3'UTR can be 
exchanged, between PV3 and HRV14 (Rohll et al., 1995) and a defect in replication can be 
seen in viruses containing an altered 3'UTR (Melchers et al., 1997, Mirmomeni et al., 
1997, Pilipenko et al., 1996). The 3'UTR of poliovirus has also been shown to interact 
with cellular factors such as p105, p68 and p45 (Waggoner et al., 1998). Further studies 
expressing these cellular proteins and investigating the nature and functions of the 
interactions need to be conducted in order to understand the precise role of the 3'UTR 
cis-acting element. The poly-A tail, attached to the 3'end of the genome, is essential for 
poliovirus infectivity (Rohll et al., 1995; Sarnow et al., 1989), however other functions of 
the poliovirus poly-A tail still remain to be investigated. 
1.3.2.6.3 Model of poliovirus replication 
The model of the poliovirus replication has been proposed to occur in two phases: the 
synthesis of negative-sense strands followed by the production of positive-sense strands 
templated from the negative-sense strands. The first step to occur is that of genome 
circularisation (Herold et al., 2001) by protein-protein interaction that enable the formation 
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of a bridge between two molecules of 3CDpr°. The uridylylated VPg is then thought to 
serve as a primer for negative strand synthesis and elongation, catalysed by the RdRp 3Dp°I 
(Goodfellow et al., 2003; Morasco et al., 2003; Murray et al., 2003). Following the 
termination of the negative-sense strand synthesis, the viral RdRp uses VPg-pUpU 
complexed with the 3' termini of double stranded negative-sense strands, known as the 
replicative form or RF, as a primer for initiation of positive strand synthesis (see figure 
1.9). Binding of the 3D'°'-VPg-pUpU complex to the RF is responsible for unwinding and 
disrupting the double-stranded helices thereby generating partially double-stranded 
negative strands or replication intermediates (RI). This event leads to the exposure of more 
residues free for interaction with numerous polymerase/primer complexes. The 
CRE-generated VPg-pUpU primer is then released from the template (Goodfellow et al., 
2003). The large number of released VPg-pUpU primers, during negative-sense strand 
synthesis, enables the polymerase to initiate multiple rounds of positive strand synthesis 
from a single RF template. This asymmetric replication gives rise to high ratios of readily 
packageable positive-sense progeny RNA molecules to negative-sense template strands 
(Jarvis et al., 1992). 
1.3.2.7 Encapsidation 
1.3.2.7.1 Viral particle assembly and RNA encapsidation 
Viral particle assembly and encapsidation of the newly synthesised viral genome are 
essential steps of the poliovirus life cycle. These processes have been hypothesised to 
occur via two alternate pathways. 
Copies of the structural proteins VPO, VP! and VP3 assemble into 60 protomers to form 
poliovirus capsids. A late VPO cleavage event during the maturation of the virus particles 
gives rise to VP4 which is located inside the mature virus particle and VP2. The carboxyl 
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Figure 1.9: Poliovirus translation, poliovirus genome circularisation and genome 
replication. 
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end of VPO is associated with the amino end of VP3 and the carboxyl end of VP3 is 
associated with the amino end of VP 1 (Arnold et al., 1987) forming a 6S protomer. Five 6S 
protomers then assemble to form 14S pentamers. Cleavages and repositioning of the ends 
of VP1, VP3 and VPO lead to the assembly of twelve 14S pentamers into immature 
icosahedral 80S procapsids, which encapsidate genomic RNA to form -160S particles (see 
figure 1.10). 
Alternatively, it has been hypothesised that the pentamers could assemble around a newly 
synthesised progeny viral RNA genome to form the 160S particles. Some viral proteins, 
such as 2C, could be involved in the assembly of poliovirions (Li et al., 1990; Vance et al., 
1997). Assembly and encapsidation processes involve protein-protein interactions of 
capsid proteins, RNA-protein interaction between the viral genome and the capsid proteins, 
potential host protein-viral protein and host protein-viral RNA interactions and 
autocatalytic cleavage, however the exact succession of events and the precise mechanisms 
remain unclear. 
1.3.2.7.2 Poliovirus encapsidation signals 
The process by which the poliovirus genome is encapsidated into capsid proteins has yet to 
be resolved. Poliovirus genome encapsidation is a specific process and the existence of a 
specific encapsidation signal is strongly supported by work carried out by Barclay and 
co-workers. Indeed, Barclay and co-workers showed that the HRV 14 and CB4 capsid 
proteins, provided in trans, could not encapsidate a replication competent poliovirus CAT 
(Chloramphenicol acetyl transferase) replicon, lacking most of the P1 coding region. 
However, poliovirus type 1, poliovirus type 2 and poliovirus type 3 capsid proteins were 
able to specifically encapsidate the poliovirus CAT replicon (Barclay et al., 1998). 
I 
3 
RNA 
Figure 1.10: Model of poliovirus particle assembly 
l- VPO, VPI and VP3 assembly into 6S protomer; 2- assembly of five protomers into 
pentamers; 3- assembly of 12 pentamers into empty 80S procapsids and encapsidation 
of newly synthesised RNA genome leading to maturation cleavage and generation of 
mature icosahedral progeny virion. 
Claire Blanchard Introduction Chapter 1 19 
The exact localisation of the specific encapsidation signal remains unidentified. Defective 
interfering poliovirus genomes, containing deletions within the VP2/VP3-coding regions, 
were shown to be encapsidated even though these lacked as much as 13% of the genome 
(Ansardi et al., 1993a, Kuge et al., 1986). These studies were supported by more recent 
data. The observation that poliovirus replicons, lacking all but the last two amino acids of 
the P1-coding region, could be encapsidated by capsid proteins provided in trans showed 
that the specific poliovirus-packaging signal could not be located within the P 1-coding 
sequence (Ansardi et al., 1993b; Barclay et al., 1998). Other genome-encoded proteins 
have been thought to play a role in packaging with the exception of the 2A protein that 
does not appear to be involved in encapsidation (Ansardi et al., 1995). The substitution of 
the poliovirus type 1 2A-coding region with the CVB4 2A-coding region and the 
generation of a hybrid CVB3/PV 2B protein proved to have no effect on the virus viability 
(Lu et al., 1995; van Kuppeveld et al., 1997) suggesting that 2A and the first 30 amino 
acids of 2B did not contain a specific encapsidation signal. There is no direct evidence of 
the VPg viral protein playing a role in encapsidation, which was previously thought to be 
the case (Nomoto et al., 1977a; Nomoto et al., 1977b). An exchange of the poliovirus type 
3 VPg-coding sequence with the CVB4 VPg-coding region did not cause an encapsidation 
defect (unpublished data of Percy and Moon; see Barclay et al., 1998). Moreover the 
5'UTR (Rohll et al., 1994; Xiang et al., 1995) and the 3'UTR (Rohll et al., 1994) of 
poliovirus can be exchanged for those of certain picornaviruses suggesting that if an 
encapsidation signal exists it is most likely to reside in the region of the genome encoding 
2B to 3D (Barclay et al., 1998) or to be discontinuous. 
However, the previous results do not exclude 2A, part of 2B, capsid proteins and RNA 
structures from playing a role in the packaging of the poliovirus genome. Indeed the 
stimulation of encapsidation by unidentified signals of the 5'UTR strongly supports this 
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statement (Johansen et al., 2000). Moreover the specificity of the encapsidation process is 
not absolute as some poliovirus RNA appears to be packageable by coxsackievirus 
(Holland et al., 1964; Soloviev et al., 1968; Barclay et al., 1998), HRV and mengovirus 
particles (Jia et al., 1998). The overall encapsidation efficiency of the poliovirus genome 
by heterologous capsid proteins provided in trans is however significantly lower than 
encapsidation efficiency of the poliovirus genome by homologous capsid proteins. The 
specificity of the interspecies trans-encapsidation process could be due to the existence of 
specific replication compartments and thus inefficient mixing (Ansardi et al., 1993a), or to 
a requirement for specific interactions between genomic RNA sequences or structures and 
the capsid proteins (Barclay et al., 1998). 
13.2.7.3 Maturation cleavage 
Juxtaposition of catalytically active amino acid residues in the immature virion (Hindiyeh 
et al., 1999) and encapsidation of the RNA genome (Arnold et al., 1987) trigger the final 
stages of assembly by "maturation" cleavage of the VPO precursor protein between the 
C-terminal asparagines (N) of VP4 and the N-terminal serine (S) of VP2 (Basavappa et al., 
1994; reviewed in Hellen et al., 1992). This autocatalytic event provides the concluding 
stage to the production of mature infectious progeny virions (Ansardi et al., 1996; Rueckert 
et al., 1996) and release into the extracellular environment. 
1.3.2.8 Release 
Lytic release of newly synthesised virions, seen in poliovirus infection, can occur via 
virus-induced cytopathic effect or host-cell apoptosis defense mechanism, triggered by 2A 
(Barco et al., 2000b; Goldstaub et al., 2000) and 3C (Barco et al., 2000a) protease damage. 
Apoptosis can be interrupted by the activation of anti-apoptotic pathways, which have been 
shown to be inhibited by interaction of VP2 of CVB3 with the siva host apoptotic 
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regulatory protein (Henke et al., 2000). Recent studies have provided evidence that the 
enterovirus 2B protein was able to form pores in the ER and Golgi membranes thereby 
reducing Ca2+ levels and interefering with the ER-mitochondrial Ca 2+ signalling. This 
prevented premature apoptosis and allowed completion of the virus reproductive cycle 
(van Kuppeveld et al., 2005). Most poliovirus apoptotic and anti-apoptotic pathways have 
been reviewed by Blondel (Blondel et al., 2004). 
Several poliovirus proteins have been involved in host cell translation/transcription shut 
off. PV 2A mutagenesis studies demonstrated that 2A was involved in specific host cell 
shut off, a process different from that induced by the use of non-viral host inhibitors 
(Bernstein et al., 1985). PV 3A is a protein involved in the rearrangement of host cell 
membrane structures and was also shown to have a cytopathic effect on poliovirus-infected 
cells (Lama et al., 1998). Furthermore, accumulation of progeny virions and increase in 
size of the infected host cell causes cell burst and release of progeny virions into the 
intercellular environment, where these are then able to infect the neighbouring cells. 
1.4 Receptors: pathogenesis and tropism 
1.4.1 Picornavirus receptors and diseases 
The pathogenesis of picornaviruses or range of clinical symptoms observed as a result of 
virus infection varies depending on a number of factors such as the receptor and tissue 
tropism, the dose required for infectivity and the cellular immune response to a particular 
viral infection. Picornaviruses are pathogens that cause a wide range of diseases such as 
respiratory diseases, encephalitis, hepatitis, foot-and-mouth disease, myocarditis, 
non-specific febrile symptoms, aseptic meningitis, congenital and neonatal infections, 
encephalomyelitis, the common cold and poliomyelitis (see table 1.11). Picornaviruses 
Claire Blanchard Introduction Chapter 1 22 
have evolved to use a variety of cell surface molecules as receptors for attachment and 
entry of picornaviruses into the cell. This section discusses enterovirus receptors and 
tropism in more detail. 
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Virus genus/species Receptors Accessory factors Pathogenesis 
Enteroviruses 
Poliovirus type 1,2 Paralytic 
and 3 
PVR (Ig-like) N/A poliomyelitis and 
mild febrile illness 
Coxsackievirus A13, 
18,21 ICAM-1 (Ig-like) N/A Aseptic meningitis 
Coxsackievirus A9 avß3 Vitronectin N/A 
Hand, foot and 
mouth disease receptor inte rip 
Coxsackievirus A21 DAF (SCR-like) ICAM-1 I -like 
Common cold 
Coxsackievirus BI, 3, DAF (SCR-like) av06 (integrin) 
Aseptic meningitis 
5 Myocarditis, 
pleurodynia, 
severe systemic 
disease in infants 
Coxsackievirus BI, 6 CAR (SCR-like) N/A Upper respiratory 
tract illness, 
pneumonia 
and post-viral 
fatigue syndrome 
Echoviruses 1 a2 1 inte rip 2m Aseptic meningitis 
Echoviruses 3,6,7, Paralysis 
11-13,20,21,24,29, DAF (SCR-like) 02m Respiratory 
33 disease 
Myocarditis 
Echoviruses 22 av03 Vitronectin N/A 
Epidemic 
myalagia receptor (integrin) Hepatic 
disturbances 
Acute 
Enterovirus 70 Sialic acid N/A haemorrhaging 
conjunctivitis 
Rhinoviruses 
Major receptor group ICAM-1 like (g-) N/A 
rhinoviruses 
LDLR (low 
Minor receptor group density 
rhinoviruses lipoprotein 
N/A Common cold 
receptor) 
Rhinovirus 87 
Sialic acid 
(carbohydrate N/A 
He atoviruses 
HAV 
HAVcr-1 (Ig-like 
and mucin-like) N/A Hepatitis 
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Aphthoviruses 
a305 Vitronectin 
receptor, aß(36 
FMDV (Jackson et al., Heparan sulphate Foot-and-mouth 2000), av3i proteoglycan disease 
(Jackson et al., 
2003)- integrins 
Cardioviruses 
VCAM-1 (Ig-like) 
Encephalomyocarditis or or 
Sialylated 
A N/A Encephalitis and 
virus (carbohydrate) myocarditis 
24 
Table 1.11: Picornavirus receptors and accessory molecules involved in cell infection. 
Table was adapted from Evans & Almond (1998). A list of clinical diseases associated 
with picomavirus infection and exacerbation was added to provide a complete picture of 
receptors and role in pathogenesis. Abbreviations used: ß2m, ß2-microglobulin; CAR, 
coxsackievirus and adenovirus receptor; DAF, decay-accelerating factor; HAVcr-1, 
hepatitis cellular receptor type 1; N/A, not applicable (no accessory molecules are currently 
implicated in virus infection); PVR, poliovirus receptor; SCR, short consensus repeat (s); 
VCAM-1, vascular adhesion molecule type 1. 
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1.4.2 Identified enterovirus receptor 
1.4.2.1 Receptors 
Human enteroviruses exhibit great diversity in the range of molecules used as cell surface 
molecules for attachment. Enteroviruses have evolved to use cell surface receptors that 
have a defined role in cell recruitment, attachment, infiltration or other aspects of the 
immune system. Certain enteroviruses, such as some coxsackieviruses and poliovirus, 
appear to have evolved to attach immunoglobulin-like molecules. It is possible either that 
the viruses have evolved to use immunological molecules or that the receptor bound by 
these viruses are immunoglobulin-like as the structural fold of these molecules is stable. 
The majority of enterovirus receptors are immunoglobulin-like molecules, other proteins 
such as integrins or SCR-like molecules, glycosaminoglycans (GAGs), sialic acid and 
other molecules such as heparan sulphate, which are all involved in a broad number of 
cellular functions (see figure 1.12). 
The intracellular adhesion molecule type 1 (ICAM-1), the poliovirus receptor PVR, CD 155 
and the Coxsackievirus and adenovirus receptor (CAR) belong to the inununoglobulin-like 
family of cell surface molecules. 
ICAM-1, a molecule involved in the adhesion between leukocytes and endothelial cells, 
has been identified as the receptor for human enterovirus species C coxsackieviruses A 
(Colonno et al., 1986; Shafren et al., 1997a) and the major receptor group human 
rhinoviruses (HRV) (Greve et al., 1989; Staunton et al., 1989). 
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Figure 1.12: (lasses of molecules that serve as cell receptors for picornaviruses. 
inn J 1: 1 
The structures shown are generic structures. CAR: coxsackie-adenovirus receptor, PVR: 
polio%irus receptor. ICAM-l : intracellular adhesion molecule type 1, VCAM-l: vascular 
cell adhesion molecule type 1. DAF: decay-accelerating factors. SCR: short consensus 
repeat. GPI: glycosylphosphatidylinositol, LDL-R: low density lipoprotein receptor, 
[. [)l.: Ios density lipoprotein. HAVCR-1: hepatitis A cellular receptor type 1. T/S/P: 
threonine/serine/proline. The domains indicated in white are the domains implicated in 
virus binding. The domains in black are the domains that do not play a role in virus 
binding. All the other domains are domains for which no information is available. Figure 
taken from Evans & Almond (1998). 
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CD155 is an 80kDa cell surface molecule, expressed as four splice variants of which a and 
5 act as a receptor for poliovirus attachment and entry (PVR) (Mendelsohn et al., 1989). 
Subsequent studies demonstrated that infection of non-transgenic mice with the 
mouse-adapted strain of poliovirus type 2 (Lansing) induced fatal poliomyelitis in mice 
(Murray et al., 1988), as seen in infection of PVR-transgenic mice with poliovirus type 1 
(Ren et al., 1990). These two pathogens were shown to infect different cell types by 
histopathological analysis. The study of the PVR-transgenic mice infected with poliovirus 
type 1 Mahoney strain implies that the use of PVR is involved in causing poliomyelitis 
(Ren et al., 1990) and defines a virus as a poliovirus. However the precise role of the PVR 
in the host still remains to be identified even though it is involved in embryonic CNS 
development and cell to matrix contacts by specific binding to vitronectin (Lange et al., 
2001). The PVR was recently shown to be a ligand for the natural killer cell (NK) 
triggering receptor DNAM-1 (CD226). Upon binding of CD 155 to DNAM-1, activation of 
lysis of PVR-expressing cells by NK occurred. This was inhibited by the use of 
anti-DNAM-1 monoclonal antibody (Bottino et al., 2003). Until the identification of a 
CD155 mouse homolog (Morrison et al., 1992), poliovirus was believed to only infect 
primates as no non-primate CD155 homologs were thought to exist (Koike et al., 1992). 
Transgenic mice expressing the human PVR (Koike et al., 1991; Ren et al., 1990) have 
proved to be a very useful animal model for the study of poliovirus pathogenesis in a 
laboratory environment. Studies investigating the expression of CD155 have suggested that 
the protein seems to be regulated on a developmental level. CD155 expression in 
embryonic anatomical structures giving rise to spinal cord anterior horn motor neurons 
may contribute to the restricted host cell tropism of poliovirus for these compartments of 
the CNS (Gromeier et al., 2000). The PVR has also been suggested to have a part in 
intracellular transport (Mueller et al., 2002) and maybe retrograde axonal transport. 
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The CAR molecule, the identified receptor for CVBs and adenoviruses type 2 and type 5 
(Bergelson et al., 1997), is expressed during the embryonic development in the central and 
peripheral nervous systems (Tomko et al., 2000) as well as in many other human tissues. 
CAR has cell adhesion functions (Honda et al., 2000). 
The enteroviral receptor DAF, a GPI-anchored complement regulatory cell surface 
molecule protecting host cells from autologous lysis (Lublin et al., 1989) has four short 
consensus repeats (SCRs), which mediate binding with human enteroviruses species B, C 
and D. DAF was demonstrated to be the human receptor for enterovirus 70 (Karnauchow 
et al., 1996). Haemagglutinating echovirus strains (Ward et al., 1994; Powell et al., 1997; 
Williams et al., 2004), echovirus 7 (Powell et al., 1997), CVA21 (Shafren et al., 1997a; 
Newcombe et al., 1994; Johansson et al., 2004) and CBV1,3 and 5 (Bergelson et al., 1995; 
Shieh et al., 2002) have since been shown to interact with DAF. DAF-inhibition studies 
have shown that EV6, EV7, EV 12 and EV21 infections were DAF-dependent (Powell et 
al., 1998; reviewed in He et al., 2002). Many picornaviruses have been shown to bind DAF 
indicating that adaptation to use DAF as a receptor is likely to result from evolutionary 
selective pressure. DAF may therefore offer a selective advantage over other cell surface 
molecules. DAF has been thought to facilitate internalisation of virus receptor or 
recruitment of naive cells and activation of the apoptotic pathway and therefore virus 
release and spread (Evans et al., 1998). DAF is also a molecule involved in controlling the 
host immune response and adaptation of viruses to use DAF could enable masking and 
inhibition of the immune system. 
Heparan sulphate is a ubiquitous cell surface glycosaminoglycan (GAG) that interacts with 
a wide range of virus families, such as a herpesviruses (Shieh et al., 1992) and 
picornaviruses (Jackson et al., 1996). A number of human enteroviruses have been 
reported to use heparan sulphate as a receptor for attachment and entry. Coxsackievirus B3 
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uses heparan sulphate as well as CAR for virus entry (Zautner et al., 2003) and echovirus 6 
clinical isolates use heparan sulphate as an alternative receptor to DAF for virus 
attachment and entry (Goodfellow et al., 2001). 
Sialic acid, a family of unique 9-carbon monosaccharides, plays an essential role in 
enterovirus 70-attachment (Alexander et al., 2002). Indeed EV70 is able to bind 
neuraminidase-treated cells, in which DAF was neutralised, as the molecule is sensitive to 
neuraminidase. This is further supported by Haddad's work demonstrating that 
DAF-binding is not required for EV70 infection of a human leukocyte cell line (Haddad et 
al., 2004). It is thought that EV70 primarily binds sialic acid. EV70 is likely to have 
evolved to use DAF as a receptor by passage in cell culture (Karnauchow et al., 1996). 
Increasing evidence indicates that dual tropism (simultaneous or sequential binding of a 
virus to two cell surface molecules) can be used for attachment and entry of enteroviruses 
into cells. The CVB3-Nancy strain uses the CAR receptor for attachment and entry and is 
unable to infect RD cells, as they do not express the CAR receptor. CVB3 serially 
passaged in RD cells (CVB3-RD) was able to productively infect these cells by DAF entry 
(Bergelson et al., 1995; Schmidtke et al., 2000) whilst retaining its ability to bind CAR 
(Schmidtke et al., 2000). CVB3-RD was however unable to infect CHO-DAF cells 
suggesting that accessory factors, molecules involved in subsequent stages of entry and 
uncoating, present in RD cells but not in CHO-DAF cells might play a role in infection 
with CVB3-RD adapted strain. Recent studies demonstrated that CVB3 was also able to 
use heparan sulphate as well as CAR for virus entry (Zautner et al., 2003). CVA9 is 
another enterovirus that is able to use more than one cell surface molecule for attachment. 
CVA9 uses the vitronectin receptor as a molecule for attachment to host cell (Roivainen et 
al., 1991). The inactivation of an RGD motif of the virus, by trypsin cleavage, does not 
prevent infection of African green monkey cells thereby indicating that there is an 
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alternative cell surface molecule used by CVA9 for attachment and entry (Roivainen et al., 
1994). Echoviruses use DAF as a receptor (Bergelson et al., 1994; Powell et al., 1998; 
Ward et al., 1994) however recent studies suggested the potential use of DAF and heparan 
sulphate, a second receptor, by these viruses (Goodfellow et al., 2001) 
Dual tropism could be due to capsid surfaces having evolved to contain two 
receptor-binding sites. However, distinguishing between molecules only involved in 
binding and molecules required for subsequent stages of infection such as entry and 
uncoating (known as accessory factors) can be difficult. 
1.4.2.2 Accessory factors 
As we understand more about viruses it is clear that accessory factors are important for 
infection. A number of accessory factors have been identified for different families of 
viruses and are thought to be important determinants of tissue specific pathogenesis and 
tropism. Accessory factors still need to be established for picornaviruses, however studies 
strongly suggest the involvement of such factors in the infection process (see table 1.11). 
Moreover, several entities have been reported to enhance infectivity of enteroviruses; in 
fact DAF has been demonstrated to enhance efficiency of CVA21 uptake, an ICAM-1 
using virus (Shafren et al., 1997a; Johansson et al., 2004). MAP70, an MHC class I 
protein, has been suggested to be an accessory factor in infection with CVA9 (Triantafilou 
et al., 2000). CD59, a complement control protein, appears to be important in echovirus 
infection, in particular infection with echovirus 7 (Goodfellow et al., 2001). a,. ß6 is thought 
to enhance CVB lytic infection of human colon cancer cells (Agrez et al., 1997). 
ß2-microglobulin (ß2-m), a component of the MHC class I has been indirectly implicated in 
the infection of RD cells with echoviruses, since treatment with 02-m antibody was able to 
block infection but not binding in RD cells (Ward et al., 1998). A similar event was 
Claire Blanchard Introduction Chapter 1 30 
observed in CVA9 infection of CHO cells, where CVA9 was able to bind aß3 but no 
infection was observed after ß2-m antibody treatment (Triantafilou et al., 1999)(see table 
1.11). In all these cases, the role of these accessory factors remains ill defined. 
1.4.3 Tropism and its determinants 
It is clear that several factors are involved in the determination of pathogenesis and 
tropism, the affinity of picornaviruses for a population of host cells or a specific host tissue 
composed of susceptible cells (Shafren et al., 1997a; Johansson et al., 2004; Triantafilou et 
al., 2000; Goodfellow et al., 2001; Agrez et al., 1997; Triantafilou et al., 1999). The 
tropism of a virus is often defined by the receptor usage. Within each genus exist 
sub-divisions of viruses using the same receptor for attachment and entry. Some genera are 
directly correlated to receptor usage such as aphthoviruses that use the vitronectin receptor, 
and rhinoviruses and Coxsackievirus A2 1, both causing respiratory tract infections, that 
use either the intracellular adhesion molecule type 1 (ICAM-1: major receptor group) or 
the low-density lipoprotein receptor (LDLR: minor receptor group). However there is little 
or no direct correlation between the genetic similarity and receptor use for the remaining 
picornaviruses, for which the receptor has been identified, in particular for human 
enteroviruses as they exhibit the most diversity in receptor usage. 
Pathogenesis is also variable. Different viruses can cause the same clinical symptoms 
(Melnick, 1996). Indeed Coxsackievirus B3 and Coxsackievirus B4 (CVB3 and CVB4) 
strains can vary in their ability to cause particular syndromes such as cardiovirulence and 
diabetes (Cao et al., 1991; Dunn et al., 2000). The two different viruses, closely related in 
their non-structural coding region of the genome, can infect the same cell type through 
attachment to the same receptors DAF or different receptors: DAF and CAR (Bergelson et 
al., 1995; Shafren et al., 1997b). This and the recent recombination data (described in 
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Chapter 3) suggest that the predominant - if not the primary - determinant of virus 
pathogenesis is the receptor to which it attaches. 
Similarly, the same virus can infect different cell types, expressing the same cellular 
receptors, situated at distinct locations in the host, causing different symptoms. Poliovirus 
is a very good example as it can infect cells of the intestinal epithelium causing mild 
enteric syndromes whereas infection of the CNS motor neurons, expressing the same PVR 
cell surface receptor molecule, causes AFP. 
The choice of receptor or cell surface molecule, determining the cell type infected, is a 
major factor contributing to symptoms observed in a viral infection. Receptors are 
therefore very important pathogenesis and tropism determinants. However, it is unclear 
whether these cell surface molecules are the sole determinants of tropism or whether other 
factors are involved. Factors such as the immune status of a particular host and different 
environmental conditions may be involved in the determination of tropism and 
pathogenesis. Whilst poliovirus appears not to require additional factors for cellular 
infection to occur, this is not the case for all enteroviruses. 
Non-poliovirus enteroviruses, like CVA7, CVA9 (Grist et al., 1970), EV70 (Wadia et al., 
1983), EV71 (Chumakov et al., 1979) and recently CVA21 (Shaffren et al., 1997) are 
nonetheless able to cause poliomyelitis-like syndromes. Despite acquiring particular 
receptor af'inity, infection by some of these viruses can be blocked by antibodies to their 
original receptors. EV70 and EV71 have been shown to cause acute haemorrhagic 
conjunctivitis and hand-foot-and-mouth disease (Wang et al., 1999; Yin-Murphy et al., 
1984). It has been thought by many that non-poliovirus enteroviruses could potentially 
acquire affinity for CD 155 through adaptive changes in the P1 structural proteins coding 
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region (Gromeier et al., 1999). The hypothesis still needs to be tested and the following 
project was an attempt to determine whether such an evolutionary event could occur. 
1.5 Evolution 
RNA virus evolution occurs under selective pressure, provided by physical, selective, 
functional, developmental and/or genetic constraints, and is driven by two mechanisms 
enabling the viruses to adapt, survive and multiply in a new cellular environment: 
polymerase error rate leading to the introduction of mutations within progeny genomes and 
RNA recombination. The evolution of picomaviruses is driven by accumulation of point 
mutations, short insertions/deletions and genomic changes due to the exchange of genetic 
material, with related or non-related sequences, that lead to the generation of divergent 
RNA and protein sequences, with conservation of essential functions and viability of the 
virus. The evolution of picornaviruses occurs via both these mechanisms. 
1.5.1 Evolution of picornaviruses 
1.5.1.1 Mechanisms of evolution 
1.5.1.1.1 RdRp mutation rate and error polymerase rate 
Replication of all positive-sense strand RNA viruses is driven by RNA-dependent 
RNA-polymerases (RdRp), apart from retroviruses that replicate using RNA-dependent 
DNA-polymerases. RdRps lack a proofreading mechanism (Ishihama et al., 1986) and are 
therefore unable to correct mutations or mismatches introduced during viral replication. 
The polymerase error rate of picornaviruses has been shown to be as high as 2.1x10 to 
5.9x104 substitutions per nucleotide (Crotty et al., 2001; Sierra et al., 2000). As a result 
positive-sense strand RNA viruses exist as quasispecies, or an ensemble of related but 
genetically different viral genomes (Eigen et al., 1988), and exhibit high evolution rates, 
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discussed further in chapter 2. Existing as a quasispecies is an evolutionary advantage as 
the mutant spectrum contains viral sequences that may be efficient at evading the immune 
response, having increased resistance to antiviral agents, escaping specific antibodies and 
cytotoxic T cells and altering their induction of interferon capacity (Ruiz-Jarabo et al., 
2000). 
1.5.1.1.2 Recombination 
1.5.1.1.2.1 Definition and description 
The second process that drives positive-sense single strand RNA virus evolution is that of 
recombination between viral RNA genomes and was first described in poliovirus in the 
1960's (Hirst et al., 1962; Ledinko et al., 1963). It is a widespread mechanism known to 
occur in animal, plant and human viruses (Chetverin et al., 1997; Lai et al., 1992b; 
Slobodskaya et al., 1996) and it enables the generation of fitter viruses, able to survive in 
an altered environment, or the preservation of wild-type viral sequences. Recombination is 
the generation of a new combination of genes that are more advantageous for the survival 
of a specific viral population. Recombination between two pieces of RNA can be either 
homologous, and occur between two identical or similar molecules recombining in a 
precise (junction sites occupy different positions in recombining molecules) or imprecise 
(producing molecules with duplications and deletions) manner, or non-homologous, and 
occur between two different RNA molecules. 
1.5.1.1.2.2 Different processes of recombination 
Recombination of positive-sense single strand non-segmented RNA genomes can occur via 
two distinct mechanisms: a replication-dependent copy-choice mechanism where the viral 
replicase-nascent strand complex switches from one template to another during replication 
(Coffin et al., 1979; Kirkegaard et al., 1986; Figleworicz et al., 1997; Figleworicz et al., 
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1998) and a replication-independent mechanism of breakage and rejoining of pieces of 
genetic material (Kirkegaard et al., 1986). Until recently, very few studies had investigated 
the second process, however recent studies have provided definitive evidence of 
recombination occurring via a replication-independent mechanism of template breakage 
and rejoining (Chetverin et at., 1997; Gallei et al., 2004; Gmyl et al., 2003). 
1.5.1.1.2.2.1 RdRp copy choice mechanism 
Copy-choice recombination is the result of the RdRp template switching during replication 
(Figlerowicz et al., 1998; Jarvis et al., 1992; Kirkegaard et al., 1986; Lai et al., 1992a; 
Nagy et al., 1997; Nagy, 1998; Pilipenko, 1995), a process described in studies of 
pseudorevertant genomes in Theiler's murine encephalomyelitis virus (TMEV) and 
poliovirus (Pilipenko et al., 1995). Pausing of the nascent strand due to misincorporation 
by the RdRp, dissociation of the RNA polymerase from the nascent strand, re-annealing of 
nascent and template strands and resumption of the synthesis are the various stages of the 
copy-choice mechanism (reviewed Nagy et al., 1997). Studies in the 1960's demonstrated 
that poliovirus recombinants could arise as a result of mixed infection of a cell with two 
different serotypes of polioviruses (Hirst et al., 1962; Ledinko et al., 1963). This was later 
shown to occur inside specific compartments used for RNA replication (Bienz et al., 1990). 
1.5.1.1.2.2.2 Replication-independent recombination 
Unlike template switching, non-replicative recombination has not been studied extensively. 
Chetverin carried out experiments on Qß replication demonstrating non-replicative 
recombination of RNA fragments (Gmyl et al., 1999; Chetverin et al., 1997). These in vitro 
studies, however, did not exclude the possible low levels of replication due to the presence 
of the Qß replicase required for amplification of the recombinant molecules. 
Recombination could still be accounted for by a copy-choice mechanism. Even if we 
assume that Chetverin's studies demonstrate non-replicative recombination in vitro it has 
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not been demonstrated in an in vivo system until recently. Experiments studying the 
co-transfection of incomplete poliovirus RNA sequences demonstrated the generation of 
viable viruses and gave strong but not definitive evidence of a replication-independent 
recombination mechanism (Gmyl et al., 2003). However, the definitive evidence of such an 
event occurring was provided by the recent studies carried out in BVDV, where viable 
recombinants would arise from co-transfection of segments of RNA, each containing 
deletions in the RdRp-coding genes thereby completely ruling out the possible 
involvement of replication in the process (Gallei et al., 2004). 
1.5.1.2 Evidence of emergence of recombinants in nature 
The emergence of viruses as a result of recombination represents an important threat to the 
world as they have the potential to cause major outbreaks and pandemics. Indeed virus 
recombination, leading to the emergence of completely new viruses, has been a concern for 
many years. The recent outbreak of SARS, a coronavirus that is thought to have recently 
evolved from its natural reservoir to infect humans, illustrates the impact such emerging 
viruses can have both economically and demographically. Another example of 
recombination occurring in nature is that of bovine viral diarrhea viruses (BVDVs). Recent 
phylogenetic studies of BVDVs suggested that recombination between different virus 
strains had occurred in animal hosts (Nagai et al., 2004). HIV is an RNA human retrovirus 
that has had a huge impact on the world. Recombination has been reported to be a frequent 
event contributing to the generation of genetically diverse strains of HIV with different 
pathogenesis characteristics (Robertson et al., 1995). 
1.5.1.3 Evolution amongst enteroviruses 
Recombination plays a major role in enterovirus evolution. In fact, numerous 
recombination events have been reported in both a natural host environment and a 
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laboratory environment. Certain human enteroviruses are thought to have arisen from 
ancient recombination events and this was suggested to have occurred for CVA16 and 
bovine enteroviruses as sequence comparison studies of these viruses indicated strong 
phylogenetic relationships (Hyypiä et al., 1997). Genetic recombination between different 
human enteroviruses type B echovirus serotypes has been reported to occur when multiple 
epidemic strains were circulating simultaneously (Oprisan et al., 2002). This was 
confirmed by recent work studying the phylogenetic relationships between various 
enteroviruses species B (Oberste et al., 2004a). Further phylogenetic analysis of 
enteroviruses species C (Brown et al., 2003) and enteroviruses species A (Oberste et al., 
2005) included strong evidence that recombination amongst enteroviruses is a common 
occurrence. CVA2 1, currently defined as an enterovirus expressing the same tissue tropism 
as HRV and causing respiratory infections, was suggested to be a recombinant between a 
rhinovirus and a poliovirus in studies carried out in the mid 1980's (Stanway et al., 1984). 
1.5.1.4 VDPV and vaccine revertants 
Live-attenuated strains of poliovirus, containing mutations rendering the strains unable to 
cause poliomyelitis but still able to infect cells; have proved to an essential tool for 
vaccination and eradication of poliovirus. Sabin was one of the first generated 
live-attenuated poliovirus vaccine strains (Krugman et al., 1961), and these are now used in 
many countries as means of immunisation through vaccination with OPV, a live-attenuated 
vaccine containing three serotypes of live-attenuated poliovirus wild-type strains. Since the 
first use of live-attenuated poliovirus strains, the secretion of neurovirulent revertants have 
been reported (reviewed Dowdle et al., 2003) and have been shown to cause infection in 
immunodeficient patients and the non-immune population in close contact with the 
excreting vaccinee. However, recent data from retrospective studies have shown the 
presence of recombinant VDPVs (vaccine-derived poliovirus) circulating in the wild. 
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VDPDs isolates were circulating in Egypt for over 10 years, between 1983 and 1993, and 
circulation ceased with rising coverage of OPV vaccination (Yang et al., 2003). These 
studies not only suggest that OPV vaccine strains can recombine and cause acute flaccid 
paralysis (AFP) but that VDPVs can circulate for extended periods of time in an 
environment where low vaccination coverage is prevalent. Further retrospective studies of 
the poliovirus Sabin type 3-associated outbreak in Poland in 1968 (Martin et al., 2000) 
demonstrated that VDPV-related outbreaks were not restricted to tropical developing 
countries such as Hispaniola (Kew et al., 2002) and that VDPVs were able to cause AFP in 
developed countries with temperate climates and moderate population densities if the 
population immunity to one of the vaccine strains of poliovirus is low. Moreover studies of 
1963-1966 VDPV isolates in Belarus (Korotkova et al., 2003) reinforced the point that 
maintenance of sufficient levels of OPV vaccination coverage is essential to avoid 
circulating VDPVs from occurring. 
1.5.1.5 Recent outbreaks and recombinants between poliovirus and human 
enterovirus C 
The outbreak of recombinant vaccine strains in Hispaniola in 2000-2001 (Kew et al., 2002) 
caused an immediate public health concern, as the country had been free of wild-type 
poliovirus since 1991. Isolates were collected, sequenced and had Sabin poliovirus type 1 
5'UTR and P 1/2A-coding sequences and unidentified human enterovirus C 3'UTR, 
2B/2C/P3-coding sequences, thereby giving evidence for a recombination event. This 
recombination event is the first report of human enteroviruses C recombining with a Sabin 
poliovirus vaccine strain with a crossover point within the 2A/2B-coding region (see figure 
3.38). Other circulating VDPVs were also identified in the Philippines in 2001 (MMWR 
2001). More recent studies carried out by Delpeyroux's group isolated strains from 
outbreaks of AFP in Madagascar (Rousset et al., 2003) and identified a number of human 
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enterovirus C strains that were circulating at the time of vaccination (Rousset et al., 2004). 
Studies of both Haitian and Madagascan cVDPVs suggested that live-attenuated poliovirus 
vaccine strains were able to recombine with circulating enterovirus C causing a 
poliomyelitis-like disease. In fact, further studies carried out by Delpeyroux's group 
identified two unspecified recombination crossover points within the 2A-coding region and 
a definitive recombination between vaccine strains Sabin type 2 and enteroviruses species 
C (Rousset et at., 2004). These studies not only highlighted the risk of recombinant viruses 
emerging and causing outbreaks, as a result of low vaccination coverage, but the fact that 
enteroviruses C were able to recombine just confirmed the difficult obstacles the WHO 
would have to overcome in order to succeed in eradicating poliovirus from the world. The 
emergence of such recombinant viruses may lead to a persistence of circulating 
polioviruses in the wild. So far the circulating recombinant VDPVs isolated and analysed 
from outbreak cases had structural proteins of a vaccine strain and the remainder of the 
virus genome had sequences of unidentified viruses within species of HEV-C (Stanway et 
al., 2000). An urgent understanding of such recombinants is essential for the monitoring 
and control of transmission or re-emergence of poliomyelitis post-eradication. Failure to 
investigate concerns regarding the polio eradication programme could lead to the 
re-emergence of poliovirus and actually reverse the efforts and progress already achieved 
by the WHO. 
1.5.1.6 Vaccines and revertants 
Vaccine-derived polioviruses have been responsible for many reported acute flaccid 
paralysis (AFP) cases. Stability of live-attenuated vaccines has been a concern since the 
first evidence of the appearance of vaccine-associated paralytic poliomyelitis VAPP soon 
after the OPV vaccine was licensed for commercial use. With a large part of the world 
being polio-free OPV has always been considered as a very efficient and fairly safe 
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vaccine. However, recent retrospective studies and outbreaks of paralytic poliomyelitis 
associated with circulating vaccine-derived polioviruses (cVDPVs) have highlighted 
pre-existing concerns. 
1.5.2 WHO eradication program and rising concerns 
In the 1950's poliomyelitis was an important disease prevalent in both the developed and 
the developing world. Salk vaccine, a poliovirus inactivated vaccine (IPV), was initially 
used as a prevention method and is still used in many countries. Since the 1960's Sabin's 
OPV (trivalent live-attenuated oral poliovirus vaccine) has been used, in most parts of the 
world, as the preferred prevention method. IPV and OPV are still being used but the low 
cost of OPV production makes its administration in developing countries more manageable 
and realistic. This pattern is likely to change as eradication is achieved and every means 
possible will be made to exclude the potential reintroduction of circulating paralytic 
poliovirus. 
The 1979 smallpox eradication prompted the Pan American Health Organisation (PAHO) 
and World Health Organisation (WHO) to initiate a poliovirus eradication program, in 
1985, aiming to eliminate poliomyelitis worldwide by 1990 using the OPV as the means to 
the end. Mass immunisation campaigns were initiated with national immunisation days 
(NIDS), in which millions of children in a country are immunised in a single day, and 
sub-national immunisation days (SNIDS), in which smaller areas are immunised in one 
day. These have shown to abruptly reduce the number of susceptible individuals thereby 
interrupting transmission of the virus. However, widespread vaccination can prove to be 
challenging and some parts of tropical and developing countries have very low 
immunisation coverage. This leads to the emergence of vaccine-associated paralytic 
poliomyelitis (VAPP) caused by circulating vaccine-derived poliovirus strains (cVDPVs). 
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The WHO polio eradication program has achieved the eradication of circulating wild-type 
poliovirus in many parts of the world (figure 1.13), however the transmission of wild-type 
poliovirus still occurs in India, Pakistan, Afghanistan, Egypt, Niger and Nigeria and the 
emergence of more VAPP cases by cVDPVs in Haiti (Kew et al., 2002), Egypt (Yang et 
al., 1997), Philippines (MMWR 2001) and Madgascar (Rousset et al., 2003) have raised 
issues about the successful eradication of poliomyelitis. Better monitoring has enabled the 
detection of emerging recombinant viruses between vaccine strains and human enterovirus 
species C (Kew et at., 2002; Rousset et al., 2003), able to cause outbreaks, highlighting the 
importance of vaccine-derived polioviruses (VDPV) and the need for a better 
understanding of recombinants both in vitro and in vivo. 
The re-emergence of poliomyelitis due to undetected circulating wild-type strains or 
recombinant vaccine strains is a major concern. Monitoring and control methods need to be 
carried out and extended to the post-eradication era as poliovirus could escape or be 
released from laboratories and potentially cause a pandemic in a non-immune susceptible 
population. Vaccine strains need to be kept in case such an event was to happen and it is 
likely that vaccination in the developed world will switch to IPV in the end stages of the 
eradication program. Non-poliovirus enteroviruses are known to be capable of causing a 
poliomyelitis-like disease in humans. The eradication of poliovirus does not remove the 
possibility of another enterovirus evolving to use the poliovirus ecological niche left vacant 
post-eradication and cause poliomyelitis. 
1.6 Aims of the project 
As the world gets closer to poliomyelitis eradication, progress in vaccination distribution, 
detection methods and laboratory containment are becoming more important. The 
emerging VDPVs causing outbreaks of AFP are a major source of concern and various 
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issues need to be tackled. How do recombinants arise and do recombination hotspots exist? 
With the eradication of poliovirus and the ecological niche being left vacant, what are the 
chances that a non-poliovirus enterovirus could evolve to use the poliovirus receptor and 
cause poliomyelitis? What are the implications of such recombinants? Would these 
recombinants cause poliomyelitis due to their PVR usage and what are the determinants of 
tropism and pathogenesis? 
The initial aim of the project was to investigate the tropism of enteroviruses and to 
determine whether enteroviruses could evolve to use a novel receptor. Receptor 
interactions are important determinants of tissue tropism and numerous experiments have 
been carried out describing the evolution of a particular picornavirus to use an alternate 
receptor in a tissue culture environment. Evidence of Coxsackievirus A 21 adapting to use 
DAF as a receptor in tissue culture as opposed to its identified receptor ICAM-1 was 
recently provided by Johansson (Johansson et al., 2004). FMDV tissue culture adaptation 
to use heparan sulphate as a receptor is another interesting example of novel tropism 
(Jackson et al., 1996). Infection of ICAM-1 negative cells by human rhinovirus 14 
(HRV 14) was also shown (Reischl et al., 2001). Recent studies demonstrating enterovirus 
70 sialic acid usage (Alexander et al., 2002) and suggesting that EV70 had evolved to use 
DAF as a receptor again provided evidence that picornaviruses can evolve to use alternate 
receptors. 
Furthermore, the Haitian and Madagascan outbreaks caused by emerging recombinant 
viruses indicate that recombinants provide a source of continued circulation of PVR-using 
enteroviruses, which are known to be capable of causing poliomyelitis. 
The project was designed to investigate these issues. The project was divided into three 
major sets of experiments: mutagenesis selection and adaptation studies, in vitro generation 
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and characterisation of recombinant viruses and in vivo selection for novel tropic 
recombinant viruses. 
Mutagenesis studies to select for novel tropic viruses using an antiviral mutagen were 
carried out. These were designed to enable the generation of divergent mutant viruses 
using a process reproducing evolution. 
In vitro generation of recombinants with pre-determination of the crossover sites was 
initiated to investigate heterologous processing requirements of enteroviruses. The aim was 
to generate recombinant viruses that had the capsid-coding region of a non-poliovirus 
enterovirus and the remainder of the genome of a poliovirus. Reciprocal recombinants 
were also constructed in attempt to provide a better understanding of the VDPVs 
recombined with enterovirus species C (Kew et al., 2002; Rousset et al., 2003). The 
circulating VDPVs, isolated from outbreak cases in Haiti and Madagascar, were 
demonstrated to be recombinants between the structural protein-coding region of vaccine 
strains, Sabin poliovirus type 1 (Haiti) and Sabin poliovirus type 2 (Madagascar), and the 
non-structural protein-coding region of human enteroviruses species C. The viability of 
these isolates indicated that the 3CD of an enterovirus type C could efficiently process the 
P1 of a poliovirus vaccine strain. 
In vivo selection for novel tropic recombinant viruses by co-transfection of two defective 
viral RNA sequences constituted the final part of the project. Previous evidence of 
successful generation of recombinants by co-transfection of incomplete viral RNA 
transcripts, reports of emergence of recombinants between human enteroviruses C and 
Sabin poliovirus vaccine strains and the implication of such recombinants in view of 
poliomyelitis eradication formed the basis of the next set of experiments. Successful 
selection of capsid recombinants in tissue culture without predetermining crossover 
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points/exact recombination sites and characterisation of such recombinants could provide 
valuable information on properties, stages of life cycle affected, tropism determinants, 
potential location of recombination hotspots of enteroviruses and the potential emergence 
of a virus with a novel sequence to occupy the ecological niche that would be left vacant 
following poliovirus eradication. Generation of such recombinants could also potentially 
be a tool for enabling identification of compatible domains of the genome involved in 
packaging and give us insights into protein-protein, protein-RNA and potentially 
RNA-RNA interactions involved in replication. 
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2 Selection of novel tropic viruses using a mutagen 
2.1 Introduction 
All RNA viruses, except for retroviruses, use RNA-dependent RNA-polymerases (RdRps) 
as a catalytic enzyme for RNA synthesis. RdRps lack proofreading activity thereby 
introducing errors to the newly synthesised progeny genomes. RNA viruses can therefore 
exhibit a high mutation rate. These viruses exist as quasispecies or large population of 
related but divergent viral sequences, which may be an evolutionary advantage. The 
frequency at which errors occur in a viral genome is known as error frequency, which is 
the measure of genetic drift or gradual adaptation to new environments due to external 
stresses also known as selective pressure. 
However, the evolution rate of RNA viruses is not solely determined by the fixation rate of 
mutations as it is also dependent on environmental factors. Measles virus exhibits a high 
mutation rate but has evolved slowly due to a low fixation rate of mutations (Schrag et al., 
1999) whereas HIV shows a higher evolution rate even though its mutation rate is similar 
to that of measles virus. The evolution rate of HIV has been extensively documented and 
has been shown to be dependent on mutation rate as well as on the host immune system 
(Wolinsky et al., 1996) and other factors, which select for viruses that exhibit particular 
phenotypes. Indeed a virus could evolve faster in a new host but keep the same polymerase 
error rate or fidelity, due to a variability in the fixation rate of mutations. Recent studies 
carried out by Andino (Crotty et al., 2001), Domingo (Ruiz-Jarabo et al., 2000; Sierra et 
al., 2000) and co-workers confirmed the mutation rate of picornaviruses to be between 
2.1x10 and 5.9x104 substitutions per nucleotide. These figures were obtained by direct 
sequencing analysis of many viral genomes and by using the frequency at which genetic 
markers are isolated from a given virus population. These studies confirmed the initial 
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poliovirus mutation rate calculation (Ward et al., 1988). More investigations have 
quantified the poliovirus mutation rate in a long-term immunodeficient excretor to be 1% 
per base per annum (Martin et al., 2000; Minor, 1996), again supporting initial calculations 
(Ward et al., 1988). Recent investigations demonstrated that the VP1-coding region of 
Sabin type 1 VDPV, isolated from the gut of a healthy child, exhibited a sequence drift of 
over 2% per base per annum. This figure proves that certain VDPVs exhibit higher 
mutation rates than that initially observed for poliovirus, and that these viruses are able to 
replicate in the gut of healthy individuals for long periods of time (Martin et al., 2004). 
Selective pressure occurs during processes such as replication, cell lysis and virion release 
into the intercellular environment, where these come into contact with cells from the 
immune system. The combination of variation and large replication yield during infection 
is considered to be advantageous to virus populations. If the host specific immune response 
results in the near elimination of wild-type viruses, quasispecies may contain escape 
mutants that do not express the specific epitopes recognised by cytotoxic T cells, 
antibodies or innate responses. These escape mutants will then quickly replicate and give 
rise to a new population of quasispecies, allowing the survival of the viral population as 
was shown for Hepatitis C virus (HCV) (Erickson et al., 2001) and HIV (Pircher et al., 
1990). However, errors can lead to the generation of non-viable viruses and the extinction 
of a particular virus population in the event of excessive number of mutations being 
introduced, a consequence known as error catastrophe (see figure 2.4 and 2.5). 
RNA virus recombination can be beneficial to mutant viral sequences and can allow 
recovery of fitness-impaired sequences (Chao et al., 1997). However, recombination can 
also lead to the generation of non-viable viruses due to incompatibility between genomes, 
RNA structures and/or proteins. 
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In an environment where the mutation rates are high, a significant proportion of mutations 
are deleterious. This leads to the generation of non-viable or otherwise disadvantaged 
genomes. Miiller's ratchet is the selection by serial passages of virus populations through a 
narrow genetic bottleneck, an evolutionary process whereby a significant percentage of a 
virus population is killed or prevented from reproducing, which leads to the reduction in 
the population and survival of a subset of viruses (transmitted from host to host) (Duarte et 
al., 1992; Chao et al., 1990; Domingo et al., 1985). In this context, wild-type viruses are 
defined as viruses that have sufficient fitness to survive and be transmitted from host to 
host. Mailer's ratchet could have significant implications for variability of disease severity 
during virus outbreaks. 
Evolution of picornaviruses, and more specifically poliovirus, occurs via two mechanisms: 
the introduction of mutations due to the error rate of RdRp and intra-/inter-typic 
recombination. The fixation rate and phenotypic selection may result in viruses with 
altered tropism at an enhanced level of mutation. The use of a mutagen in vitro may enable 
the selection for novel tropic mutant progeny viruses. 
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2.1.1 Ribavirin: a mutagen and its effect on virus life cycle 
Ribavirin, 1-0-D-ribofuranosyl-1; 2,4-triazole-3-carboxamide (see figure 2.1), is a 
synthetic broad-spectrum non-specific ribonucleoside analog with antiviral activity. 
Ribavirin is currently used for the treatment of a variety of RNA virus infections. In 
humans, the drug is used as monotherapy for Lassa fever virus infections and severe 
respiratory syncytial virus infections, and in combination with interferon-a as treatment for 
Hepatitis C virus (HCV) infections (Crotty et al., 2002a). 
Despite the extensive use of ribavirin, the detailed understanding of the activity of the drug 
is still unclear thereby preventing further development of enhanced derivatives with 
improved properties for clinical use. Recent studies have shown that ribavirin is an RNA 
virus mutagen (Crotty et al., 2000) and lethal mutagenesis has been proposed to be its 
mechanism of action (Crotty et al., 2001). 
Once inside the cell ribavirin is phosphorylated by adenosine kinase to generate ribavirin 
monophosphate (RMP). Sequential phosphorylation events then give rise to ribavirin 
triphosphate (RTP). RMP is an inosine monophosphate dehydrogenase (IMPDH) inhibitor 
(Muller et al., 1977; Streeter et al., 1973). IMPDH is a cellular enzyme used for de novo 
synthesis of guanosine triphosphate (GTP), which is itself required for translation, 
transcription and replication of all viruses. IMPDH inhibition triggers a decrease of 
intracellular levels of GTP, which could account for antiviral activity. 
RTP is a substrate for the poliovirus RNA-dependent RNA polymerase and acts as a purine 
nucleoside analog by presenting two distinct hydrogen-bonding conformations to 
complementary bases. Low intracellular GTP levels favour the incorporation of RTP into 
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Figure 2.1: Chemical structure of ribavirin (1-ß-D-ribofuranosyl-1, -2,4-triazole-3- 
carboaamide). 
Figure taken from Crotty et al. (2002 b). 
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Figure 2.2: Hydrogen-bonding conformations of ribavirin, a purine analog, with cytosine 
and uracil, pyrimidine bases. 
Figure taken from Grad et al. (2002). 
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the genome, promoting G to A and A to G transitions due to its ability to base pair with C 
and U (see figure 2.2) and disrupting RNA structures, which can be critical for virus 
replication (Crotty et al., 2000). 
Number of mutations Total mutation Total mutation Ribavirin 
observed in the frequency (/104 frequency 
concentration 
sequenced window nucleotides) (/genome) 
G-->A C-4T 
0 µM 0.5 1.2 2.1 1.5 
100 µM 0 1.3 2.5 1.8 
400 µM 4.4 5 9.3 6.9 
1,000 µM 6.8 12 20.8 15.6 
Table 2.3: Mutation frequency in ribavirin-treated RNA poliovirus populations. Data 
was taken from Crotty et al. (2001). 
2.1.2 Effect of ribavirin on poliovirus infection life cycle 
Andino and co workers (Crotty et al., 2000) established a relationship between ribavirin 
concentration and the mutation rate of poliovirus. In their study they also showed the effect 
ribavirin exerted on viral translation and production. The increase of the mutation 
frequency caused by ribavirin, shown in table 2.3 and the effect of ribavirin on translation 
and production of poliovirus were demonstrated by Andino and co-workers (Crotty et al., 
2000). Poliovirus replication and translation, determined using a subgenomic replicon, is 
reduced only very slightly in the presence of up to 1mM ribavirin. Under similar 
conditions virus yield is reduced by up to 3 loglo. The normal mutation rate of poliovirus, 
1.5 mutations per genome (Crotty et al., 2001), was increased to approximately 6.9 
mutations per genome in the presence of 0.4 mM ribavirin. This was shown to cause a 95% 
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decrease in the fitness of the viral population compared to that of wild type (Crotty et al., 
2001). Because the normal poliovirus population exists on the threshold of error 
catastrophe, accumulation of too many mutations can lead to lethal mutagenesis of 
poliovirus leading to a decrease in virus titres to near background levels (see figure 2.4: 
Crotty et al., 2001). RNA viruses are unstable and a small increase in mutation levels can 
result in a reduction of virus viability. This has been shown for poliovirus, vesicular 
stomatitis virus (Holland et al., 1990), and HIV (Loeb et al., 2000). Moreover, serial 
passages in the presence of a mutagen were shown to be sufficient for viral extinction of 
HIV populations (Loeb et al., 2000). The relationship between virus survival and error 
catastrophe is fragile and the application of random mutagenesis experiments might cause 
a shift in the equilibrium relationship towards error catastrophe (see figure 2.5). 
2.2 Aims 
Will the poliovirus niche remain vacant after the eradication of poliomyelitis or could 
viruses evolve to occupy the empty ecological niche? Enteroviruses exhibit a high 
mutation rate in nature. Over time, mutations cause changes in the capsid-coding region 
that could lead to a change in receptor usage. Moreover, it has been extensively reported 
that picornaviruses can adapt to use alternative receptors in tissue culture. Various 
examples provide evidence that picornaviruses can use more than one cell surface 
molecules for cell attachment. Indeed, FMDV can adapt through a single mutation to use 
heparan-sulphate as a receptor in tissue culture as opposed to the identified receptor avß3, 
(Jackson et al., 1996). Human rhinovirus 14 has been shown to be able to infect ICAM-1 
negative cells (Reischl et al., 2001). Coxsackieviruses have adapted to attach DAF and 
infect RD cells (Reagan et al., 1984). A DAF-binding echovirus 6 has been demonstrated 
to have the ability to use heparan sulphate as a receptor (data not published David 
Williams). An echovirus 11 variant has also adapted to not use DAF as a receptor for 
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Figure 2.4: Error catastrophe 
Relationship of mutation frequency to genomic RNA infectivity (Crotty et al.. 2002 b). Specific 
infectivity of normal poliovirus RNA was set to 100°0. The graph shows that poliovirus 
populations exist near the edge of error catastrophe, as there is a rapid decline in RNA genome 
infectivity at levels of mutagenesis only slightly higher than normal. The L150 (50°° loss of 
specific infectivity) is defined as the mutation frequency at which 50°0 of the viral genomes are 
lethally mutated. indicated by the dashed line. Wild-type poliovirus genomes contain an average 
1.5 mutations genome. Poliovirus genomes from cells treated with 400 µM and 1000 µM 
ribavirin respectively contain an average -6.9 mutations/genome and -15.5 mutations/genome. 
Taken from Crotty et al. (2001). 
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'I 'he majority of viruses in a normal picornavirus population are viable. But a small increase in 
mutation frequency is predicted to push the virus population into error catastrophe (the 
mutagenised population. Right), where the number of errors per viral genome is sufficiently high 
to lethally mutate a majority of the virus population. White indicates live virus, gray indicates 
dead virus. Figure and legend taken from Crotty et al. (2001). 
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infection (Stuart et al., 2001). Finally, CVA21 DAF-binding has been demonstrated and 
confirmed (Shafren et al., 1997; Johansson et al., 2004). 
The aim of the experiment was to investigate whether accelerating evolution in vitro, by 
combining the use of a non-specific mutagen with the natural variability exhibited by 
enteroviruses, would generate key mutations resulting in a virus receptor-usage shift. 
Selection of mutagen-treated virus populations, by conducting serial passages on a variety 
of cell lines, could enable the isolation of specific tissue-tropic viruses. The potential 
outcome of such experiments could be the selection of a population of enteroviruses that 
have evolved to use an alternative receptor or the selection of a population of 
non-poliovirus enteroviruses that use the PVR. 
To investigate this, a closely related human enterovirus species C to poliovirus was used as 
a HEV representative for this experiment. CVA21 is a REV-C closely related to PV3 with 
an amino acid sequence identity of 84.2%. CVA21 and PV3 have evolved from a common 
ancestor to use different virus receptors. The aim of this experiment was to try and select 
for mutated CVA21 virus populations that bind the PVR. However, divergence from the 
common ancestor is an ancient event and it is possible that CVA21 is too genetically 
distant from poliovirus to be able to evolve to use the PVR (see figure 2.6). However, there 
are similarities in virus-receptor interaction of both viruses, as they both interact with 
Ig-like receptor molecules via a canyon interface. It is therefore possible that CVA21 could 
evolve to use the PVR as opposed to the ICAM-1 cell surface molecule. Can CVA2 1, a 
well-characterised HEV-C, undergo a shift in receptor usage in the presence of ribavirin? 
Can CVA21 evolve to use PVR? Such findings would be crucial information for the WHO 
poliomyelitis eradication program and would contribute to our understanding of virus 
evolution and the evolution of receptor tropism. 
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Figure 2.6: Compared evolution of CNA21 and P\'3 
evolution from 
common ancestor 
Figure illustrating different possible outcome of the designed strategy: switch 
from ICAM-1 usage to PVR-usage, switch to non-PVR alternate receptor-usage 
and death of mutated virus population due to introduction of fatal errors or 
mutations that do not allow alternate recptor usage. The switch from ICAM-1 
usage to PVR-usage could occur, however it is also possible that the shift in 
receptor requires too great a genetic shift. Discussed section 2.2. chapter 2. 
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2.2.1 Experimental model 
Initial titration of ribavirin was carried out to determine a concentration that would lead to 
the introduction of a number of mutations whilst retaining significant fitness levels of a 
CVA21 viral population. Once determined, CVA21 infection of a permissive cell line was 
conducted in the presence of ribavirin. RD cells (rhabdomysarcoma cells) express both 
PVR and DAF molecules on their cell surface and fully support replication of 
enteroviruses. RD-ICAM cells are RD cells engineered to express the ICAM-1 receptor for 
CVA21 attachment and entry and were used for the rounds of CVA21 infection in the 
presence of ribavirin. The resulting mutated progeny viral population would then be 
submitted to selection by passage on a variety of cell lines: RD cells, L20B cells and L 
cells (see figure 2.7). RD cells would allow for selection of DAF or PVR-tropic viruses. L 
cells, a murine fibroblast cell line, lack any identified human enterovirus receptors but are 
fully permissive for enterovirus replication and L20B cells are L cells expressing PVR 
(Wood & Hull, 1999). Compared analysis of selection experiments carried out in L cells 
and L20B cells would be the most restrictive strategy. Mutated enterovirus populations 
growing on L20B cells but not L cells would be PVR-tropic. This could lead to the first in 
vitro report of an enterovirus that had evolved to use PVR. 
2.3 Results and Discussion 
2.3.1 Effect of ribavirin on CVA21 yields and determination of 
concentration to use for experimental system 
The introduction of 6-9 mutations per poliovirus genome resulted in a 95% reduction in 
fitness of the viral populations (Crotty et al., 2001). The effect of a range of ribavirin 
concentrations on CVA21 was not expected to differ greatly from those observed with 
poliovirus, due to the similarity of the virus, the replication cycle and the similarity of 
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Figure 2.7: Selection of noel tropic viruses: infection of CNA21 in the presence of 
ribavirin (a random mutagen). 
FIow chart representing a diagram of the experimental procedures. Rn indicates passage in 
the presence of ribavirin. where n is the passage number, and rn indicates passage in the 
absence of ribavirin. where n is the passage number. 
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growth of the viruses in vitro. Only concentrations spanning the upper limits of ribavirin 
concentrations used by Andino and co-workers were tested during PV3 and CVA21 viral 
infections were used in this assay. 
Pre-treatment with ribavirin concentrations ranging from 0.5 mM to 6 mM was carried out 
and repeated four times. Pre-treatment with the mutagen would be expected to cause a 
reduction in intracellular levels of GTP and an increase in the levels of RTP incorporated 
in viral genomes (Muller et al., 1977; Streeter et al., 1973), as a GTP analog. Cells were 
then infected with CVA21 or PV3 viruses at an MOI of 1. CVA21 and PV3 infections of 
untreated cells in the presence and absence of a virus replication inhibitor GuHCI were 
conducted to check that the observed CPE were virally induced. Mock infections in the 
presence of ribavirin, to monitor the effect the mutagen exerted on cells, were carried out 
in parallel. The samples were incubated until full CPE was observed, progeny virus was 
harvested and the titre determined by TCID50 assay (Figure 2.8). 
An initial sharp decrease in viral titre followed by a drop in the rate of decrease of viral 
yields in the presence of increasing concentrations of ribavirin was observed. The CPE 
exhibited by PV3 infection of ribavirin pre-treated RD-ICAM cells and the effect of 
ribavirin on virus titres was similar to those previously observed (Crotty et al., 2000). 
Unlike PV3, CVA21 did not show as strong a decrease in titre at lower concentrations of 
ribavirin. A 1-log titre reduction of CVA21 was observed in the presence of 1mM 
ribavirin, a 2-log decrease was observed when CVA21 was treated with 3mM ribavirin and 
a 4-log decrease was seen in the presence of 6mM of the mutagen. With such a significant 
decrease the overall fitness of the mutated viral populations was expected to be too low 
due to an excessive number of mutations being introduced and the volume handled in the 
assay would need to be too high. 1 mM of ribavirin was the chosen concentration for the 
following assays, as a sufficient decrease in CVA21 virus titres (1-log) was achieved and a 
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Figure 2.8: Titration of CVA21 and PV3 in the presence of increasing 
concentrations of ribavirin, a nucleoside analog. 
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TCID50 assays of PV3 and CVA21 virus grown in the presence of a range of 
ribavirin concentrations were carried out four times. Plates were fixed and stained. 
Titres were calculated and plotted using a log scale. The 4 repeats of the assay 
exhibited similar results. Standard deviation values were calculated and are 
represented as error bars on the graph. 10mM ribavirin concentrations exerted a 
cytotoxic effect on mock infected cells and was therefore not used in the experiment. 
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significant number of mutations were expected to have been introduced. None of the 
ribavirin concentrations used (with the exception of the 10mM samples), had a cytotoxic 
effect on the cells. This basic titration assay did not enable any direct comparison with the 
data observed in the Crotty papers, as it did not analyse the effect of ribavirin on different 
stages of the virus life cycle. 
To detect the introduction of mutations in the genomes of a population of progeny viruses, 
vRNA was extracted from harvested viruses grown in the presence of 0.5 mM, 0.75 mm (a 
concentration not tested in the previous assay), 1 mM, 3 mM and 6 mM ribavirin. Reverse 
transcription reactions were carried out using the extracted vRNA as a template. The VP 1 
coding region of CVA21 was amplified by PCR (using CVA21 specific oligonucleotide 
primers) and sequenced. The results are shown in figure 2.9. No product could be 
amplified and sequenced from the samples of the virus grown in the presence of 3mM and 
6mM ribavirin. Mutations of the primer binding sites or poor sensitivity of the PCR 
reaction could both be responsible for this phenomenon. A window of the CVA21 
VP 1-coding region of the virus samples grown in the presence of 0.5 mM, 0.75 mM and 
1 mM ribavirin was amplified by PCR and sequenced. The results are shown in figure 2.9. 
The sequencing results show that within a 1778-bp window two C to T coding changes, 
reflecting C to U substitutions in the original viral sequence, that were absent from the 
original CVA21 viral sequence, were introduced when the virus was grown in the presence 
of 1 mM ribavirin and no third-base changes were seen. No changes were detected in the 
sequences of the 0.5mM and 0.75mM ribavirin samples. Amplification reactions were 
carried out from a population of DNA molecules since the fragments were not cloned 
therefore the mutations seen are likely to have been fixed at early stages of the replication 
cycle and calculation of mutation rates would therefore be inaccurate. 
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Figure 2.9: Sequencing analysis of input CV%21 virus and CN A21 virus sequences 
passaged in the presence of 0.5mNI, 0.75m11 and 1.0mM1 ribavirin. 
The RNA of the various samples was extracted using a QlAamp® Viral RNA mini kit, 
%RNA as reverse transcribed and newly synthesised cDNA was amplified by PCR using 
CVA21 Pl specific oligonucleotide primers (CVA21-F0, CVA2I-R11). The PCR products 
were purified and sent for sequencing. Here the two nucleotide changes, both from C to T, 
due to the presence of ribavirin are illustrated and cause two coding amino acid changes. 
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It is unclear how many mutations are needed for a receptor shift to happen. However, it has 
recently been suggested that minimal changes in viral genomes could lead to a shift in 
receptor usage (Baranowski et al., 2001). There are 27 amino acids involved in the 
interface interaction between poliovirus and the PVR, 19 of which differ between PV3 and 
CVA21. A normal poliovirus has a mutation frequency of 1.5 mutations per genome or 1 
mutation per 5000 nucleotides. To have 19 amino acid changes, assuming that a single 
nucleotide change is sufficient to lead to an amino acid change, every virus would have a1 
in (5x103)19 or 2x1070 chance to mutate the correct 19 nucleotides. Even with a mutation 
rate of 1 mutation per 600 nucleotides, increase induced by treatment with a mutagen such 
as ribavirin, every virus would have a1 in (6x102)19 or 6x1052 chance to mutate the correct 
19 nucleotides and therefore amino acids for a shift in receptor usage. However, it is likely 
that more than one nucleotide change is required for an amino acid change and the chance 
of getting all 19 amino acid mutations would therefore be expected to be even lower. This 
describes the worst-case scenario whereby all 19 amino acids involved in the interface that 
differ between CVA21 and PV3 would need to be changed for a switch in the receptor 
usage of CVA21 to occur. 
However, due to the nature of the interaction of the canyon with the virus receptor, the 
importance of all amino acids involved in the interaction between a virus particle and a 
receptor molecule is not equal. For example, only 3 amino acids out of the 30 
residue-interface contribute 80% of the total energy of the interaction between EV7 and 
DAF (Bhella 2004). Similarly, Akio Nomoto's group suggested that only 3 amino acids are 
key to the interaction between PV 1 and the PVR (Arita et al., 1998). A single amino acid 
change has been shown to alter Echovirus type-6 receptor usage (unpublished data by 
David Williams). So it is very likely that significantly fewer amino acids than all 19 of 
those that differ between PV3 and CVA21, involved in the interaction, would need to be 
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changed for the virus to use a different cell surface molecule as a receptor for attachment 
and entry. If three amino acids need to be changed for the receptor swap to occur at a 
mutation rate of 1 in 5x103 then a population of (5x103)3 or 1.25x1011 would have to be 
screened, a more reasonable and manageable number. In fact in a hypothetical case where 
the mutation rate was increased to 1 mutation in 600 nucleotides the minimum population 
screened would have to be (6x102)3 or 2.1x108 viruses. A smaller number of mutations 
than that required for CVA21 adaptation to use the PVR could be required for CVA21 to 
adapt to use DAF, heparan sulphate or other enterovirus receptor molecules. The use of a 
random mutagen to accelerate evolution and select for a human enterovirus type C that has 
evolved to use an alternate receptor, and more specifically the PVR, is a feasible 
experiment, due to the small number of mutations actually required for a receptor shift to 
occur and due to the possible handling of large population sizes in small volumes. 
2.3.2 Determination of optimal concentration of ribavirin 
The assays carried out in this chapter do not enable the determination of the optimal 
ribavirin concentration to attain the correct equilibrium of introducing enough mutations 
and maintaining sufficient fitness of the mutated viral populations. Sequencing of 
independent clones from PCR reactions at each concentration and overlaying graphs 
plotting the number of mutations introduced versus ribavirin concentrations and the viral 
titre drop versus ribavirin concentrations (see figure 2.10) could be carried out. There is 
likely to be a balance between the number of mutations introduced and the decrease in 
viral titres. It would therefore be possible to determine the optimal ribavirin concentration 
needed to introduce a maximal number of mutations in a virus population without shifting 
to error catastrophe. 
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Figure 2.10: Graph of a hypothetical determination of optimal ribavirin 
concentration to use for the selection of novel tropic mutant viruses experiment. 
The optimal concentration is determined based on the amount of ribavirin needed to 
cause a signficant number of mutations whilst retaining the ability to replicate and 
produce progeny viruses. In this hypothetical situation the optimal concentration to use, 
shown by the red arrow, would be that causing a 2-log reduction in titre whilst 
introducing 2.5 mutations per genome. Such an assay needs to be carried out and the 
experiment needs to be repeated using the determined optimal ribavirin concentration. 
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2.3.3 Results and discussion of the selection experiment 
RD-ICAM cells, pre-treated with 1mM ribavirin, were infected with CVA21 at an MOI of 
1. Each sample was harvested and passaged onto fresh pre-seeded RD-ICAM cells. Four 
subsequent serial passages or rounds of selection were carried out using the same 
pre-incubation, infection and incubation stages in the presence of ribavirin, in which 1 ml 
out of 5mls were transferred. The first round of selection was named r1 (samples incubated 
in the absence of the mutagen) or R1 (for the samples incubated in the presence of 1 mM 
ribavirin), the second round r2 or R2 and so on (see figure 2.7). The samples were then 
screened on various cell lines. The selection strategy applied would allow a population of 
mutated viruses to evolve to use other receptors such as heparan sulphate, DAF alone, 
murine DAF or PVR, by comparison of infection of L cells and L20B cells. Each sample 
from each round of selection was tested on each cell line and serially passaged on the 
respective cell lines in order to enable potential infection and amplification of less fit novel 
tropic mutant CVA21 populations. The results are shown in table 2.11. The assay was 
repeated four times. On no occasion were novel tropic mutant viruses detected and isolated 
from the reactions. 
Claire Blanchard Selection of novel tropic viruses using, a mutagen Chapter 2 57 
Cell line infected 
Test samples RD-ICAM RD L L20B 
CVA21 r'   MI Q Q 
CVA21 R'   Q Q 
Cells R' Q Q Q Q 
CVA21 r2   Q Q 
CVA21 R   L Q Q 
cells R` c Q Q Q 
CVA21 r3   Q Q 
CVA21 R3   M Q Q 
cells + R3 Q Q Q 
CVA21 r4   Q Q 
CVA21 R4   Q Q 
cells R4 Q Q Q Q 
CVA21 r'  a Q Q 
CVA21 R'  a Q Q 
cells R' Q Q Q Q 
Table 2.11: Results of screening of samples of CVA21 serially selected in the presence 
of ribavirin. The read-out of the experiment was the presence ( ) or absence (E) of 
('PE observed in the transfected cell sheet.:, represent very low levels of CPE 
observed on the infected cell sheet (-20% CPE). 
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Ribavirin did not have a cytotoxic effect on any of the cell lines and serial passaging in the 
presence of the mutagen did not affect the readout of the experiment. No CPE was 
observed in L cells or L20B cells implying that CVA21 had not evolved to use murine 
fibroblast cell surface molecules or the PVR. As expected RD-ICAM cells always 
exhibited CPE in the passaged virus samples tested, but not in the absence of the virus. The 
ribavirin-independent result in RD cells was however intriguing. CVA21 virus alone and 
CVA21 virus incubated in the presence of 1 mM ribavirin caused low levels of CPE in RD 
cells. This outcome could be due to a positive selection for a subpopulation of virus that is 
able to grow. However the CPE levels were not amplified after several passages in the cell 
line indicating that low CPE due to a positive selection is unlikely. Possible contaminations 
of either the CVA21 virus stocks with RD-tropic virus or the RD cells with low levels of 
RD-ICAM or another cell line permissive for CVA21 growth were checked and different 
virus stocks were tested on different batches of RD cells. No contamination was detected. 
A likely explanation for the limited CPE observed in RD cells could be that CVA21 is able 
to use DAF as a cell surface receptor (Shafren et al., 1997; Johansson et al., 2004). 
Although the strain of CVA21 used for the experiment was not adapted to grow in RD 
cells, the limited CPE observed in the assay could be due to the fact that in the absence of 
ICAM-1 cell surface molecules CVA21 is able to attach DAF to some extent and actually 
cause some CPE. 
Under the conditions tested, the selection for novel tropic viruses was not successful, 
however the use of different parameters could potentially allow for the selection of such 
viruses. Several factors, such as the ribavirin concentration, the incubation time, the cell 
type chosen and the pre-incubation stage, might have biased the experiment. Reducing the 
pre-incubation time could mean that the intracellular levels of GTP were still significant. 
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Intracellular GTP could therefore have been used during virus replication as opposed to 
RTP, leading to the generation of wild-type virus sequences and the absence of mutations. 
It would be interesting to repeat the experiment with a longer pre-incubation period so that 
a better environment for the introduction of mutations may be created. 
A ribavirin concentration of 1mM caused a 1-log reduction in CVA21 viral titres which, 
combined with the long incubation stage after infection of RD-ICAM cells, could have 
affected the outcome of the experiment. Indeed the risk of carrying out a long incubation is 
that of allowing fitter viruses, like wild-type viruses, to outgrow novel tropic mutants of 
lesser fitness. High mutation rates could lead to the introduction of lethal mutations 
affecting essential protein coding sequences and the overall RNA structure. Using random 
mutagenesis as a selection method combined with high mutation rates increases the risk of 
lethal mutagenesis. If random mutations are introduced at a high rate the probability of 
affecting a key sequence is increased and the mutated virus is less likely to be able to 
survive and outgrow wild-type viruses during the first round of infection in RD-ICAM 
cells in the presence of ribavirin. Multiple nucleotide changes may disrupt the overall RNA 
structure and therefore seriously impair downstream events that are dependent on such a 
structure. By attempting to speed up evolution there is a risk of reaching extinction without 
going through the various transitional stages. RNA viruses such as CVA21 and PV3 
already exist on the brink of error catastrophe and random mutagenesis might have 
destroyed a fine equilibrium and might have accelerated extinction. However, the 
experiment provides no evidence for error catastrophe in the studied virus populations, as 
virus titres were still significant (3.6 x 104 TCID50/ml, data not shown) after multiple 
passages of CVA21 in the presence of 1 mM ribavirin. 
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2.3.4 Future work 
Some variables of the described experiment could be altered. Indeed, repeating the 
experiment using high multiplicity of infection coupled with rapid passages could 
potentially alter the outcome. Furthermore, determination of the optimal ribavirin 
concentration to use for the introduction of a sufficient number of mutations is essential. 
Moreover, a variety of alternative assays with a more stringent selection applied to a 
variety of reference viruses, could be designed. 
The selection for novel PVR-tropic viruses would potentially mean the loss of ICAM-1 
affinity by the emerging virus populations. One way to select for recombinants in vivo is to 
select against parental viruses using ICAM-1, by repeating the assay in the presence of 
both ribavirin and soluble ICAM-1. The samples would then be washed to get rid of 
ICAM-1 tropic viruses allowing for recovery and growth of non-ICAM-1 binding novel 
tropic recombinant viruses. Should novel tropic mutant viruses be selected for, 
characterisation of such viruses by assays such as antigenicity testing, specific infectivity 
assessment and nucleotide sequence analysis would be carried out. 
Due to time restrictions and progress on the generation of recombinants in vitro project it 
was not possible to carry out the described assays. 
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3 Chapter 3: In vitro recombination 
3.1 Introduction 
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Human enterovirus (HEV) evolution is a consequence of selective pressure, error rate and 
recombination. Recombination plays a major role in the emergence of viruses with novel 
sequences. Emerging recombinant enteroviruses have been a major concern for the WHO 
poliomyelitis eradication program and have been reported to occur both in the laboratory 
environment and in nature. The exact circumstances, processes and factors contributing to 
the emergence of such recombinant viruses are unclear. 
So far the circulating vaccine-derived polioviruses (cVDPVs), isolated from outbreak 
cases, were found to have a structural protein-coding region derived from a vaccine strain 
and the remainder of the genome from an unidentified virus strain from the same species as 
poliovirus (Stanway et al., 2000). This was the case of the cVDPVs isolated in Egypt 
(Yang et al., 2003) and the Philippines (WMMR, 2001). Recently, cVDPVs isolated from 
Haiti, Egypt, the Philippines and Madagascar seemed to have arisen from a recombination 
event between Sabin poliovirus strains and enteroviruses circulating in the gut of vaccinees 
at the time of vaccination (Kew et al., 2002; Rousset et al., 2003). These emerging 
cVDPVs (reviewed in Kew et al., 2004) highlight the importance recombination plays in 
enterovirus evolution. 
The initial aim of the project was to generate and study viruses with mosaic non-poliovirus 
HEV-C P1-coding sequence resulting from shuffling that may use the PVR, thereby 
mimicking evolution. The generation of viable viruses would require cis-processing of the 
polyprotein. However, the exact requirements for the processing of the P1-coding region 
by a heterologous 3CD protease to occur in trans were unclear. The cis-processing 
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requirements were therefore investigated prior to shuffling by constructing and analysing 
recombinants with a precise exchange of the P 1-coding region. These in vitro generated 
recombinants exhibited interesting phenotypes and further characterisation was conducted. 
3.1.1 Aims 
To attempt to provide a greater understanding of the different factors involved in the 
generation and infection of recombinant enteroviruses, chimeras between a poliovirus and 
a human enterovirus type C (HEV-C) were generated in vitro. The studies described in this 
chapter were designed to broaden the understanding of key factors and mechanisms and 
enable a better knowledge of processing requirements. 
It was proposed to generate recombinants with a precise exchange of the P1-coding region 
between a poliovirus and a non-poliovirus ITV-C, using basic molecular cloning 
techniques. The source of the genomes used for the experiments were selected on the 
availability of infectious clones. Poliovirus type 3 Leon (PV3), a neurovirulent poliovirus, 
was chosen as one of the wild-type viral sequences. Sabin poliovirus type 1 (Sabin 1), a 
vaccine poliovirus strain, was an additional parental genome used for the experiments 
(kindly provided by Dr A. Macadam, National Institute for Biological Standards and 
Control). 
As the non-poliovirus HEV-C, a genome closely related to that of poliovirus type 3 Leon 
was chosen. CVA21 exhibits 84.2% identity of the polyprotein with PV3 (Brown et al., 
2003). The amino acid identity deduced from nucleotide sequence relationships of a range 
of HEV-C viral proteins is illustrated in appendices 3,4 and 5 of this thesis. Other HEV-Cs 
are more closely related to PV3; for example CVA20 has 90.2% amino acid identity to 
PV3. However, CVA21 was the closest relative to PV3 for which an infectious clone was 
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available. Recombinants between Sabin 1 P1-coding region and the remainder of the 
CVA21 genome and PV3 P1 coding region and the remainder of the CVA21 genome 
were generated for subsequent investigation. Reciprocal recombinants between the 
structural coding region of CVA21 and the remainder of the PV3 genome were also 
constructed. 
3.2 In vitro generation of recombinants 
3.2.1 Construction of recombinant plasmid DNA 
The recombinant sequences were generated so as to have reciprocal precise exchanges of 
heterologous P 1-coding regions without modifying the backbone sequences. The 
phenylalanine/glycine (F/G in the case of CVA21) and tyrosine/glycine (Y/G in the case of 
PV3 and Sabin 1) amino acid sequences at the VP 1/2A junctions, essential for correct 
processing to occur, were retained (Luke et al., 2001). This would therefore create a perfect 
exchange of the P1-coding region. 
3.2.1.1 Generation of backbone cassette vectors 
CVA21 and PV3 backbone vectors lacking the P1-coding regions were constructed. The 
first 14 amino acids of VP4 are identical in human enteroviruses. Synonymous codon 
variation was used to maintain, in the case of PV3, or introduce, in the case of CVA2 1, a 
Sac I cloning site at the start of the P1-coding region for the construction of backbone 
vectors. 
Synonymous codons were also used to maintain the native amino acid sequence at the start 
of the 2A-coding region of the backbone vectors. PV3 and CVA21 2A-coding regions start 
with respective GGC and GGG codons encoding a glycine (G). A Sma I site was created 
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by PCR in the PV3 backbone vector, where the second half of the site (GGG) replaced the 
original GGC sequence thereby maintaining the amino acid at the start of the PV3 2A. 
Similarly a Nae I site was introduced by PCR in the CVA21 backbone vector. The second 
half of the Nae I site has a GGC sequence coding for a glycine and again enabled 
conservation of the glycine present at the start of the native CVA21 2A. 
3.2.1.1.1 PV3 backbone vector (PV3BK) 
The PV3 backbone vector was derived from pT7FLC/REP3 (Barclay et al., 1998), using 
GEN-3'BK'F and GEN-3'BK-R oligonucleotide primers and the Nsi I restriction 
endonuclease. The PV3 backbone vector cloning strategy is illustrated figure 3.1. 
3.2.1.1.2 CVA21 backbone vector (CVA21BK) 
The CVA21 backbone vector was derived from pRibo-CAV21-NaelDel (David Williams). 
A 5' fragment of the 5'UTR and start of the coding-region was amplified by PCR using 
T7-F forward primer and CA21-5'-BK-R Sac I-containing reverse primer. The 5' PCR 
fragment was ligated to a Sac I digested 3' fragment, amplified by PCR, using 
GEN-3'BK-F-Nae (a Sac I and Nae I- containing primer) and GEN-3'BK-R (reverse 
primer annealing the 3C coding-region). A 3.9kb ligated fragment was re-amplified by 
PCR using T7-F and GEN-3'BK-R. The Mlu I and Bgl II double-digested PCR fragment 
was then ligated to a Mlu I and Bgl II double-digested pRibo-CAV21-NaelDel. The 
CVA21 backbone vector cloning strategy is illustrated figure 3.2. The clones were checked 
by RFLP analysis and sequencing of the ligation junctions. 
Once the backbone vectors were constructed, P1-coding regions were introduced to 
generate recombinants. The complete P1 sequences were generated by PCR using forward 
oligonucleotide primers, containing a Sac I site, and virus-specific blunt ended reverse 
oligonucleotide primers. 
Sac 1 (752) 
Bcpn HI (674) Bgl II (1528) Bgl II (3171) . '4si I (3270) Bgl 11 (4415) 
`--_ - 
T7 promoter =* 
5'UTR 3'll"1R 
GEN-3'BK'F 
pT7FLC/REP3 
5700 bp 
313 
(3FN-3'13K-R 
GEN-3'BK'F 
--i Bgl 11 (1528) Bgl 11 (3171) a'si 1 (3270) 
I- 
3B GFN-3'Bh-R 
PCR product derived from p"T7F!. ('/RH: P3 
Sac I (752) Sma I (762) 
Bam HI (674) X Bgl II (806) 
Bgl 11 (2449) Xsi 1 (2548) Bgl 11 13693) 
T7 promoter 
5'UTR 
ACCACT 
GTGGTG 
3B 
Sac 1 (752) Sma 1 (762 ) 
pT7FLC/RH; P3-BK 
4851 bp 
Figure 3.1: The construction of pT7FLC/REP3-BK (henceforth 
referred to as PV3BK). 
3'[JTR 
CA2I-5'-13K-R GEN-3'BK-F-Nae GEN-3'BK-R 
. 
ttlu 1 (276) Bam HI (776) Bgl II (5089)/ 
T7-F 
T'7 ....,. «.. ýf o. 1/ ýIVIIIVIGI 
' ý UTR $@E*M>uo 2B 
VP4 
FkCCACAGCCGGaTT 
3'UTR 
T7-F Sac I (72 1) GEN-3'BK-F-Nae Bgl II (5089) 
-4 -º 
4 
CA2I-5'-BK-R Sac I (3350)Nae I (3360) GEN-3'BK-R 
784 bp 2378 bp 
17-F Nae I (73 1) Bgl II (2471) 
ý 
I 
H 
. 
tllu I (2 76) Suc I (721) GEN-3'BK-R 
3946 bp 
PCR products generated for construction of pRibo-CAV21- 
NaeDel-BK derived from pRibo-CAV21-NaeDel 
Sac 1(721) Nae1(731) Bgl11(2471) 
T7 promoter 
5'UTR 2B 3A 3B 3'UTR 
GAGCTC 
CTCGAG Il'GGTGT 
3A 3B 
pRibo-CAV21-NaelDel 
7426 bp 
Sac 1(721) NäeI(731) 
pRibo-CAV21-NaeDel-BR 
4891 bp 
Figure 3.2: The construction of pRibo-CAV21-NaeDel-BK (henceforth 
referred to as CVA21 BK). 
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3.2.1.2 Generation of homologous P1 recombinants 
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First the backbone vectors had to be checked to ensure that they were competent to make 
viable vectors. The PV3 P1-coding region and the CVA21 P1-coding region were 
respectively introduced into the PV3 backbone vector (PV3BK) and the CVA21 backbone 
vector (CVA2IBK), thereby re-creating full-length sequences of the source genomes 
(figures 3.3 and 3.4). The clones were sequenced at the key junctions. The expected 
non-coding changes, introduced by PCR, were present thereby excluding the possible 
presence of contaminant wild-type sequences. When transfected into RD-ICAM cells, the 
homologous recombinants caused a cytopathic effect (CPE) and were therefore assumed to 
be viable. Subsequent cloning of heterologous recombinants was then carried out. 
3.2.1.3 Generation of heterologous P1 recombinants 
The cloning strategies for individual clones are illustrated in figure 3.5,3.6 and 3.7. 
Sac I-digested blunt-ended P1-coding regions amplified by PCR were introduced to 
respective Sac I and Sma I double-digested PV3 backbone vector and Sac I and Nae I 
double-digested CVA21 backbone vector. The same strategy was applied to all the clones. 
The P1-coding region PCR products were derived from pT7/SL3, pRiboCAV21 and pS1F 
using a generic forward primer (P1-GEN-F) and specific blunt-ended reverse primers 
(PV3-P1-R, CVA21-PI-R and Sabin 1-P1-R). The remainder of the genome was derived 
from PV3BK and CVA21BK. The clones were checked by RFLP analysis and sequencing 
of the 5'UTR/P1, complete PI and VP1/2A coding regions (see table 3.8.2 and figure 3.9). 
The CVA2IBK based clones were constructed in practical collaboration with David 
Williams. 
Sac I (752) Sma I (762) 
Bam 111 (674) Bgl 11 (806) 
Bgi 11 (2449) N'si 1 (2548) Bgl II (3693 ) 
T7 promoter 
5'UTR 3B 
_=. __.. 
ýýýýG: ý 
ý. ýý_`: ýýýý`ý 
. Sac 1 17 
ý_' 1 Sma 1 (762) 
PN'3 BK 
4851 bp 
3'UTR 
TTTGACCACATAT 
AAACTGGTGTATA P1-GEN-F 
Sac 1 (752) Sac 1 (1900) 
VP-1 ~ 
2648 bp PV3-P 1-R 
ATvv: y -TCAAG 
TriC -- -- 
7 ýýy: T7C 
P('R amplification of the pT7/SL3 P1 coding region 
Bair 11 1 (674) Bam 111 (887) Bg111 (3421) 
Sac I (75_') Sac 1 (1900) 
T7 promoter 
S'l'"IR VP4 
GAGCTCAAG 
CTCGAGTTC 
TTTGACCACATATGGG 
AAACTGGTGTATACCC 
pT7FLC/REP3-BtiSL3P1 
7466 bp 
Bgl II (5064) 
3B 
Bgl 11 (6308) 
3'UTR 
Figure 3.3: The construction of pT7FLC/REP3-BISL3P1 (henceforth 
referred to as PV'3BkPN'3PI). 
Sac I (721) Nae I (73 1) Bgl II (2471) 
, -- /i 
T7 promoter 
r-_ _- 
5'UTR 
Sac 1(721) 
2B 3A 3B 
CCAC GCCGG T CAV21BK 
GGTG CGGCC A 4891 bp 
NäeI(73I) 
P 1-GEN-F 
Sac 1 (752) Bam HI (807) 
ACCACTTTT 
TGGTGAAAA 
Vp4 CVA21-P1-R 
2637 bp 
ATGGGAGCTCAAG 
TACCCTCGAGTTC 
T7 promoter 
Bam HI(776) 
5'UTR VP4 
ACCACTTTT GGCTTTGGC 
TGGTGAAAA CCGAAACCG 
PCR amplified CVA21 P1-coding region 
derived from pRiboCAV21 
pRibo-CAV21-NaeDel-BKCVA21P1 
7440 bp 
Bgl 11 (5089) 
3B 
3'UTR 
3'UTR 
Figure 3.4: The construction of pRibo-CAV21-NaeDel-BKCVA21P1 (henceforth 
referred to as ('VA21 BKCVA21 P1). 
Sac I (752) Sma I (762) 
Bam HI (674) Bgl II (806) 
ýý %" Bgl 11 (2449) Nsi 1 (2548) Bgl 11 (3693) 
3' UTR 
GAGCT 
CTCGA 
CACCAC 
GTGGTG 
CCCGGG 
GGGCCC 
PV3BK 
4851 bp 
SacI(752) Sma 1 (762) 
ACCACTTTT 
TGGTGAAAA Pl -GEN-F 
Sac 1 (752) Bam HI (807) 
ATGGGAGCTCAAG 
TACCCTCGAGTTC 
Bam HI (674) Bam HI (807) 
VP4 CVA21-P 1-R 
2637 bp 
PCR amplified CVA21 P1-coding region 
derived from pRiboCAV21 
Sac 1 (752) Bgl 11 (3424) Bgl 11 (5067) Bgl 11 (6311) 
h' K 
-' 
ßý -äL 1--. L 
,, 
rr ir -r, 1-r 
T7 promoter 
SUTR 3B 3'UTR 
ACCACTTTTGGGTTTGGGCAC 
TGGTGAAAACCCAAACCCGTG 
pT7FLC/REP3-BK-CA21-P1 
7469 bp 
Figure 3.5: The construction of pT7FLC/REP3-BK-CA21-P1 (henceforth 
referred to as PV'3BKCV'A21PI). 
Sac 1 (721) 1Vae 1 (731) Bgl 11 (2471) 
\ ý' 
T7 promoter 
5'UTR 
Sac 1(721) 
2B 3A 3B 
CCACA CCGG T CVA21BK 
GGTGT GGCC 4891 bp 
Aäe 1 (731) 
Pl -GEN-F 
-4 
Bam HI (1358) Bam HI (1388) 
VP4 
ATGGGAGCTCAGGTTT 
TACCCTCGAGTCCAAA 
GACCACATAT GGCTTCGG 
CTGGTGTATA CCGAAGCC 
Sac 1 (721) 
PCR amplified Sabin 1 P1-coding region derived from PSIF 
Sac1 (721) 
Bain HI (2069) Bam HI (2089) Bgl II (5095) 
L 
T7 promoter 
5'UTR 
Sabin 1-P1-R 
GACCACATAT 
CTGGTGTATA 
3'UTR 
2147 bp 
3B 3'UTR 
pRibo-CAN'21-NaeDel-BKSabinlPl 
7506 bp 
Figure 3.6: The construction of pRibo-CAV21-NaeDel-BKSabin1P1 (henceforth 
referred to as CV A21BKSAbin1PI). 
Sac 1 (721) Nae 1 (73 1) Bgl II (2471) 
\... /: , 
T7 promoter 
5'UTR 
Sac 1 (72 1) 
2B 3A 3B 
CCACPIGCCGGCrT CVA2IBK 
GGTGjCGGCCGýA 4891 bp 
A'ae 1 (73 1) 
TTTGACCACATAT 
AAACTGGTGTATA 
Sac 1 (752) Sac I (1900) 
P 1-GEN-F 
-4 
rnA f-. 
V Y4 
ATGGGAGCTCAAG 
TACCCTCGAGTTC 
PV3-PI-R 
2648 bp 
PCR amplification of the pT7/SL3 P1 coding region 
Sac I (721) Sac I (1869) 
Bam HI (856) Bgl 11 (5086) 
3'UTR 
MMI 0- IFF 
T7 promoter 
5'UTR 3B 3'UTR 
ACCACATAT GGCTTCGG 
TGGTGTATA CCGAAGCC 
pRi bo-CAV21-NaeDel-BKSL3P 1 
7506 bp 
Figure 3.7: The construction of pRibo-CAV21-NaeDel-BKSL3PI (henceforth 
referred to as CVA2IBKPV3PI). 
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The in vitro generated recombinants were named in two parts. The second part of the name 
corresponded to the origin of the P 1-coding region and the first part of the name 
corresponded to the source of the remainder of the genome (see table 3.8.1). 
Name of the plasmid as indicated in the 
laboratory database 
Henceforth simplified name of the 
plasmids 
pT7FLC/REP3-BK PV3BK 
pRiboCAV21-NaeDel-BK CVA21BK 
pT7FLC/REP3-BKSL3P1 PV3BKPV3P1 
pRibo-CAV21-NaeDel-BKCVA21 P1 CVA21 BKCVA21 P1 
pT7FLC/REP3-BK-CA21-P 1 PV3BKCVA21 1 
pRibo-CAV21-NaeDel-BKSabinlP1 CVA21BKSabinlP1 
pRibo-CAV21-NaeDel-BKSL3P1 CVA21BKPV3P1 
Table 3.8.1: Names of constructed plasmids 
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Digested plasmid DNA Bam HI (sizes in bp) Bgl H (sizes in bp) 
pT7FLC/PV3 10996 8241 
133 1643 
1244 
PV3BK 8513 5626 
1643 
1244 
PV3BKCVA21P1 10998 8244 
133 1643 
1244 
pRiboCAV21 10429 10429 
CVA21BKCVA21P1 10429 10429 
CVA21 BKPV3P 1 10426 10426 
CVA21BKSabinlPl 10405 10435 
30 
pS1F 5721 10101 
2471 
1879 
30 
Table 3.8.2: Predicted RFLP analysis of the in vitro generated P1 recombinants. The 
fragments expected from the restriction digests reactions are in base pairs (see figure 
3.9 for actual result). 
The RFLP analysis data indicated that the clones constructed were correct. The key 
junctions 5'UTR/P1-coding region and the VP1/2A-coding regions of the constructed 
clones were checked by sequencing. The cDNA sequence of the entire P 1-coding region of 
the CVA21BKSabin1P1 61-9, CVA21BKPV3P1 c6 and PV3BKCVA21P1 3 clones were 
also determined and shown to be correct (data not shown). The clones were amplified, 
purified from bacterial cultures and stored in the laboratory communal stocks. Subsequent 
analyses were then initiated. 
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Figure 3.9: Restriction length polymorphism analysis of in vitro generated 
Pl recombinants and controls. 
Recombinants and controls plasmid DNA was digested with Bgl 11 (A) and 
Bam HI (B) and run on a I% agarose gel. 
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3.3 Phenotypic analysis of in vitro generated recombinants 
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Phenotypic analysis of in vitro generated recombinants was carried out by transfection of 
T7 RNA transcripts derived from linearised plasmid DNAs in both RD-ICAM cells and 
HeLa cells, and the samples were screened for the presence or absence of cytopathic effect. 
3.3.1 Transfection of Pl recombinants 
Transfection of the chimeras was carried out in a Containment Level 3 laboratory (CL3). 
Recombinants with enhanced pathogenicity or altered tropism could be generated and 
higher safety levels should be applied when handling the potential viruses resulting from 
the reaction. The CL3 rules prevented transfected cells from being imported. All 
transfections were therefore carried out in a CL3 laboratory and were conducted so as to 
avoid the production of aerosols. 
T7 RNA transcripts were derived from linearised plasmid DNA, purified, quantified by 
spectrophotometric analysis and normalised. Either 1 µg or 5 gg of RNA were transfected, 
by DEAE-dextran or Lipofectamine 2000, into RD-ICAM cells and HeLa cells. RD-ICAM 
cells and HeLa cells support infection and replication of both parental viruses and should 
therefore be permissive for infection with potential chimeric viruses. The transfection 
samples were incubated at 37°C with 5% CO2 for 3-5 days to allow for any recombinant 
viral genomes of lesser fitness to recover and be amplified by repeated replication/infection 
cycles. Cells were examined by light microscopy to observe a cytopathic effect. The results 
are shown in table 3.10. No photographic evidence was provided due to the equipment 
restrictions and difficulty of removing material from the CL3 environment. 
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Input T7 RNA transcripts Cytopathic effect monitoring 
RD-ICAM cells HeLa cells 
CVA21 0 N 
PV3 E 0 
pS1F (Sabin 1) 
PV3BK 
0 
Q 
0 
Q 
PV3BKPV3P1 
PV3BKCVA21P1 1 
N 
Q 
0 
Q 
PV3BKCVA21P1 3 
PV3BKCVA21P1 4 
CVA21BK 
Q 
Q 
Q 
Q 
Q 
Q 
CVA21 BKCVA21 P1 0 N 
CVA21BKPV3P1 c6 Q Q 
CVA21 BKSabin1P 1 61-5 Q Q 
CVA21BKSabin1P1 61-9 Q Q 
CVA21BKSabin1P1 66-6 Q Q 
CVA21BKSabinIP 1 66-8 Q Q 
CVA21BKSabin1P1 69-1 Q Q 
CVA21BKSabin1P1 69-3 Q Q 
PV3 linearised in 3D Q Q 
Mock transfection Q Q 
Cells alone Q Q 
Table 3.10: Cytopathic readout of transfection of chimeric T7 RNA transcripts into 
RD-ICAM cells and HeLa cells. The read-out of the experiment was the presence ( ) 
or absence (o) of cytopathic effect observed in the transfected cell sheet. The numbers 
after each plasmid name represent individual clone numbers resulting from the 
cloning reaction. 
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As expected, control transfections of PV3, CVA21 and Sabin 1 RNAs caused CPE in cells 
after both transfection and serial passage. Similarly CPE was observed in the cells 
transfected with PV3BKPV3P1 and CVA21BKCVA21P1 RNAs. It was concluded that the 
experimental system allowed virus recovery following transfection and that the vectors 
could be used as a basis to create viable recombinants. These were consistent with the 
results previously seen. 
A number of heterologous P1 recombinant clones were prepared and analysed. These were 
based on CVA21BK and PV3BK, suffixed with clone numbers, and were expected to 
behave in a similar manner. RD-ICAM cells transfected with each of the heterologous P1 
recombinant clones RNAs exhibited very low levels. of CPE. However, serial passage of 
the samples did not appear to increase CPE and it appeared as though viruses could not be 
amplified. The initial low levels of CPE observed were likely to have been induced by the 
production and activity of 2A protease, a cytotoxic viral protein. The assay was repeated 
on several occasions and the same results were obtained. In addition, the same 
observations were made from transfections carried out in HeLa cells indicating that the 
observed results were not cell specific and were reproducible in other cell lines. The 
transfected chimeric T7 RNA transcripts did not cause CPE in HeLa cells. The results were 
consistent and identical to those observed in RD-ICAM cells (see table 3.10). It is possible 
that the transfection of recombinants did not give rise to viable viruses or that acytopathic 
viruses were produced, explaining the lack of CPE. 
The CVA2IBKCVA2IP1 and PV3BKPV3P1 clones were viable thus indicating that there 
were no defects in the backbone vectors. It appeared unlikely that the recombinants had 
errors in the sequences as all the clones were derived from the CVA21BK and PV3BK 
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vectors. Furthermore, RFLP analysis and sequencing of key junctions of all the clones and 
complete P1 coding region sequencing of the CVA21BKSabin1Pl 61-9, 
CVA21BKPV3P1 c6 and PV3BKCVA21P1 3 chimeras confirmed there were no errors in 
the constructed clones. It therefore seemed likely that the inability to produce viable virus 
was due to a defect in the replication cyle, rather than the chimeric viral genome. Further 
characterisation of the in vitro generated recombinants was therefore initiated. The possible 
acytopathogenicity of the in vitro generated P1 recombinants was investigated by an 
immunofluorescence assay to detect virus antigen. 
3.3.2 Immunofluorescence study of viral protein expression and 
determination of the acytopathogenic phenotype of chimeras 
Immunofluorescence analysis was carried out to detect VP 1 protein production, using a 
specific anti-enterovirus VP1 mouse monoclonal antibody (DAKO). The specificity of the 
antibody for the P1 capsid precursor protein was unclear. Subsequent in vitro translation 
studies appeared to indicate that the antibody was specific to VP 1 as no extra bands were 
observed in western blot analysis (see figure 3.17). 
The VPI capsid protein production would be expected to occur post-transfection. Viable 
chimeric viruses would be expected to produce VPI and protein expression would be 
detected after passage of RNAse treated transfected samples. The detection of VP I 
expression in both transfected RD-ICAM cells and RD-ICAM cells in which harvested 
RNAse treated samples had been passaged would suggest that the chimeric viruses were 
acytopathic. 
Duplicates of the transfected cells were lysed to release any intracellular virus particles, 
samples were harvested and RNAse treated to prevent RNA carry over onto a fresh cell 
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sheet. The harvested samples were passaged onto fresh cell sheets and VP 1 
immunolabelling was conducted. Cells were treated with a primary anti-VP1 DAKO 
mouse monoclonal antibody followed by treatment with a secondary anti-mouse 
FITC-conjugated polyclonal antibody (see appendix 1). Sample-coverslips were mounted 
on slides and visualised using a confocal microscope. All the confocal imaging was carried 
out at the same time. The results are illustrated in figure 3.11,3.12 and 3.13 using a range 
of magnifications. 
VP 1 expression was detected in cells transfected and passaged with control samples PV3, 
Sabin 1 and CVA21. These control samples are known to produce cytopathic viruses. 
These results suggested the assay had been successful. Mock transfection and passage 
controls were carried out in parallel as negative controls for non-FITC labelled cells and 
did not exhibit expression of VP1 after transfection or passage. A PV3-infected control 
singly labelled with the secondary FITC-conjugated antibody was used as a control for 
monitoring background levels of non-specific detection of FITC fluorescence. 
VP 1 expression was detected in all cell sheets transfected with RNA derived from 
recombinant cDNAs but not in other cells. A weak signal was detected in the cells 
passaged with the CVA21BKSabin1Pl RNA transfected cell harvest solutions. The 
detection of VP1 expression in the transfected cells indicated that translation had occurred. 
The lack of VP 1 expression in cells passaged with samples harvested from the chimera 
transfections would suggest that the recombinants were not acytopathic. If the 
recombinants were acytopathic the levels of VP1 expression in the passage samples were 
below the level of detection by immunofluorescence. These results suggested that the 
defect had to be at some stage post-transfection, such as processing, replication, packaging, 
assembly, and release or host cell entry. Further experiments were conducted to investigate 
PV3E3KCVA21P1 3 
! \ \_ 
iI% _; 
IA 
-, )13K( 
V: A_' 1 I' I 
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C' VA? 1 
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ý III, IdoliL Cells alone 
Figure 3.11: Detection of P\ 3BK('%'. %21P1 3 VPI expression 
fhe left hand Column represent the pictures of transfected cells and the right hand column are pictures 
of the supernatant passaged onto fresh cell sheets RNA transcripts from the indicated plasmids were 
transfected into RD-ICA\1 cells. The presence of VP1 virus antigen was determined by 
immunotluorescence analysis using as primary antibody the anti-HEV VPI (DAKO) \1Ab at 10 hours 
post-transfection or 10 hours after passaging of RNAse-treated culture supernatant to fresh cells. Mock 
transfected cells are also shown. 
CVA2IBKSabinlPl 61-5 
i\\, Ifihý, ihinll'1 (d -`) 
PIN II 
( \\, l 
(AA-'I l3KSahunl III 01-S 
( \'. A2 I BKSahin 111 161 -1) 
I' lý II 
c ý'A ,i Cells alone 
Figure 3.12: Detection of CV. &2IBkSabinIP1 61-5 and 61-9 VP1 expression 
I he left hand column represent the pictures of transfected cells and the right hand column are pictures 
ofthe supernatant passaged onto fresh cell sheets. RNA transcripts from the indicated plasmids were 
transfected into RI)-IC. \M cells. The presence of VPl virus antigen was determined by 
immunotluorescence analysis using as primary antibody the anti-HEV VPI (DAKO) MAb at 10 hours 
post-transfection or 10 hours after passaging of RNAse-treated culture supernatant to fresh cells. Mock 
transfected cells are also shown. 
CVA2IE3hPV3PI c6 
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CAA-l I 
P\ 11 
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f Figure 3.13: Detection of ('N. 121 B1: P% 3P1 e6 VP1 expression 
The left hand column represent the pictures oftransfected cells and the right hand column are pictures 
of the supernatant passaged onto fresh cell sheets. RNA transcripts from the indicated plasmids were 
transtected into RD-ICAM cells. The presence of VPI virus antigen was determined by 
immunotluorescence analysis using as primary antibody the anti-1IEV VPl (DAKO) MAb at 10 hours 
post-transfection or 10 hours after passaging of RNAse-treated culture supernatant to fresh cells. Mock 
transfected cells are also shown. 
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the defect. As the results suggested that translation had occurred, in vitro translation assays 
were undertaken to confirm the initial observations. 
3.3.3 In vitro translation 
The processing of the P1 capsid precursor and its cleavage from the non-structural proteins 
are mediated by two viral proteases, 3C and 2A. The proteases and the capsid proteins, in 
the in vitro generated recombinants, are derived from separate viral sources and processing 
could be absent, incomplete or inefficient due to an incompatibility of the proteases with 
the P1 capsid precursors. Therefore the investigation of the protein processing properties of 
the in vitro generated chimeras, by in vitro translation assays, was essential. Initial 
characterisation of wild-type viral proteins and processing pattern was therefore conducted. 
3.3.3.1 Wild-type controls characterisation 
Radiolabelled infected cell lysates of control viruses CVA21, PV3 and Sabin 1 were 
prepared as an in vivo source of large amounts of correct processing products (figure 3.14). 
These were later used for comparison with the in vitro processing products, obtained using 
HeLa S 10 extracts. Control radiolabelled infectious virus particles, with a sedimentation 
coefficient of 160S, were also prepared in parallel, to identify the capsid proteins. VP I, 
VP3 and sometimes VP2 of the 160S particles were observed on the gels and comparison 
with the migration patterns exhibited by the infected cell lysates samples enabled the 
identification of capsid proteins (see appendix 1). These are illustrated in figure 3.14. 
CVA21 160S particles and Sabin 1 infected cell lysates consistently labelled poorly. 
CVA21 VP 1 and VP3 labelled protein bands are indicated with dots in figure 3.14. CVA21 
VP2 detection was not apparent due to the poor labelling of the virus. 
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identification of capsid proteins. CVA21 160S particles consistently labelled poorly 
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The SDS-PAGE gel (figure 3.14) shows that CVA21 and PV3 exhibited a similar 
migration pattern for the P1,2BC, 2C and 3CD proteins. However, VP1, VP3 and 2A 
proteins of PV3, CVA21 and Sabin 1 control viruses differed in their migration patterns 
and were therefore diagnostic for the relevant parental sequences of each chimera. CVA21 
VP1 appeared to migrate faster than Sabin 1 VP 1, which itself migrated faster than PV3 
VP 1. Similarly, CVA21 VP3 migrated fastest whereas PV3 VP3 migrated slowest. The 
CVA21 2A protease appeared to migrate faster than PV3 2A and pS1F 2A, which migrated 
the slowest. 
Once characterisation of control viruses processing patterns was completed, in vitro 
transcription/translation assays using HeLa S 10 nuclear extracts supplemented with flexi 
rabbit reticulocyte lysates were conducted to determine the products encoded by the 
chimeras. The reactions were denatured and run on a 12.5% SDS-PAGE gel for analysis. 
The results are shown in figures 3.15,3.16 and 3.18. 
3.3.3.2 PV3BKCVA21P1 recombinants 
The in vivo infected cell lysates samples patterns and the in vitro patterns obtained using 
HeLa S10 nuclear extracts of control viruses were compared on the PV3BKCVA21P1 
processing gel (figure 3.15). These patterns were similar, apart from few additional cellular 
proteins present in the in vivo infected cell lysates. The CVA21 and PV3 infected cell 
lysates samples consistently migrated slightly faster than other lanes. This was taken into 
consideration for recombinant sample analysis. 
The PV3BKCVA21P1 recombinants appeared to exhibit the correct processing pattern (see 
figure 3.15). PV3BKCVA21P1 recombinants should express a PV3 non-structural protein 
pattern and a CVA21 capsid protein pattern. 3CD, P1,2BC and 2C could not be used for 
comparison purposes since the migration pattern of these proteins did not differ amongst 
IZI 
ý 
! 
3 
f 
:. r 
ý' CCC 
ý ^/ nl r1 ` 
; `". 
ý ` 
, ýý' , 
Q' , ý' 
ý 
"S ý C, C, C, ý .ý. v 1ý-- . -. .ýýýý . \i . \/ . \i ý 
ýý r,, ý ný 4zý' Zý m Cl) 
ý Jý ýý ,, 
ý ý ý^ ý^ý ý^ý 
ýý ý- ýCCCC 
I 
ý 
I 
ý^ý Jý 
CC 
1 5OkDa 
PI 
3CnPru 
P? 
3 DP°I 
213C 
., ý. 
VPI 
VP3 
-ýº -ý ý__. 
ampow 
lb# 494 
R! 4if 
"I It 
y-0 
rdý 
"ý 
w. e 
* 
ýýý ý_ 
.,. ý, _.. 
ýý 
_ý 
ý rim - rAiii 
0--ft 
0 
0 -0 "-r 
... ý emso 
0--m OWN" 
s" 
mat 
I OOkDa 
III 
3C[)Pro 75kDa 
3DPol 
2BC 
50kDa 
2C 
VPl 
VP2 
VP3 
37kDa 
25kDa 
20kDa 
2A ---º ý --# - 2A I 5kDa 
ýýrýam ý 
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lOkDa 
fhc samples Mere run alongside the 2 control viruses. PV3BKCVA21P1 1, 
PV3BKCV. 421 Pl3. PV3BKCVA21 Pl 4 represent individual clones isolated from the 
cloning experiment. The arrows highlight the bands used for characterisation and analysis 
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CV112 I infected cell lysates appeared to migrate faster than PV3 and CVA2 I HeLa SIO 
samples. 
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various samples. PV3BKCVA21P12A had the same migration phenotype as that of PV3 
2A and migrated slightly slower than the CVA21 2A. However, the CVA21 S10 sample 
consistently labelled poorly and 2A was hardly detectable on the protein gel. These results 
indicated that the non-structural proteins of the PV3BKCVA21P1 recombinants appeared 
to be PV3-like. 
VP1 of CVA21 and PV3 had similar migration patterns and could not be used as 
identification proteins for the PV3BKCVA21P1 recombinants analysis. However, VP3 of 
PV3 migrated significantly slower than CVA21 VP3 and the gel demonstrated that 
PV3BKCVA21P1 VP3 was CVA21 VP3-like. The results suggested that 
PV3BKCVA21P1 3 and PV3BKCVA21P14 proteins were correct and that the processing 
pattern in vitro was also correct. Therefore the P1 of CVA21 was processed in trans by the 
3CD of poliovirus. 
VP1 of the PV3BKCVA21P1 1 recombinant migrated slower than that of other 
recombinants and control viruses (indicated by an asterisk in figure 3.15). 
PV3BKCVA21P1 1 VP1 was aberrant in size and appeared to be approximately 35 kDa as 
opposed to native VP1, which is approximately 33 kDa. The 2A protease being correct, 
inefficient 2A-mediated cleavage event could not have caused the observed result. The 
2-kDa difference in size would correspond to an 18 amino acid difference, or 
54 nucleotides. This difference in size would not have been apparent during the RFLP 
analysis of the clone. Moreover, initial sequencing analysis of the constructed clones was 
restricted to the 5'UTRNP4 and VP1/2A junctions. Complete sequencing of the P1-coding 
region was only carried out on the clones that appeared to express the correct 
protein-processing pattern but not on the PV3BKCVA21P1 1 clone. Either PCR error or 
aberrant processing at the VP3/VP1 junction could account for the observed result. 
Claire Blanchard In vitro recombination 
3.3.3.3 CVA21BKSabin 1P1 and CVA21BKPV3P1 recombinants 
Chapter 3 76 
Comparison of the infected cell lysates with the HeLa S10 samples of CVA21, PV3 and 
Sabin 1 control viruses demonstrated similar processing patterns. The in vivo samples 
consistently migrated slightly faster than the in vitro samples. The in vivo samples are not 
shown in the CVA21BKSabinIP1 and CVA2IBKPV3P1 SDS-PAGE gels due to poor gel 
quality. 
The results of the CVA21BKSabin1Pl SDS-PAGE gel are illustrated in figure 3.16. VP3 
and 2A were the two proteins used for the identification and analysis of the 
CVA21BKSabinlPI recombinants in vitro processing. The gel shows that VP3 of the 
CVA21 BKSabin 1P1 recombinants migrated as Sabin 1 VP3 and 2A migrated as CVA21 
2A (see figure 3.16). The presence of VP1, as opposed to the uncleaved VP1/2A product, 
was detected by DAKO anti-VP 1 labelling western blot. VP 1 was present in all the 
samples, apart from the mock, and was estimated to be the correct size (see figure 3.17). 
No other bands were present on the western blot, confirming the specificity of the 
antibody, the correct cleavage of the P1 capsid protein precursor from the non-structural 
proteins and efficient processing into VP I. 
The CVA21 BKPV3P 1 c6 recombinant processing pattern was then analysed (figure 3.18). 
CVA21BKPV3P1 c6 appeared to express a PV3 VP3 migration pattern and a CVA21 2A 
migration pattern suggesting that the recombinant processed efficiently in vitro. It is 
important to note that the PV3 P1 chimera consistently labelled poorly, explaining the poor 
quality of the SDS-PAGE analytical gel. 
However in vitro translation did not enable the study of the kinetics of the processing 
cascade and in vivo translation should be investigated. Pulse-chase labelling type assays 
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Figure 3.17: Western Blot probing for HEM' ß'PI 
ý 
VPI western blotting using a 11EV-specific DAKO anti-VP 1 mouse monoclonal 
antibody (1: 1000). Samples, generated during the in vitro S 10 
translation/processing assay, were run on an SDS-PAGE gel, transferred onto a 
membrane for protein analysis and probed for VP 1. A secondary anti-mouse 
HRPO-conjugated secondary antibody was then used at a dilution of 1/5000 in 
PUS-A. The western blot was developed with ECL western blot developing 
reagents for a couple of minutes and exposed on an X-Ray film. The film was 
developed and the hands represent VP1 proteins. 
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based on transfection would not be practical. It is therefore possible that the recombinants 
may have temporal defects in translation. 
In vitro translation assays suggested that the correct proteins were produced and the 
processing pattern appeared to be authentic. The recombinant proteins were consistently 
processed, the P1 and the VP1 proteins released from the non-structural proteins and the 
proteins involved in replication expressed. The chimeras would therefore look like 
sub-genomic replicons and would be expected to replicate. Replication of the virus 
genomes was therefore analysed by dot blot hybridisation assays. 
3.3.4 Replication assay 
Replication studies were carried out as described in Chapter 6: Materials and methods. 
RNA samples, normalised to I µg, were transfected individually into RD-ICAM cells. The 
transfected cells were harvested at different time points post-transfection and viral RNA 
extraction was carried out. The RNA samples were then transferred and fixed onto a 
membrane and hybridised to a generic [32P] probe. The probe was expected to bind the 3D 
polymerase-coding region of all viral RNAs used in the reaction and would therefore be 
expected to enable quantification of RNA production. The membrane was exposed to a 
phosphoimager screen. Figure 3.19 shows an example dot blot membrane. Radioactivity 
was then quantified and plotted onto graphs. The results are expressed in percentage fold- 
increase of viral RNA levels and are illustrated in figures 3.20 and 3.21 and summarised in 
table 3.22. 
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Samples Replication phenotype 
CVA21BKSabinlPl 61-5 +++ 
CVA21BKSabin1P1 61-9 + 
CVA21BKPV3P1 c6 +++ 
PV3BKCVA21P1 1 + 
PV3BKCVA21P1 3 + 
pRiboCVA21 ++/++ 
pS1F ++ 
PV3 +++ 
PV3 + 4mM GuHCI - 
Cells alone / mock transfection - 
Table 3.22: Summary of replication phenotype determination assay of in vitro P1 
recombinants. The replication phenotype was determined from graphs obtained, 
figure 3.20 and 3.21, based on [32P1 signal detection and quantification. Replication 
competent (+) and replication incompetent (-) samples are illustrated. Number of + 
signs indicate different levels of replication (see graphs 3.20 and 3.21). 
Graphs summarising the results of the time course/dot blot assay are illustrated figures 3.20 
and 3.21. The control samples behaved as expected. The control CVA21 and PV3 parental 
genomes exhibited an increased signal over time indicating that these were replicating. 
PV3 transfected in the presence of 4mM GuHCI, an inhibitor of viral replication (Molla et 
al., 1993), did not replicate. 
However, the Sabin 1 genome control sample, derived from the pS1F infectious clone, 
showed apparent lower replication levels than the PV3 and CVA21 controls. This was 
surprising considering the in vitro protein-processing pattern of Sabin 1 appeared to be 
correct. However, throughout the project the pS1F plasmid caused problems and exhibited 
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ý 
PV3 
PV3BKCVA21P1 3 
PV3BKCVA2IPI I 
pRiboCVA21 
PV3 + GuHCI 
This figure is an example dot blot similar to those used for the replication 
curses. Several dot blots were carried out. The primary data was then used 
tier quantification and plotted onto graphs. 
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a few unexplained abnormalities, such as slow virus production and genome replication. It 
is not clear why this was the case. 
All the recombinants exhibited different levels of replication. The PV3BKCVA21P1 1 and 
PV3BKCVA21P1 3 recombinants appeared to be replication-competent. However, levels 
of replication were not as high as those observed in the positive control samples (see figure 
3.20). The CVA21BKPV3P1 c6 recombinant appeared to be highly efficient at replicating. 
The CVA21BKSabinIP1 61-9 recombinant replication seemed to be at least as efficient as 
the control virus replication. CVA21BKSabinlP1 61-5 was also replication-competent but 
to lower levels than those observed in the other test samples (see figure 3.21). These results 
confirmed the in vitro translation assay initial findings whereby the correct proteins had 
been synthesised and could catalyse the replication process. 
Under the conditions used, the levels of replication at different time points were 
reproducible. Each individual clone analysed is characteristic and consistent with previous 
assays. The assay needs to be repeated for the data to be statistical relevant. Repeating the 
assay in L cells may enable cleaner and more statistically relevant data to be generated. 
The defect, which prevented the chimeras from causing cytopathic effect must therefore be 
due to a late event such as maturation, assembly, packaging or infection of new cells. 
Because of the availability of relevant expertise and reagents, the packaging phenotype of 
the recombinants was analysed. 
3.3.5 Trans-encapsidation assays 
The trans-encapsidation assays were conducted to determine whether the P1 recombinant 
viral genomes had a packaging defect. 
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3.3.5.1.1 Method 
The trans-encapsidation assay was conducted to monitor whether the T7 RNA transcripts 
of the P1 recombinants and progeny RNA, synthesised after transfection of the transcripts 
into RD-ICAM cells, could be encapsidated by CVA21 or PV3 helper viruses (protocol 
described in figure 3.23). Both CVA21 and PV3 are infectious and generate viral capsid 
proteins that assemble and package progeny genomes leading to the production of mature 
virions. Chimeric genomes being packaged into the helper virus empty capsids would 
demonstrate that the recombinants are competent for packaging. 
The recombinants are effectively replicon systems, as they are able to translate, process 
and replicate. However, these lack a reporter gene or other readily assayable marker and 
encapsidation was therefore screened for by PCR. An RFLP type analysis was then carried 
out to differentiate between chimeric genomes packaged into helper virus capsids and 
helper viruses, taking advantage of the differences at the 5'UTR/P1-coding regions. 
T7 RNA transcripts derived from the recombinants and controls were transfected into 
RD-ICAM cells. Six hours post-transfection the samples were infected with the helper 
viruses and incubated for 8-10 hours. Viral RNA was extracted from the various samples 
and reverse transcribed to generate cDNA. A 900-1000 bp window of the cDNA 
5'UTR/P 1-coding regions were amplified by PCR, using generic oligonucleotide primers 
(CVA21-CAPF and ENT-GEN-2R), digested with Bam HI endonuclease and run on a 2% 
agarose gel for analysis. Predicted RFLP patterns were generated using Vector NTI and are 
illustrated in figures 3.24 and 3.25. The ability of Vector NTI to predict priming of 
oligonucleotide to sequences does not take into consideration factors such as PCR 
Transfection of in vitro generated recombinant T7RNA transcript 
1 
80% confluent RD-ICAM cells 
1 
Incubation at 37°C for 6 hours 
1 Infection with helper virus at an moi of 10 
1 Incubation at 37°C for 8-10 hours to allow for helper virus 
progeny capsids synthesis and recombinant genome encapsidation 
1 I lan esting of viruses and RNase A treatment to avoid any carry over of 
RNA and to ensure only ancapsidated RNA infects the new cell sheet 
1 
f'aaaýýe Unto a fresh cell sheet of 80% confluent RD-ICAM cells 
1 I Ian sting of iruscs and DNase treatment to avoid detection of 
a non-specific signal in RT-PCR reaction 
1 Reverse transcription of isolated , RNA and newly synthesised cDNA 
analysis by PCR amplification and restriction digest 
Figure 3.23: Flo" chart summarising the method and analysis of the trans- 
encapsidation of recombinant genomes by helper virus assay. 
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conditions like the magnesium concentrations or the annealing temperatures and does not 
necessarily give a true representation of what is actually generated. 
pRiboCAV21 and pSIF control RNAs were transfected individually and co-infected with 
PV3 virus (figure 3.28). pT7FLC/PV3 and pSIF control RNAs were also transfected 
individually and co-infected with CVA21 virus (figure 3.28). These control samples were 
carried out in parallel to monitor the efficiency of the assay and to ensure that successful 
heterologous packaging had occurred. The Bam HI digestion was carried out on a series of 
PCR products amplified from control plasmid sequences: pT7FLC/PV3, pRiboCAV21, 
pSIF, PV3BKCVA21P1 3, CVA21BKSabin 1P1 61-9 and CVA21BKPV3P1 c6 (figure 
3.27). The expected sizes of fragments resulting from both digestion of the plasmid 
amplified sequences and of the encapsidation samples are shown in table 3.26. 
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trans-encapsidation experiment with PV3 helper virus. 
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Figure 3.25: Predicted RT-PCR-Bam HI RFLP analysis of the 
trans-encapsidation experiment with CVA21 helper virus. 
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Trans-encapsidation samples : RNA + virus Bam HI digests (in kb) 
PV3BKCVA21P1 3+ PV3 virus 
0.433,0.430,0.393,0.313,0.213, 
0.133 
CVA21 SabinlP 161-9 + PV3 virus 0.9,0.433,0.313,0.213 
CVA21BKPV3P1 c6 + PV3 virus 0.615,0.433,0.344,0.313,0.213 
pS IF + PV3 virus 0.9,0.433,0.313,0.213 
pRiboCVA21 + PV3 virus 0.535,0.454,0.433,0.313,0.213 
PV3BKCVA21P1 3+ CVA21 virus 0.535,0.454,0.430,0.393,0.133 
CVA21 Sabin 1P 161-9 +CVA21 virus 0.9,0.535,0.454 
CVA21BKPV3P1 c6 + CVA21 virus 0.615,0.535,0.454,0.344 
PSI F+ CVA21 virus 0.9,0.535,0.454 
pT7FLC/PV3 + CVA21 virus 0.535,0.454,0.433,0.313,0.213 
pT7FLC/PV3 0.433,0.313,0.213 
pRiboCVA21 0.535,0.454 
pS1F 
No fragment generated, CAV21- 
CAPF does not anneal to pS1F. 
PV3BKCVA21P1 3 0.430,0.393,0.133 
CVA21BKSabin1P1 61-9 0.9 
CVA21BKPV3P1 c6 0.615,0.344 
Table 3.26: RFLP analysis of alternative trans-encapsidation assay sample testing for 
packaging capacity of in vitro generated P1 recombinant DNAs. Fragments expected 
from the Bam HI restriction digests. 
a 
ý 
b 
,.,, ý 1b 
!o 
4 
.ýCQ \' M' M 
.\ý 
\) 
Jý 
' C" C CJ GG 
i. okb- IN-now m 
() Ikh -_ 
1 
wrrorr 
s 
Figure 3.27:: analysis of control plasmids by PCR and Bam 111 RFLP analysis. 
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Figure 3.28: Analysis of trans-encapsidation assay by P('R and Bam III RFLP 
analysis. 
The dots in figure A indicate artefeacts seen in the vRNA/RT-PCR/digests of CVA21 
virus sho%%n in figure B. These were therefore not taken into consideration during the 
analysis of results. 
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3.3.5.1.2 Results and analysis 
3.3.5.1.2.1 Plasmid controls 
PCR and Bam HI RFLP analysis of pT7FLC/PV3, pRiboCVA21, pS1F, PV3BKCVA21P1 
3, CVA21BKSabin1P1 61-9 and CVA21BKPV3P1 c6 control plasmid DNAs are 
illustrated figure 3.27. The fragment sizes obtained were as expected and were used as 
controls for sample analysis. The generation of an unexpected -0.9 kb PCR product 
resulting from amplification of pS IF was surprising. The observed result could have been 
due to the CVA21-CAPF oligonucleotide predicted to bind pS1F 0.927 bp upstream of the 
ENT-GEN-2R pS 1 F-binding site with 45% homology. 
3.3.5.1.2.2 Virus controls 
Control infections of RD-ICAM cells with CVA21, PV3 and Sabin 1 virus samples were 
also undertaken (see figure 3.28.8). The PCR/RFLP investigation of the PV3 infected 
sample generated the expected fragments. The CVA21 infected sample study exhibited two 
additional unidentified bands, not detected in the plasmid digests (result discussed later). 
The PCR/RFLP analysis of Sabin 1 did not yield fragments, as initially expected. This 
conflicted with the pS1F plasmid control analysis. It could have been due to the 
CVA21-CAPF oligonucleotide having primed a vector-specific site, not present in the 
Sabin 1 viral genome. The Sabin 1 data were not used for further analysis. 
3.3.5.1.2.3 Trans-encapsidation by PV3 helper virus capsids 
The control sample of pRiboCAV21 RNA + PV3 virus showed PV3 fragments as well as 
CVA21 fragments. It is important to emphasize that the detection of both CVA21 and PV3 
bands could have been due to both PV3 helper virus and CVA21 virus production from 
pRiboCVA21 RNA transfection. However, the presence of both CVA21 and PV3 bands 
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could indicate that pRiboCAV21 derived genomic RNA had been encapsidated in PV3 
capsids. 
The screening method used in this assay did not enable the detection of Sabin 1-specific 
bands, as one of the oligonucleotide primers used for amplification was unable to anneal to 
the Sabin 1 genome. The pS1F RNA + PV3 virus and pS1F RNA + CVA21 virus samples 
were therefore not used for the analysis. 
The test samples co-infected with PV3 virus presented a PV3-like RFLP pattern. No other 
bands were observed suggesting that no recombinant genomes could be detected. 
3.3.5.1.2.4 Trans-encapsidation by CVA21 helper virus capsids 
As expected, the control sample of pT7FLC/PV3 RNA + CVA21 virus exhibited PV3-like 
bands as well as CVA21 virus-like bands. This result suggested that either the PV3-like 
bands were derived from PV3 virus resulting from the transfection of pT7FLC/PV3 RNA 
or that a heterologous packaging event had occurred. The two possibilities could not be 
distinguished. 
Two unidentified bands, absent from the Bam HI digested pRiboCAV21-derived PCR 
product, were present in all the samples. The bands were observed in the Bam HI digestion 
of the CVA21 virus alone control and were thought to have been artefacts resulting from 
the vRNA extraction and/or reverse transcription reactions. These were excluded from the 
characterisation studies. All the samples co-infected with CVA21 virus, only had a 
CVA21-like RFLP pattern. 
The trans-encapsidation assay results indicated that no packaged recombinant genomes 
could be detected in the reactions. However, it is not possible to differentiate between lack 
of encapsidation and poor sensitivity or screening of the experiment. The former would not 
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be surprising; as previous studies have demonstrated that poliovirus subgenomic replicons 
could be encapsidated by poliovirus capsids and to some levels by CVA21 capsids but no 
conclusive evidence was given for the encapsidation of a poliovirus subgenomic replicon 
by CB4 or HRV14 heterologous capsids (Barclay et al., 1998). Contradictory studies 
reporting that successful encapsidation of a poliovirus subgenomic replicon by CVB4 and 
HRV14 heterologous capsid proteins had occurred (Ansardi et al., 1996). The in vitro 
generated recombinants could lack a specific functional packaging signal. The design and 
use of highly specific primers, amplifying the 5'UTR/P 1 region, may enable a more 
sensitive analysis of the recombinant genome trans-encapsidation experiment. 
Can capsid proteins, generated from transcription/translation of the recombinant RNA 
genomes, assemble and encapsidate a known packageable genome? To investigate this, a 
reciprocal trans-encapsidation experiment was carried out. 
3.3.5.2 Luciferase encapsidation by recombinant capsids 
3.3.5.2.1 Method 
To detect whether the P1 recombinant genomes were capable of providing capsids in trans 
a luciferase-encoding subgenomic replicon was provided in the same cells (see figure 
3.29). To confirm the packaging assay behaved correctly, a poliovirus type 3 packageable 
luciferase subgenomic replicon (pT7REP3-L) was co-infected with PV3, CVA21 and 
Sabin 1 control viruses into RD-ICAM cells (figure 3.30). 
Co-transfection of pT7REP3-L RNA with chimeric RNA was then carried out. The 
co-transfected RD-ICAM cells were incubated at 37°C overnight to allow generation of 
progeny virus. The samples were harvested, RNase treated, passaged onto a fresh 
RD-ICAM cell sheet and incubated for 6-8 hours at 37°C to allow expression of the 
Transfection of in vitro generated Transfection of pT7REP3-L T7RNA 
recombinant T7RNA transcript transcript 
Si 
80% confluent RD-ICAM cells 
1 
Incubation at 37°C for 12-16 hours 
1 
I larvesting of viruses and RNase A treatment to avoid any carry over of 
RNA and to ensure only encapsidated RNA infects the new cell sheet 
1 
Passage I onto a fresh cell sheet of 80% confluent RD-ICAM cells 
Ii 
I larN esting of samples and 
Luciferase assay 
Incubation at 37°C for 12-16 hours 
Harvesting of viruses and RNase A 
treatment to avoid any carry over of 
RNA and to ensure only encapsidated 
RNA infects the new cell sheet 
I 
Passage 2 onto a fresh cell sheet of 80% 
confluent RD-ICAM cells 
1 
Harvesting of samples and 
Luciferase assay 
Figure 3.29: Flow chart summarising the method and analysis of the 
trans-encapsidation assay by co-transfection 
Figure 3.30: Trans-encapsidation of pT7REP3-1. RNA bv control viruses in RD- 
1tA\1 cells. 
The assay was carried out five times, standard deviation values were calculated and 
are illustrated as error bars in the graph. 
Figure 3.31: Trans-encapsidation of pT7REP3-L RNA by recombinants: first 
passage into RI)-ICA\I cells post-co-transfection of T7 RNA transcripts. 
The assa' was carried out five times, standard deviation values were calculated and 
are illustrated as error bars in the graph. 
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luciferase gene. A luciferase assay was carried out and results were plotted as histograms 
(figure 3.31). Viable capsid proteins cannot be produced as a result of transfection with the 
poliovirus type-3 luciferase subgenomic replicon, as most of the P1-coding region is 
substituted for the luciferase reporter gene. The recombinant genomes are unable to 
produce progeny viruses. Any transfer of the luciferase signal onto a fresh cell sheet, after 
RNAse treatment, would be expected to be due to a luciferase genome packaged into 
capsids derived from the chimeras. 
The assay was also conducted on L20B cells (figure 3.33) and L cells (data not shown), 
cell lines, which could only be used to test PV3- containing capsid sequences. The 
PV3BKCVA21P1 3+ pT7REP3-L sample would therefore not be expected to yield a 
luciferase signal in L20B cells and was used as a negative control monitoring for the 
detection of non-specific luciferase activity. These were first passage samples. 
Samples passaged for the first time onto a fresh RD-ICAM cell sheet were incubated for 
12-16 hours at 37°C, harvested, RNAse treated and passaged for the second time onto a 
third RD-ICAM cell sheet. Should a luciferase signal be detected in the first passage of the 
test recombinant samples, transfer onto a third cell sheet should not occur as the 
recombinants are unable to make viable viruses that would enable the signal transfer. The 
assay was repeated five times. 
3.3.5.2.2 Results and analysis 
3.3.5.2.2.1 Control samples of transfected pT7REP3-L RNA co-infected with helper 
virus 
As expected, the control sample co-infected with PV3 virus exhibited a significant 
luciferase activity. The control sample co-infected with CVA21 virus exhibited a 
detectable but low luciferase signal indicating poor encapsidation of the poliovirus replicon 
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by heterologous capsids. The sample co-infected with Sabin 1 virus exhibited very low 
luciferase activity indicating poor if not non-existent trans-encapsidation. The consistent 
abnormal pS1F and Sabin 1 virus behaviour could not be explained. 
The control assay demonstrated efficiency of the method and was applied to the 
recombinant samples. 
3.3.5.2.2.2 Co-transfection of pT7REP3-L RNA with Sabin 1, CVA21 and PV3 
control RNAs 
Genomic RNA derived from PV3, CVA21 and pS1F co-transfected with pT7REP3-L RNA 
exhibited the expected luciferase activities in all the cell lines tested and confirmed the 
success of the trans-encapsidation assay. As expected, no luciferase signal was detected in 
any cell line tested after passage of the transfected pT7REP3-L alone sample and mock 
transfections. 
3.3.5.2.2.3 Co-transfection of pT7REP3-L RNA with PV3BKCVA21P13 RNA 
No luciferase signal was detected in the co-transfection of luciferase type 3-replicon RNA 
with PV3BKCVA21P1 3 RNA (pT7REP3-L + PV3BKCVA21P1 3) samples in RD-ICAM 
cells (see figure 3.31). This could be due to inability of PV3BKCVA21P13 capsid proteins 
(CVA21-like) to package the luciferase genome. In fact previous reports showed that 
CVA21 capsids appeared to reproducibly package poliovirus subgenomic replicons at very 
low levels (Barclay et al., 1998). 
3.3.5.2.2.4 Co-transfection of pT7REP3-L RNA with CVA21BKSabinlPl 61-9 RNA 
Significant luciferase signals were detected in RD-ICAM cells, from the co-transfected 
luciferase type 3-replicon RNA and CVA21BKSabin1P1 61-9 RNA 
(pT7REP3-L+CVA21BKSabinIP1 61-9). The CVA21BKSabinIP1 61-9 recombinant 
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should synthesise Sabin 1-like capsids. The luciferase signal was also detected in L20B 
cells (figure 3.33), but not L cells (data not shown), implying that virus entry was 
PVR-dependent. Only very low amounts of viral RNA could be extracted and reverse 
transcribed. PCR amplification of a range of windows of the 5'UTR/P 1, P1/P2 and 
3D-coding regions, RFLP and sequencing analysis of the samples were inconclusive. 
When the samples were passaged for the second time onto a fresh RD-ICAM cell sheet, a 
very low luciferase signal, close to background levels and considered as negative, was 
detected in the pT7REP3-L + CVA21BKSabin1P1 61-9 sample (figure 3.32). These results 
suggested that CVA21BKSabin1P1 61-9 was capable of encapsidating the luciferase type 
3-replicon genome. 
3.3.5.2.2.5 Co-transfection of pT7REP3-L RNA with CVA21BKPV3P1 c6 RNA 
The samples co-transfected with T7 RNA transcripts of the luciferase type 3-replicon and 
CVA21 BKPV3P 1 c6 exhibited a high luciferase signal in both RD-ICAM cells and L20B 
cells (figures 3.31 and 3.33) but not L cells (data not shown), again implying a 
PVR-dependent signal. The CVA2IBKPV3P1 c6 recombinant seemed to be able to 
generate capsid proteins that were then able to assemble and encapsidate the luciferase 
type 3-replicon progeny RNA. The output luciferase signal of the CVA21BKPV3P1 c6 + 
pT7REP3-L sample passaged onto a second cell sheet was strikingly high (figure 3.32). 
This was confirmed by repeating the entire trans-encapsidation assay several times. 
A possible contamination event with an infectious virus could explain this result. However, 
a contamination with poliovirus seemed unlikely as all the test samples were put in an 
incubator prior to handling the control samples, samples that would generated a positive 
signal. Moreover, ART-filter tips were used throughtout the experiments to avoid aerosol 
contamination of the pipettes. 
Figure 3.32: Trans-encapsidation of pT7REP3-L RNA by recombinants: second 
passage into RI)-I('A\I cells post-co-transfection of T7 RNA transcripts. 
The assay N% as carried out five times. standard deviation values were calculated and are 
illustrated as error bars in the graph. 
Figure 3.33: Trans-encapsidation of pT7REP3-L RNA by recombinants: first 
passage into 1.20B cells post-co-transfection of T7 RNA transcripts. 
The assay %N as carried out five times, standard deviation values were calculated and 
are illustrated as error bars in the graph. 
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Further investigation of this surprising result was conducted. Viral RNA extraction, reverse 
transcription, amplification of the 5'UTR/P 1 -coding region, P1/P2 and 3D-coding regions 
by PCR, RFLP and sequencing analysis of the sample were carried out. The P1/P2 and 3D 
coding-regions had a PV3 RFLP and sequencing pattern (data not shown), strongly 
suggesting a contamination event. However, the 5'UTR/P 1 PCR amplification 
(ID-1/ENT-GEN-2R) and the Bam HI RFLP analysis indicated that the samples had a 
CVA21 5'UTR and a PV3 P1 pattern (see figure 3.34.1 and 3.34.2). This suggested that a 
recombination event between the CVA2IBKPV3P1 c6 recombinant and the pT7REP3-L 
replication-competent RNA genomes had occurred. This resulted in the generation of a 
recombined chimera containing a CVA215'UTR and the reminder of the genome of PV3 
(CVA215'UPTR/PV3). Sequencing data analysis was poor, as it was apparent that mixed 
viral sequences were present, probably corresponding to the presence of both 
CVA2IBKPV3P1 c6 and CVA215'UTR/PV3 sequences (data not shown). A series of 
analyses were conducted in order to further investigate these observations. 
Interestingly, the sample with high luciferase activity also caused CPE when passaged onto 
fresh cell sheets. It should be noted that neither input genome alone caused CPE (see table 
3.10 and table 4.3). The samples were harvested, isolated and plaqued. A mixed plaque 
phenotype was observed with a population of small plaques (see figure 3.35 and 3.36) that 
were consistently smaller than those seen in a typical PV3 infection (data not shown). 
Previous studies demonstrated that, when 220 nucleotides of the 5'UTR of CVB3 were 
changed for PV 1, the viability of the virus was maintained. These viruses, however, had 
smaller plaques than that of PV3 wild-type plaques (Zell et al., 1995). Replacement of the 
complete PV3 5'UTR with the CVB4 5'UTR was demonstrated not to affect sub-genomic 
replicon replication (Rohll et al., 1994). Furthermore, chimeric CVB4/PV3 5'UTR did not 
appear to affect levels of virus production (Rohll et al., 1994). 
5'UTR pt 
Bam HI Bam HI 
pT71: 1_C PV. 1181bp ID-1/ENT-GEN-2R PCR product 
1 I ra_gments generated from the Bain HI digestion of the 
II)-I f: til'-Gl: N-2R amplified PCR products (in kb). 
p l'? lýl. C' PV3 0.673.0.296.0.2 13 
pRiboC'VA21 0.775.0.376 
CVA21131tiPV3Pl c6 0.855.0.296 
Figure 3.34.1: Bam III digestion of ID-I/ENT-GEN-2R PCR products 
of p-T'FI. (''PV 3, pRibo('\: %21 and ('x: -%21 BKPV'3PI c6. 
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Figure 3.34.2: 5'l'TR/P1 RT-PCR RFLP analysis of the trans- 
encapsidation samples 
Samples. resulting from the trans-encapsidation transfection experiments, 
were reverse transcribe and the 5'UTR/VP4-coding region was amplified 
by PCR using generic primers (ID-I and ENT-GEN-2R). The amplified 
fragments were then digested with Bain HI and run on a 2% agarose gel. 
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Infectious recombined chimeric viruses would have been able to infect the third cell sheet 
and provide capsids in trans as they appear to cause CPE. Furthermore it is likely that the 
luciferase subgenomic replicon was packaged into CVA215'UTR/PV3 capsids during the 
first passage. The particles were then able to attach, enter and release the replicon into 
fresh cells. This could explain the transfer of a luciferase signal onto a third cell sheet. 
Another possible explanation is that a recombination event occurred generating a large 
genome containing both the luciferase-coding gene and the complete genome coding 
sequence. This is improbable, as a larger genome is less likely to be packaged into the 
empty virus particles, as it is not an evolutionary advantage. The plaque purified isolated 
viruses were passaged onto a fresh cell sheet and luciferase activity detection assay was 
carried out. No luciferase signal was detected thereby suggesting the absence of a large 
super-recombinant genome. 
The elevated luciferase signal seen after the first passage could also be due to the 
CVA21BKPV3P1 c6 recombinant capsid proteins assembling to form a virus particle 
packaging the luciferase replicon genome (see figure 3.30). This could also have been the 
case, as similar results were observed in the case of CVA21BKSabin1P1 61-9 (see figure 
3.30). It is likely that the two events together- trans-encapsidation and subsequent transfer 
of the luciferase genome and recombination to form a viable CVA215'UTR/PV3 
genome-were responsible for the present observations. The latter would amplify the 
former. However, it is still unclear why such high readings were observed. 
3.4 Discussion 
In vitro generated recombinants between polioviruses and a HEV-C, with a perfect 
exchange of the complete P 1-coding region, were unable to cause cytopathic effect when 
Figure 3.35: Plaque phenotype determination 
in RI) cells of'plaque purified virus isolated after the second passage of 
('V: \2l I3KP\'3Pl c6 + pT7REP3-L samples and plaque purified twice: 
A- h'l-7RI-: P 3-l. + C'V: N? I E3KPV3PI c6 4, 
E3- p1 7RE: P3-I. + C'V>2I E3E: PV3PI c6 8 
Figure 3.36: Plaque phenotype determination (continued) 
in RI) cells of plaque purified virus isolated after the second passage of 
L'V: \2113KPV3PI c6 + pT7REP3-L samples and plaque purified twice: 
: ý- p 1'7RE: P3-1. + CVA? 1 BhPV3P1 c6 11, 
13- pT7REP3-I. - CVA21E3RPV3PI c6 12 
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transfected into permissive cell lines. The generated chimeras were initially thought to be 
acytopathic or replication-defective due to a combination of protein coding regions leading 
to the generation of non-viable viruses. Immunofluorescence studies suggested that the 
chimeras were not acytopathic but that VP1 was generated and that translation had 
occurred. Therefore a defect must have affected a post-translation event of the life cycle 
such as processing, replication, assembly, encapsidation, maturation or entry of progeny 
virions into uninfected cells. A series of assays were undertaken to determine the nature 
and location of the defect affecting the recombinants. 
In vitro translation assays were conducted to confirm the immunofluorescence study 
results. Results indicated that the recombinants appeared to translate efficiently and exhibit 
the correct in vitro protein-processing pattern. In vivo control samples appeared to have 
identical protein processing patterns as the in vitro translation control samples. The in vitro 
translation assay data suggested that the correct viral proteins had been made thereby 
implying that proteins derived from chimeras were likely to be able to drive genome 
replication. However, the translation assay was carried out in vitro and it is possible that in 
a particular cellular environment the polyprotein processing would not occur as efficiently 
or would be unable to generate functional proteins. 
Recombinant genome replication was then checked by dot blot hybridisation. The 
experiment confirmed that the in vitro generated recombinants were replication-competent. 
Some replicated to wild-type genome levels, whilst others were shown to be less efficient 
at replicating. These observations indicated that the defect was either located at maturation, 
assembly, and packaging processes or affected the infection of new cells. 
The level of expertise in the laboratory enabled trans-encapsidation assays to be conducted. 
Two assays, testing for the presence or absence of a packaging signal in the recombinant 
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genomes and for the capacity to encapsidate a replicon genome by the capsid proteins 
synthesised from the chimeric genomic RNA, were carried out. Trans-encapsidation of 
recombinant genomes by infectious helper viruses was investigated first. No packaged 
recombinant genomes were detected from the RT-PCR and RFLP screening. However, the 
sensitivity of the technique was not evident, as control samples did not enable a definite 
conclusion. Subsequent co-transfection of a luciferase type-3 poliovirus replicon with the 
recombinant RNA genomes into RD-ICAM cells, sample harvesting, RNAse treatment and 
passage onto a fresh cell sheets constituted the second trans-encapsidation assay. The 
results obtained from this assay suggested that both a recombination event and the P1 
recombinants generating capsids were likely to account for encapsidation of the luciferase 
subgenomic replicon. This could be explained by the recombinant genomes lacking a 
packaging signal or having an incompatibility essential for key interactions involved in 
encapsidation. This defect would have prevented the formation of viable virions. 
Studies investigating poliovirus packaging have not yet provided a detailed understanding 
of this mechanism and the proteins involved in such processes have yet to be identified. 
The poliovirus packaging signal was shown not to be located in the 2A-coding region or in 
the P1 minus the last few amino acids of VP 1-coding region and was suggested to be 
located elsewhere in the remainder of the genome (Kuge et al., 1986; Barclay et al., 1998). 
However, packaging may be more complex and dependent on a number of factors. 
Infectious cVDPVs, isolated from the Haiti outbreaks, were shown to be recombinants 
between Sabin poliovirus type 1 and HEV-Cs, with a crossover site located in the 
2A/2B-coding regions (Kew et at., 2002 see figure 3.37). In vitro generated recombinants 
and the Haiti isolates differed in the location of their crossover sites. Similar recombination 
events were observed in Madagascar cVDPVs isolates that proved to be Sabin poliovirus 
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Figure 3.37: Location of recombination breakpoints of the four different 
recombinant classes found among Hispaniola VDPV isolates. 
In the schematic of the poliovirus genome, the single open reading frame is 
indicated by a rectangle. flanked by the 5'- and 3'-untranslated regions (UTR). 
In rectangles A to E. Sabin I -derived sequences are indicated by white fill, 
and sequences derived from enteroviruses other than the Sabin OPV strains 
are indicated by shaded or hatched fills. The rectangles symbolize sequences 
of A. Sabin 1: B. DOR00-013: C. DOR00-041 c 1: D, HA100-003; and E. 
HA101-007. Figure and legend taken from Kew et al. (2002). 
3'-UTR 
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type 2/HEV-Cs chimeras, with a non-specified crossover site within the 2A-coding region 
(Rousset et al., 2004). 
The studied viable cVDPVs had P 1,2A and/or part of the 2B-coding regions derived from 
the same source genomes. The-non-viable in vitro generated P1 recombinants differed 
from the cVDPVs as the P1 and 2A/2B-coding regions were derived from separate source 
genomes. In light of these results, packaging may be more complex than initially thought. 
A packaging signal may depend on localisation of genomes and proteins and/or on 
compatibility required for specific interactions to occur. It is possible that the genome and 
the capsid proteins of a particular virus localise in specific intracellular areas. These 
intracellular areas may differ between viruses, which may prevent specific interactions, 
and thus packaging from occurring. Compatibility between the P1 with some of the 
2A/2B-coding regions may be necessary for efficient packaging to occur, whether the 
compatibility is based on RNA structures, protein-RNA or protein-protein interactions. 
Unassembled or partially assembled capsid proteins could exhibit high specificity for a 
particular RNA structure, RNA sequence or protein present within homologous 
2A/2B-coding regions. This would explain the discrepancy seen between the results 
presented in this thesis and those observed in Haiti and Madagascar (Kew et al., 2002; 
Rousset et al, 2004). 
A repeat of the assay by sequential transfection as opposed to simultaneous co-transfection 
may prevent the occurrence of recombination events between the chimeric genomes and 
the luciferase genomes and ensure a better data interpretation. 
Further investigations need to be carried out in order to determine the exact nature of the 
defect and to enable a better understanding of this particular stage of enterovirus life cycle. 
Electron microscopy (EM) studies should enable the detection of mature virus particles. 
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The absence of mature virions would support the existence of a packaging defect. If such 
virions were to be detected in the supernatant of transfected cells, then the defect would 
have to be at the attachment and entry level of the next cell sheet, since they cannot infect 
fresh cell sheets. If no virions were to be detected in the supernatant but were present in the 
lysed cell suspension, this would imply that the mature virions could not be released into 
the extracellular environment or that the production or release of such virus particles would 
be much slower. Due to equipment breakdown and restrictions of EM, such experiments 
were not completed. Should microscopy studies confirm the absence of mature virus 
particles, the detection of assembly intermediates would be undertaken. 
The detection of assembly intermediates by sedimentation coefficient assay should enable 
the determination of the particular stage of the life cycle affected by the defect and 
potentially the assembly step at which packaging of the genomic RNA occurs. The 
determination of the presence of assembly precursors by density gradients would also 
establish whether there was a defect in the maturation process or whether the lack of 
maturation was a consequence of a packaging defect. The method used would be designed 
based on early experiments (Moscufo et al., 1991) whereby radiolabelled HeLa cell 
suspension cultures, infected with a high MOI of control viruses or transfected with high 
concentrations of recombinant RNA, would be harvested and lysed. Alternatively, 
microinjection of high concentrations of sample RNA into oocytes, supplemented with 
HeLa nuclear extracts necessary for initiation of translation and RNA synthesis (Gamarnik 
et al., 1996), may be conducted to ensure a more efficient delivery of the samples. Samples 
would then be centrifugated to eliminate cell debris and the supernatants would then be 
applied to 6-25% and 10-30% sucrose gradients. Centrifugation to allow separation of 
different assembly intermediates with different sedimentation coefficients would then be 
conducted. The 6-25% gradient would enable isolation of the 6S protomers and 14S 
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pentamers and the 10-30% gradient would allow isolation of 80S empty capsids and 160S 
mature virions. The detection of 160S particle production would suggest that assembly and 
packaging had occurred. However, the detection of assembly intermediates may give an 
insight into what stage of assembly was affected by the defect. Results could be interesting 
for the understanding of the picornavirus packaging and assembly. 
In the present assays, the cells were lysed by freeze thawing, thereby releasing any 
intracellular viable and infectious progeny virions. An incapacity of recombinant viruses to 
attach and enter cells was not likely, as the entire P 1-coding sequence of the in vitro 
generated recombinants, checked in its entirety by sequencing, remained unchanged. The 
capsids, being identical to source capsids, would be expected to have wild-type infectious 
parent virion conformation and to attach and enter cells. 
A number of experiments need to be conducted in order to get a better understanding of the 
defect seen in the in vitro generated P1 recombinants and the requirements necessary for 
packaging to occur. One way to investigate this would be the generation of P 1/2A 
recombinants where P1 and 2A-coding regions would be swapped between CVA21 and 
PV3 or Sabin 1. The in vitro generation of such recombinants might give us an insight into 
the localisation of an encapsidation signal and the compatibility requirements for efficient 
encapsidation of the genomes to occur. This would also represent a scenario closer to that 
described in nature (Kew et al., 2002; Rousset et al., 2003; Rousset et al., 2004). 
The selection of novel tropic recombinant viruses in vivo, enabling the generation of 
recombinant viruses without predetermining crossover sites, and the in vitro generation of 
P 1/2A chimeras, may enable a better understanding of the results described in this chapter 
and of the encapsidation and assembly processes. 
Claire Blanchard In vivo recombination Chapter 4 96 
4 Results 3: In vivo recombination 
4.1 Introduction 
Since the introduction of the OPV, vaccine-derived polioviruses (VDPVs) have been 
reported to cause vaccine-associated paralytic poliomyelitis (VAPP) in both 
immunocompromised patients and healthy individuals (see chapter 1: Introduction). The 
recent outbreaks of VDPVs in Hispaniola (Kew et al., 2002), Madagascar (Rousset et al., 
2003), the Philippines (MMWR, 2001) and Egypt (Yang et al., 2003) have raised concerns 
about the WHO eradication program and have highlighted the threat VDPVs cause and the 
need for a better understanding of such viruses. 
A variety of reports (see chapter 1: Introduction) have shown that human enteroviruses can 
recombine in the natural host. In fact, intraspecies recombination is a common occurrence 
in nature, and has been reported in human enterovirus species A (Oberste et al., 2004b), 
human enterovirus species B (Oprisan et al., 2002; Oberste et al., 2004a) and human 
enterovirus species C (Brown et al., 2003). Moreover recent studies provided evidence that 
intertypic recombination could occur between a HEV-C and a poliovirus. In fact, the 
poliomyelitis-causing VDPVs isolated in Haiti and Madagascar were shown to be 
recombinants between poliovirus Sabin type 1/poliovirus Sabin type 2 and human 
enteroviruses species C (Kew et al., 2002, Rousset et al., 2004). 
When recombinants between a poliovirus and a HEV-C with a precise exchange of the 
P1-coding region were generated in vitro, these proved to be non-viable. Can viable 
recombinants between poliovirus and non-poliovirus human enteroviruses occur in a tissue 
culture environment? Can recombination occur in a particular cellular environment such as 
RD-ICAM cells or does recombination only occur in the M cells of Peyer's patches? In 
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vivo recombination studies could provide valuable information and determine whether 
recombination can occur in RD-ICAM cells or whether these cells lack specific 
requirements, only found in the gut environment, necessary for a recombination event to 
occur. What viruses are most likely to recombine? The experiments described in this 
chapter were designed to select for viable recombinant viruses in a tissue culture 
environment by co-transfecting two impaired genomes in the same cellular environment. 
Two selectable defective genomes unable to make viable virus progeny would be 
introduced to the same cellular environment, passaged and growing viruses isolated. This 
would bias the assay and recombination, where the crossover sites have not been 
pre-determined, would therefore be more likely to occur in the particular cellular 
environment. The choice of input genome was critical. Various defects such as in-frame 
deletion within the capsid-coding region, mutations preventing a complete replication 
cycle or sensitivity to a particular drug, such as GuHC1, were considered for these 
experiments. Should recombinant viruses arise from the experiment, these would be 
isolated, analysed, characterised, the exact location of the crossover points identified, and 
the existence of recombination hot spots and the relevance of these in virus evolution 
would be identified. In this chapter, assays carried out in a tissue culture environment are 
defined as in vivo. 
The successful selection and characterisation of capsid recombinants in tissue culture 
without predetermining crossover points and exact recombination sites should provide very 
valuable information on properties of interspecies recombinant viruses, tropism, viability 
and fitness determinants. Previous findings, described in chapter 3, showed that 
recombinants engineered in vitro to have a precise exchange of the P1-coding region were 
non-viable. These were suggested to have a late replication defect such as packaging. In 
vivo studies may allow a better understanding of the defect affecting the in vitro generated 
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recombinants and may provide valuable information on sequences and interactions 
involved in processes such as encapsidation. 
4.2 Experimental model 
In the model used here, two impaired viral genomes were co-transfected in an 
80%-confluent cell monolayer. The co-transfected cell sheets were incubated for 3 to 5 
days at 37°C to allow for recombination, recovery and multiplication of novel chimeras to 
occur. Any virus recovered would be isolated, analysed and characterised. 
The model was designed based on a number of studies. Evidence of the generation of 
recombinants resulting from the co-transfection of two impaired viral DNA sequences, 
with an efficiency of 80-100%, has been provided in baculoviruses (Chaabihi et al., 1997) 
and adenoviruses (Elahi et al., 2002). The study of poliovirus 5' and 3' overlapping RNA 
fragments (Gmyl et al., 2003) conclusively demonstrated the production of recombinants 
resulting from a co-transfection assay. Furthermore, recent experiments describe the 
generation of cytopathic recombinant viruses from in vivo co-transfection of 
non-replicating subgenomic transcripts of the pestivirus BVDV (bovine viral diarrhea 
virus) (Gallei et al., 2004). The described method can therefore lead to cell death due to the 
emergence of chimeric viruses. This suggested that the proposed model offered a suitable 
strategy to select for recombinants in vivo. 
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4.2.1 Strategy and experimental evidence 
In order to test the viability of the experimental system two impaired poliovirus type 3 
Leon genomes were chosen, based on availability of infectious cDNAs, subgenomic 
replicons and replication-incompetent clones in the laboratory. A PV3 subgenomic 
replicon (REP3-L) was selected as one of the parental genomes. This replicon lacks all but 
82 nucleotides encoding the P1 region, but replicates well upon transfection of permissive 
cell lines. The second chosen parental impaired viral genome was a 
replication-incompetent full-length poliovirus type 3 genome (SL3), derived from the 
plasmid pT7/SL3. pT7/SL3 has eight mutations in the 2C CRE region preventing the 
formation of the stem loop structure thereby inhibiting the formation of the VPg-pUpU 
primer and thus the initiation of the positive-sense strands synthesis. However, the SL3 
genome is still capable of generating negative-sense strands, a process required for 
replication-dependent recombination (Goodfellow et al., 2003), and the remainder of the 
genome is PV3 sequences. Interestingly, SL3 revertants to replication-competency could 
not be recovered (Goodfellow et al., 2000). 
4.2.2 Transfection efficiency calculation 
The transfection efficiency of poliovirus type 3 in RD-ICAM cells was calculated by blue 
cell assay, to determine favourable experimental conditions. Transfection by CaPO4 
precipitation (Elahi et al., 2002), DOTAP (Chaabihi et al., 1996), electroporation (Gallei et 
al., 2004) and DEAE-dextran (Gmyl et al., 2003) have all been shown to be successful at 
generating recombinants. The use of Lipofectamine 2000 is another very efficient RNA 
transfection method. To maximise the chances of observing a recombination event a 
variety of transfection methods, post-transfection incubation times, cell densities and RNA 
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concentrations were tested. Transfection method and RNA concentrations test results are 
illustrated in table 4.2. 
Transfection method 
[PV3 T7 RNA] transfected into 
RD-ICAM cells 
Oµg 1µg 5µg 10µg 
DEAE-dextran 1% 10-20% 30-40% 30-40% 
Lipofectamine 2000 5% 50% 70-90% 70-90% 
Electroporation (250V, 40052,250pF) 5% 60% 70-90% 70-90% 
Table 4.2: Summary of in situ ß-galactosidase detection of a bound ligand assay to 
determine the conditions for efficient transfection of PV3 T7 RNA transcript in 
RD-ICAM cells. The values represent the percentage of blue cells in each sample. 
The negative controls for transfection surprisingly exhibited reasonably high background 
level for the samples transfected by electroporation and Lipofectamine 2000. This was 
thought to be due to non-specific staining of unattached cells. Transfection by 
electroporation often results in a significant number of dead or unattached cells that never 
recover. Similarly, large numbers of Lipofectamine 2000 liposomes fuse with the cell 
membranes, which can disrupt these structures resulting in significant levels of cell death. 
The background levels of blue cell staining observed in DEAE-dextran transfected cells 
was significantly lower than that seen post-electroporation and Lipofectamine 2000 
treatment. This is because dextran permeabilises the cell membrane allowing entry of RNA 
and results in very little cell death. However, the transfection of poliovirus type 3 into 
RD-ICAM cells by electroporation and Lipofectamine 2000 (70-90%) was significantly 
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more efficient than transfection by DEAF-dextran (30-40%). The amounts of RNA that 
yielded greater transfection efficiency were that of 5µg and 10µg. 
However, these figures were calculated based on transfection of one parent and, due to 
time restrictions, co-transfection efficiency was not determined. Assuming the transfection 
efficiency was equally high for other genomes the theoretical co-transfection efficiency 
was calculated. Around 49% (70% of 70%) of the transfected cells would be expected to 
contain copies of both parental genomes. This figure was thought to be sufficiently high 
since recombination is a frequent event. The parameters (electroporation of a total of 10µg 
of RNA into 106-107 cells/ml) were standardised and applied to the experimental model. 
4.2.3 Co-transfection of SL3 and REP3-L genomes in L20B cells 
The experimental model is described in figure 4.1. A. RNA synthesised in vitro from 
pT7/SL3 and pT7REP3-L were co-transfected by electroporation into L20B cells (kindly 
provided by Dr A. Macadam, National Institute for Biological Standards and Control), a 
murine cell line expressing the PVR. To ensure that the differences in transfection 
efficiencies would not bias the assay, different ratios of normalised concentrations of RNA 
transcripts derived from the two parental genomes were used. RNAs synthesised from 
individual control plasmids pT7/SL3 and pT7REP3-L were transfected in parallel and a 
mock transfection was carried out to monitor the effect of the transfection conditions on 
L20B cells. A parallel control transfection of the pT7FLC/PV3 RNA transcript positive 
control was conducted under the same experimental conditions at a different time to ensure 
no carryover. The results are listed in table 4.3. 
A 
Transfection of poliovirus Transfection of replication 
type 3 luciferase replicon incompetent poliovirus type 3 
pT7REP3-L T7 RNA SL3 pT7/SL3 T7 RNA 
(electroporation) (electroporation) 
S l 
80% confluent L20B cells 
i Incubation at 37°C for 3 to 5 days to allow 
recombinants to appear 
Reverse transcription of 
isolated vRNA and cDNA 
analysis by PCR amplification, 
restriction digest and 
sequencing. 
Neutralisation assay and blocking 
assay to verify that recombinant 
viruses were PVR-tropic and 
poliovirus type 3 like and not 
poliovirus type 1 thereby ruling out 
contamination with PV 1. 
E3 Transfection of CVA21 . 4ge I Transfection of replication deletion clone T7 RNA or EV7 incompetent poliovirus type 3 
. 
Vsi I deletion clone T7 RNA SL3 pT7/SL3 T7 RNA 
(electroporation) (electroporation) 
80% confluent RD-ICAM cells 
i Incubation at 37°C for 3 to 5 days to allow for 
recombinants to arise 
i 
Figure 4.1: Experimental model 
Data analysis 
I \pcnmental procedure of co-transfection experiments for the selection of 
recombinant viruses. A- Co-transfection method of the pT7REP3-L T7 RNA transcript 
and pT7/SL3 T7 RNA transcript. B- Co-transfection method of the CVA21 Age I 
deletion clone T7 RNA transcript or EV7 Nsi I deletion clone T7 RNA transcript and 
pT7/SL3 T7 RNA transcript. 
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Amounts of RNA (in µg) 
Transfection of L20B 
cells 
pT7/SL3 RNA pT7REP3-L RNA PT7FLC/PV3 RNA CPE readout 
5 5 0 
2 8 0 " 
8 2 0 " 
10 0 0 ° 
0 10 0 ° 
0 0 10 " 
0 0 0 ° 
Table 4.3: Results of co-transfection by electroporation of pT7FLC/SL3 RNA with 
pT7REP3-L RNA in L20B cells. The read-out of the experiment was the presence   
or absence Q of cytopathic effect observed in the transfected cell sheets. The amount 
of RNA transfected is expressed in pg. 
4.2.3.1 Analysis of recovered recombinant viruses 
As expected, no CPE or very low levels of CPE were observed in the negative control 
samples. The very low levels of CPE observed were thought to be induced by SL3 and 
REP3-L production of the cytotoxic functional viral 2A protein. Complete CPE was 
observed in cells transfected with the positive control full-length wild-type PV3. Finally, 
L20B cells co-transfected with both defective genomes exhibited high levels of CPE, 
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comparable to wild-type levels. The viruses were isolated from the samples, analysed and 
characterised. 
The co-transfection of a replication-impaired SL3 genome with a REP3-L luciferase 
replicon in vivo led to the successful generation of viable recombinant viruses (SL3-L) 
with PV3-like sequences and properties. The expectation that two impaired PV3 viral 
genomes can recombine in vivo was confirmed and the viable recombinant viruses were 
analysed by receptor blocking, virus neutralisation, plaque phenotype, RFLP and 
sequencing studies. 
4.2.3.2 Receptor blocking assay 
Infections with the viruses resulting from the co-transfection of pT7/SL3 RNA and 
pT7REP3-L RNA were blocked by treatment with an anti-PVR monoclonal antibody (see 
table 6.1) indicating that the isolated viruses were PVR-binding viruses (see figure 4.4). In 
the absence of an anti-PVR polyclonal antibody PV3, PV 1 and the isolated recombinant 
viruses (SL3-L) were able to exert a cytotoxic effect on L20B cells. In the presence of the 
anti-PVR polyclonal antibody infections by PV3, PV 1 and the SL3-L viruses were blocked 
and no cytolysis was observed. This result confirmed that SL3-L viruses were PVR-tropic. 
4.2.3.3 Neutralisation assay 
SL3-L recombinant viruses had a PV3-like antigenicity as neutralisation of virus infection 
in L20B cells was observed in the presence of an anti-PV3 antibody but not in the presence 
of an anti-PV 1 antibody (see figure 4.4). PV 1 infection was neutralised by anti-PV 1 
antibody, PV3 infection was neutralised by anti-PV3 antibody and no antibody 
cross-reactivity was observed. 
B- Anti-PV3 polyclonal 
antibody dilutions 
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A- Anti-PVR pol}clonal 
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Figure 4.4: Phenotypic analysis of viruses generated by co-transfection of 
p"1'7/SL3 '1'7 R\: A With p7'7REP3-1, "1'7 RNA. 
Neutralisation and blocking assay of plaque purified viruses generated by co- 
translection of p'1'7/SL3 T7 RNA transcript with pT7REP3-L T7 RNA 
transcript. A- Blocking assay using anti-PVR polyclonal antibody. B- 
Neutralisation assay using an anti-PV3 polyclonal antibody. C- Neutralisation 
assay using an anti-PV 1 polyclonal antibody. 
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4.2.3.4 Plaque phenotype 
The plaque phenotype of SL3-L viruses was indistinguishable from that of PV3 viruses 
(see figure 4.5 and 4.6). 
4.2.3.5 Genetic analysis 
SL3-L viral RNA was extracted, reverse transcribed and amplified for further analysis. 
RFLP and sequencing studies were carried out in order to determine the genotype of the 
SL3-L viable recombinant viruses isolated from the in vivo co-transfection assay. The 
cDNA generated from the reverse transcription reaction was then amplified by PCR and 
the product was purified and submitted to RFLP analysis and sequencing. Both analyses 
confirmed the SL3-L sequences were poliovirus type 3-like (data not shown). 
To check the capsid-coding region of the genome was derived from the SL3 
replication-defective genome Sac I digests were carried out. Both pT7FLC and pT7/SL3 
have a Sac I site within the P 1-coding region (confirmed by sequencing). However, it is 
unclear as to why but the former can be cut whereas the latter cannot. This Sac I site was 
therefore used for identification purposes. Sequencing data demonstrated the presence of a 
Sac I site within the P1-coding region of the SL3-L cDNA. This site was not digested by 
Sac I confirming that the SL3-L viruses isolated had SL3 P1-coding region sequences. 
The SL3 clone has a Siva I site, situated in the mutated 2C-coding region. Screening for the 
absence of that site in the SL3-L virus sequences verified that the 2C CRE region was 
PV3-like and not SL3-like. Indeed the PV3 cDNA and SL3-L cDNA sequences were not 
digested by the Siva I restriction endonuclease whereas SL3 control sequences were. 
Partial genome sequencing data further supported the result; the Siva I site was absent from 
the SL3-L cDNA. Contamination with wild-type poliovirus type 3 could not be excluded in 
Figure 4.5: Plaque phenotype of recombinant viruses generated by co-transfection 
of R\. % transcripts derived from pT7/SL3 with pT7REP3-1,. 
'1-%No of the plaque purified viruses are illustrated here. The plaque phenotypes of 
control N iruses PV3 and SL3 are also illustrated here. The plaque assays were carried 
out on 1.2013 cells. A- Plaque assay of two of the plaque purified SL3-L viruses 
generated from co-transtection of RNA transcripts derived from pT7/SL3 with 
p T7Rl: P3-1.. 1: I and 1: 6 represent initial ratios of RNA used for transfection. B- Plaque 
assay of pT7Fl. C'PV3 T7 RNA transcript transfection. C- Plaque assay of pT7/SL3 T7 
RNA transcript transfection. 
Figure 4.6: Titration of virus resulting from pT7/SL3 RNA and pT7REP3-l. 
10A co-transfection. 
Titration hN plaque assay of the third passage of plaque purified viruses generated 
by transfection of 17 RNA transcripts in L2013 cells. A- Plaque assay of one of the 
passaged (p3) plaque purified viruses generated by co-transfection of pT7/SL3 T7 
RNA transcript %N ith pT7Rf: P3-L T7 RNA transcript on L20ß cells: 
1.2ýx 107pfu ml. ß- Plaque assay of the passaged (p3) plaque purified virus 
venerated by transfection of pT7FLC/PV3 T7 RNA transcript on L20ß cells: 
1.2Sx I07pfu/111 
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these experiments but was very unlikely due to the precautions taken whilst carrying out 
the experiment and control transfections. Further analysis of possible crossover sites was 
impractical as both parental impaired genomes had type 3 sequences. 
Repeating the experiment with defective genomes derived from different poliovirus 
serotypes could enable a more detailed analysis. Indeed, the successful recovery of viable 
recombinant viruses from co-transfection of a poliovirus-type 1 impaired parent with a 
poliovirus-type 3 impaired parent, could lead to the identification of recombination 
crossover points and the potential identification of recombination hot spots due to the 
sequence differences exhibited by the parental genomes. Time constraints and lack of 
availability of defective type 1-genomes prevented this assay from being carried out. This 
additional assay would add little to the aims of the study. However, the present result 
indicated that successful recombination between two homologous defective poliovirus 
type-3 RNAs could occur in vivo, in L20B cells. 
4.3 In vivo selection for recombinants between poliovirus and 
enterovirus species C and enterovirus species B 
Can a non-poliovirus enterovirus recombine with poliovirus in tissue culture? The in vivo 
selection for viable recombinant viruses between a poliovirus and a non-poliovirus 
enterovirus was therefore carried out using the experimental system as previously 
described and tested. Before initiating the assays the appropriate and available impaired 
parental genomes were carefully chosen and designed. The aim was to choose a human 
enterovirus C, closely related to poliovirus. These would be expected to recombine in vivo, 
as HEV-C are known to recombine with poliovirus vaccine strains in nature (Kew 2002, 
Rousset 2004). A human enterovirus B reference genome, more distantly related to 
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poliovirus, was also chosen for the assay, as it would be equally interesting in the selection 
for recombinants in vivo. 
The choice of available impaired parental genomes was limited as there are very few or no 
current replicon or SL3 versions of HEV-Cs or HEV-Bs. One of the parent genomes was 
required to be poliovirus capsid-encoding as the aim was to select for PVR-tropic viruses. 
The poliovirus SL3 replication incompetent clone was chosen as one of the impaired 
parents. l lEV representatives were chosen based on availability of infectious clones in our 
laboratory and homology levels to PV3. CVA21, a HEV-C closely related to polioviruses, 
has an 84.2% polyprotein amino acid identity with PV3, and EV7, a HEV-B more distantly 
related to polioviruses, only has a 64% amino acid identity with PV 1. CVA21 and EV7 
were the chosen as HEV representatives and best available parents for the experiment. 
CVA21 and EV7 cDNAs were genetically engineered to create an in-frame deletion within 
the capsid-coding regions so that infectious wild-type virus could not be generated due to 
the absence of functional capsid proteins. Due to time constraints the replication phenotype 
of the P1-deletion clones could not be tested. Their competence to replicate was assured 
from knowledge of the poliovirus and poliovirus sub-genomic replicon system and from 
the sequencing to verify an in-frame deletion was present. The cloning strategies are 
illustrated in figure 4.7 and 4.8 and described in section 4.3.1.1 and 4.3.1.2. 
4.3.1 Design of defective genomes 
4.3.1.1 Cloning strategy for the generation of in-frame deletion within the Pl-capsid 
coding region of CVA21 (enterovirus C) 
A pT7CVA21AP 1 deletion clone was derived from the pCAV21 plasmid, which contains 
an infectious CVA21 cDNA. pCAV21 has three Age I sites within the VP2 and VP4 
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coding regions of the genome. Following Age I digestion of pCAV21, T4 DNA 
polymerase treatment was carried out to fill in 5'overhangs to form blunt ends, which were 
ligated together. The ligation reaction was then transformed, amplified in ER2738 bacterial 
cells and the DNA was purified. The clones were screened by standard digestion with 
Nco I, Bam HI and Eag I, a site created upon ligation (data not shown), and sequence 
analysis of PCR amplified VP4/VP3 coding regions (see figure 4.7). A window of the 
5'LTTR/P1-coding region spanning the in-frame deletion was amplified by PCR (using 
forward and reverse oligonucleotide primers CAV21-CAPF and ENT-GEN-2R) and 
sequenced. The analysis confirmed that the constructed clones were correct. The 5'UTR/P 1 
junction coding region of pT7CVA21 AP 1 clones 6 and 7 sequences contained the Eag I 
site and were as predicted. The PCR fragment, were approximately 600bp-long suggesting 
that clones 6 and 7 did contain a deletion, compared to the wild-type pCAV21 PCR 
product, which was approximately 900bp-long. 
4.3.1.2 Cloning strategy for the generation of an in-frame deletion within the P1 
capsid coding region of EV7 (enterovirus B) 
A pT7EV7iP1 deletion clone was derived from the pT7EV7 plasmid, containing the 
complete infectious EV7 cDNA. pT7EV7 was digested with Nsi I, purified and 
self-ligated. The ligation reaction was digested with Sal I preventing religated vector from 
being recovered. The reaction was then transformed and amplified in ER2738 bacterial 
cells and the DNA was purified. The clones were screened by standard restriction digest 
reactions with Bam HI, Nco I and Sal I (data not shown) and sequenced. The sequencing 
analysis of a PCR amplified window of the 5'UTR/P 1 coding region (using specific 
forward and reverse oligonucleotide primers CB3-1F and 591-5R: see figure 4.8) 
confirmed that the recovered clones had in-frame deletions and that the sequences were 
correct. Sequencing of PCR products generated with primers specific for sequences coding 
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Figure 4.8: Cloning strategy of EV7API at the nucleotide level 
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for the 5'LTTR/P 1 junction of pT7EV7A P1 clones 3 and 4 was carried out. The sequences 
were identical to the theoretical expected sequence generated from the cloning technique. 
The PCR fragments sent for sequencing were approximately 750bp-long suggesting that 
the pT7EV70P 1 clones 3 and 4 did contain a deletion, compared to the 2500bp fragment 
obtained from amplification of wild-type pT7EV7 sequences. 
4.3.1.3 Co-transfection of defective T7 RNA transcripts derived from engineered 
plasmid DNAs 
The co-transfection experiment was carried out as shown in figure 4.1. B. RD-ICAM cells 
were chosen because they would support growth of potential recombinant viral genomes 
and both parental genomes from which the impaired genomes were derived and would be 
expected to support growth of potential recombinant viral genomes resulting from the 
reaction. RD-ICAM cells also have a great ability to recover post-electroporation. The 
laboratory HeLa cell line, another permissive cell line, exhibited higher levels of cell death 
post-electroporation and was therefore not used for the assay. RNA synthesised in vitro 
from pT7CVA2I AP 1-6 and -7, pT7EV7AP 1-3 and -4, pT7/SL3 were DNase treated, 
purified, measured using a spectrophotometer and co-transfected into RD-ICAM cells. The 
RNA derived from each individual clone as well as RNA derived from pCAV2 1, pT7EV7, 
pT7FLC/PV3 control plasmids were synthesised and transfected. Mock transfections of 
RD-ICAM cells were also carried out to monitor background levels of cytolysis 
post-transfection. The test transfections were carried out first and removed from working 
environment to a 37°C incubator. The controls were then transfected under the same 
conditions. The results are shown in table 4.9 and 4.10. 
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Amounts of RNA transfected into RD-ICAM cells (in µg) 
pT7CVA21dP16 pT7CVA21AP17 pT7/SL3 pCVA21 pT7FLC/PV3 
CPE 
readout 
5 0 5 0 0 Q 
2 0 8 0 0 Q 
8 0 2 0 0 Q 
0 5 5 0 0 Q 
0 2 8 0 0 Q 
0 8 2 0 0 Q 
10 0 0 0 0 Q 
0 10 0 0 0 Q 
0 0 10 0 0 Q 
0 0 0 10 0   
0 0 0 0 10   
0 0 0 0 0 Q 
Table 4.9: Results of co-transfection of the CVA21AP1 RNA with the SL3 RNA in 
RD-ICAM cells. The read-out of the experiment was the presence   or absence o of 
cytopathic effect observed in the transfected cell sheet. The amounts of RNA 
transfected are expressed in pg. 
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Recovery of recombinant viruses generated in vivo between a replication-incompetent PV3 
and CVA21 with an in-frame deletion within the P1-coding region was unsuccessful. The 
CPE status of control samples was as expected, however no CPE was observed in the 
dually transfected samples. 
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Amounts of RNA transfected into RD-ICAM cells (in µg) 
pT7EV7AP1-3 pT7EV74P1-4 pT7/SL3 pT7EV7 pT7FLCIPV3 
CPE 
readout 
5 0 5 0 0 Q 
2 0 8 0 0 Q 
8 0 2 0 0 Q 
0 5 5 0 0 Q 
0 2 8 0 0 Q 
0 8 2 0 0 Q 
10 0 0 0 0 Q 
0 10 0 0 0 Q 
0 0 10 0 0 Q 
0 0 0 10 0   
0 0 0 0 10   
0 0 0 0 0 Q 
Table 4.10: Results of co-transfection of the EV7AP1 RNA with the SL3 RNA in 
RD-ICAM cells. The read-out of the experiment was the presence   or absence Q of 
cytopathic effect observed in the transfected cell sheet. The amounts of RNA 
transfected are expressed in pg. 
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As expected, the negative controls did not induce CPE in the transfected cells whereas 
transfection with RNA transcripts derived from the complete cDNAs of control viruses 
caused full CPE of the transfected cells. The absence of CPE observed in the test samples 
suggested that, under the conditions used, no viable recombinant viruses could be 
recovered between a replication-incompetent PV3 and EV7 with an in-frame deletion 
within the P1-coding region. 
4.4 Discussion 
Viable recombinant viruses were successfully recovered from in vivo selection experiments 
using two impaired PV3 viral RNA genomes. The experimental model was then applied to 
human enterovirus species C and species B defective genomes. Co-transfection of 
CVA21 AP 1 and SL3 defective genomes and EV7AP 1 and SL3 defective genomes in 
RD-ICAM cells failed to generate viable recombinant viruses under the conditions used. 
Previous studies have shown the successful generation of recombinants resulting from 
co-transfection of two impaired viral genomes in vivo (Chaabihi et al., 1997; Elahi et al., 
2002; Gmyl et al., 2003; Gallei et al., 2004). Furthermore, the Hispaniola (Kew et al., 
2002) and Madagascar (Rousset et al., 2004) outbreaks were demonstrated to have been 
caused by viable circulating VDPV strains that had emerged as a result of recombination 
between poliovirus vaccine strains and human enterovirus species C strains. It was 
therefore surprising that co-transfection of CVA21 and PV3 did not give rise to a 
recombination event leading to the generation of viable viruses. 
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4.4.1 Further investigations of the experimental conditions 
Further control experiments are required to investigate whether the results seen were due to 
the defective clones being unable to generate functional proteins and replicate or whether 
recombination between CVA21 and PV3 is not possible under the conditions used. Study 
of CVA2IAP1 and EV7AP1 translation needs to be carried out by in vitro translation 
assays using HeLa S 10 nuclear extracts and rabbit flexi-reticulocyte lysates. The 
replication competence of the generated defective RNAs also need to be determined by 
dot-blot assay or replication assay using HeLa S10 nuclear extracts, as the unsuccessful 
generation of viable recombinant viruses from the in vivo selection experiment could have 
been due to the P1-deletion genomes having a defect at the level of replication. Such a 
defect could have prevented replicative recombination from occurring. 
The precise co-transfection efficiency needs to be determined to ensure that the conditions 
used are optimal. Introduction of a tag-epitope during the in vitro generation of the P1 
deletion defective CVA21 (CVA21-tag) and co-transfection of SL3 RNA with the 
CVA21-tag RNA into RD-ICAM cells or L20B cells would constitute the basis of a 
specific probing assay. Eight hours post-transfection the cells would be fixed and 
permeabilised. Transfected cells would then be treated with both anti-VP 1 DAKO mouse 
monoclonal antibody (detecting the SL3 VP1 proteins), followed by treatment with a 
secondary anti-mouse antibody conjugated with FITC for example, and an anti-tag 
polyclonal antibody (probing for the CVA21-tag genome), followed by treatment with a 
secondary anti-polyclonal antibody conjugated with a different fluorochrome like TRITC. 
Confocal microscopy analysis would then be carried out to detect the percentage of dually 
transfected cells detected by co-localisation of the two different fluorochromes. The use of 
a fluorescence activated cell sorter (FACS) would enable detection and a more accurate 
quantification of dually-transfected cells. Once the co-transfection efficiency has been 
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determined, an improved design of the transfection technique will be possible thereby 
increasing the efficiency at which recombinants are generated. 
Recent studies, have provided definitive evidence that recombination could occur via a 
replication-independent pathway (Gallei et al., 2004), probably. involving cellular 
processes, suggesting that even in the event of the P1 deletion genomes being 
replication-incompetent, recombination could have occurred in a replication-independent 
manner. This hypothesis is further supported by the fact that defective RNA molecules can 
exert a complementing effect in a cellular environment and lead to cytopathic cell death 
(Garcia-Arrazia et al., 2004). The cellular environment used could have affected the results 
seen. The use of caco-2 cells, lining the intestinal epithelium, or pharyngeal cell lines may 
provide a more favourable environment for recombination between enteroviruses to occur. 
Moreover using such cell lines may better reflect a natural environment as it is in the sites 
of infection that recombination between two enteroviruses is more likely to occur. 
Co-transfection of defective EV7 RNA with SL3 replication-incompetent RNA did not 
generate viable viral genomes. This could be due to the distant genetic relationship 
between EV7, a human enterovirus type B, and PV3. As we were unable to reproduce the 
situation observed in nature for human enterovirus species C in vivo or in vitro such a 
conclusion could not be made. However, it is possible that human enterovirus species B 
will never be able to recombine with human enterovirus species C. Because different 
species use different cell surface receptors for infection, it may be impossible for both 
genomes to be present in the same cell type at any one time. If the genomes are not in the 
same cellular environment they may never be able to recombine and could be why there 
has been no reported evidence of such an event happening in nature. 
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4.4.2 Speculations 
There exist differences between SL3 and PV3 P1-coding regions. For example, the Sac I 
site present in the middle of the P1-coding region is not digested in the SL3, as opposed to 
the PV3 genome. It is known that these do not affect the production of viable viruses 
(Goodfellow et al., 2003; table 3.10; table 4.3). 
It is possible that the lack of pre-determined crossover sites and the randomness of 
recombination sites could have affected RNA structures preventing viable viruses from 
being generated. 
It is also possible that acytopathic recombinant viral genomes were generated in these 
experiments. The CVA21 2C CRE may have been unable to interact with the rest of the 
SL3 genome and therefore unable to take part in key interactions necessary for the 
generation of viable viruses. The primary screening method used in the described 
experiment did not enable the detection of acytopathic recombinant viruses and testing to 
determine whether the samples contained acytopathic viruses was not carried out due to 
time restrictions and prioritisation of other parts of the project. 
Recombination during mixed infection with various strains of poliovirus has been known 
to be a common occurrence in vaccinees. Recombination has also been shown to occur 
during mixed infection with various strains of poliovirus, where both genomes replicated 
in the same compartments (Egger et al., 2002). However, no study so far has provided 
proof of different enterovirus species replicating in the same compartments and it could be 
that strains belonging to either the same species (CVA21 and PV3) or different species 
(EV7 and PV3) replicate in separate replication compartments thereby making 
replication-dependent recombination impossible. 
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4.4.3 Alternative reference genomes 
It is expected that a genome exhibiting high homology with that of poliovirus would be 
more likely to recombine. Recent sequence analysis studies in which mass sequencing of 
complete genomes of the human enterovirus species A (Oberste et al., 2004b), human 
enterovirus species B (Oberste et al., 2004a) and human enterovirus species C (Brown et 
al., 2003) was carried out and inter- and intra-species amino acid percentage identity 
deduced from nucleotide sequences were calculated. These studies provided a better 
insight on evolutionary stages of human enteroviruses and a very useful report of 
homology levels that exist between enteroviruses. Some BEV-Cs, other than CVA21, have 
been shown to exhibit greater homology to PV3. CVA20, for example, would have been 
expected to be a better member to choose for the experiment, as it is 90.2% identical, based 
on complete amino acid sequence, to PV3. A more detailed comparison between CVA21, 
CVA20 and PV3 is described in table 4.11, based on the published data (Brown et al., 
2003). The way the assay was conducted did not enable us to use CVA20, as no infectious 
cDNA was available. 
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Amino acid identity with 
PV3 (in %) 
CVA21 CVA20 
5'UTR 79 81 
3'UTR 97 99 
P1 70 78 
P2 79 96 
P3 96 97 
Complete polyprotein 84.2 90.2 
Table 4.11: Amino acid sequence relationships (percent identity) between two 
members of the human enterovirus species C (CVA21 and CVA20) and PV3 (data 
adapted from Brown et al., 2003). 
An interesting alternative assay would be the transfection of SL3 RNA and subsequent 
co-infection with CVA20 virus. The progeny viruses would be harvested and passaged 
onto L20B cells, assuming CVA20 does not infect L20B cells, thereby only selecting 
PVR-binding viruses. It is unlikely that CVA20 would infect L20B cells as these are L 
cells expressing the PVR on their cell surface and that L cells are non-permissive for 
infection with any human enteroviruses. This would enable the selection of infectious 
recombinant viruses that have acquired an SL3 P1 coding region. This alternative assay 
may allow for recombination to occur. The characterisation of viable in vivo recombinants 
would then allow the mapping of recombination crossover sites and potential 
determination of recombination hotspots. 
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4.4.4 Suppression of synonymous sequence variation (SSSV) 
Suppression of synonymous sequence variation (SSSV) is a program designed by David 
Evans. The program differentiates equal distribution of the codons encoding a single amino 
acid from bias towards the use of a preferred codon encoding for an amino acid in a 
particular area of the genome. If there is equal distribution of codons encoding an amino 
acid, no bias towards use of a particular codon exists and therefore no suppression of 
synonymous sequence variation is observed. This is represented by high synonymous 
variation values. However, a trough would indicate a region where synonymous sequence 
variation was suppressed and a bias towards the use of a particular codon was observed. A 
trough is a region where there is less variation in the sequence then the amino acid 
sequence would allow. These troughs are thought to represent conserved regions that may 
play key roles in the virus life cycle. This has been confirmed to be the case of the first 
trough observed on the graphs (figure 4.12). The trough corresponds to the 2C CRE 
stemloop structure, a structure essential for priming and initiating genome replication. It is 
possible that other regions of synonymous sequence variation are structured regions. 
HEV-Bs and HEV-Cs sequences have been submitted to the SSSV analysis and the results 
are plotted on graphs illustrated figure 4.12. HEV-Bs and HEV-Cs exhibit different SSSV 
patterns in the non-structural coding region. The graph of HEV-Bs exhibits one trough, 
whereas the graph of HEV-Cs exhibits an additional two areas of strong suppression of 
synonymous variation. The trough present in both HEV-Bs and HEV-Cs graphs represents 
the region corresponding to the 2C CRE. The functions fulfilled by the two additional 
regions where troughs were observed are unknown, however sequence and maybe structure 
conservation suggests a functional role. If the HEV-Bs have a similar life cycle to that of 
HEV-Cs, some reactions are likely to be carried out in different ways, explaining the lack 
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Figure 4.12: Suppression of synonymous sequence variation analysis, 
comparison of human enterovirus genera (figure generated by David 
E: vans). 
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of troughs. Should one of these functions involve interaction with homologous capsid 
proteins, this would explain the absence of recombinants between HEV-Bs and HEV-Cs. 
4.4.5 Future experiments 
Should recombinant viruses be generated in vivo using a more accurately designed method 
or alternative assays, a series of characterisation experiments would be carried out. A 
number of sequencing studies would be initiated in order to determine the location and 
nature of the recombination crossover sites. Analysis and comparison of various 
recombinants may enable determination of recombination hotspots and the implications of 
such hotspots in enteroviral evolution. Comparison of viable in vivo generated recombinant 
viruses with the non-viable in vitro generated P1 recombinants, described in Chapter 3, 
may enable identification of the defect affecting the latter and give insights into 
picornaviral research. 
An infectious centre type assay could also be undertaken to try and generate in vivo 
recombinants. Co-transfection of L cells, which have been shown to support replication of 
human enteroviruses post-transfection, with the two impaired parental genomes, could be 
carried out. 4-6 hours post-transfection, time point at which the cells would have recovered 
following the transfection but no newly generated virus would have been released, the 
co-transfected L cells would be lifted from the transfection flasks and transferred onto an 
80%-confluent monolayer of L20B cells, cell line supporting poliovirus recombination, 
RD-ICAM cells or RD cells. Overlay media would be added and the samples would then 
be incubated at 37°C for three to five days to allow plaque formation of any in vivo 
generated recombinants. These would then be isolated from plaques, purified, amplified 
and characterised. This method is an alternative to the technique described in this chapter 
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and may enable isolation of in vivo generated recombinant viruses as opposed to 
populations of mixed recombinants. 
The advantage of generating recombinants in vivo is that a scenario closer to that seen in 
nature is reproduced in a tissue culture environment. As opposed to in vitro generation of 
recombinants the crossover sites are not pre-determined and are more likely to mimic a 
natural situation. However, the use of novel techniques such as small interfering RNAs 
(siRNAs) and DNA shuffling to select for recombinants between human enterovirus 
species in a laboratory environment are interesting alternatives to the method used in this 
chapter (see chapter 5: General discussion). 
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5 General discussion 
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In view of the poliomyelitis eradication program, several issues have become major 
concerns. What are the chances of a non-poliovirus enterovirus evolving to use the 
poliovirus receptor? Would such a virus cause poliomyelitis? What are the implications of 
such recombinants? The project aimed to investigate some of these issues. 
It was initially proposed to use DNA shuffling to create chimeric mosaic capsids that may 
interact with different cell surface receptors. DNA or gene shuffling is an elegant process 
that enables the production of in vitro recombinants with mosaic sequences of gene 
families and diverse libraries of progeny genes. This technique is very ambitious, as it 
requires very technically demanding DNA manipulations, and a number of different stages 
could become problematic. Firstly, stop codons, truncation of the sequences and incorrect 
open reading frames leading to inefficient translation could arise from DNA shuffling 
experiments. Secondly, full-length nonsense sequences encoding the capsid proteins could 
have been generated rendering any resulting viruses non-viable. Finally, full-length 
in-frame generated sequences of the capsid protein-coding regions could be processed 
inefficiently by heterologous 3C and 3CD proteases. It was therefore important to study 
processing requirements closely. To do so, recombinants with a precise exchange of the 
P1-coding region between poliovirus type 3 and CVA21, a HEV-C, were generated in 
vitro. The experiment developed into a very interesting analysis of chimeras. The in vitro 
generated recombinants were unable to cause cytopathic effects upon transfection and 
passage into cell lines permissive for infection and replication of both parental genomes. 
However, the chimeras appeared to produce the correct proteins and to exhibit the correct 
protein-processing pattern. Further assays indicated that the recombinants were 
replication-competent and suggested that these may have had a late replication defect such 
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as a packaging defect. These results indicated that relatively divergent capsids could be 
processed by viral proteases suggesting that the heterologous mosaic capsids created by 
DNA shuffling may also be processed by 3CD protease. 
The DNA shuffling technique has been applied to create recombinants of single genes such 
as cytokine (Chang et al., 1999), thymidine kinase (Christians et al., 1999), green 
fluorescence protein (Crameri et al., 1996), subtilisin (Ness et al., 1999) and a fucosidase 
(Zhang et al., 1997). However, until recently DNA shuffling had not been applied to viral 
genes. In 2000, studies described the use of the method to alter receptor tropism of a 
retrovirus by creating a recombinant mosaic of the envelope glycoprotein gene (Soong et 
al., 2000). Since then, a variety of studies have used DNA shuffling for recombinant 
generation, functional gene analysis and other purposes. RACHITT (RAndom 
CHImeragenesis on Transient Templates) is one of the best available DNA shuffling 
techniques (Pelletier et al., 2001; Coco et al., 2001; Coco et al., 2003) and it was planned 
to use this approach for the project. 
RACHITT, a templated assembly of mosaic sequences, could be used to generate 
HEV-C/PV recombinants with a mosaic P1-coding region, by shuffling several HEV-Cs or 
polioviruses P1 genes. Although ambitious, the potential recovery and characterisation of a 
PVR-tropic recombinant HEV-C virus would be very valuable. 
A range of relatively closely related input polioviruses and non-poliovirus HEV-Cs would 
be used for the experiment. The entire capsid-coding gene or a range of individual capsid 
genes of various polioviruses would be shuffled and introduced into a non-poliovirus 
HEV-C backbone vector containing the remainder of the coding and non-coding 
sequences. The experimental method is illustrated figure 5.1. First, top strands of the 
P1-coding regions of heterologous polioviruses would be partially digested with DNAse I. 
Fop strand of P1 region of heterologous poliovirus viruses 
Partial DNase digestion and isolation 
Bottom strand scaffold 
(HEV-C Pl) 
N%lk 
0000e 
-/--\-- 
Hybridisation 
I Digestion of flaps, filling gaps and ligation of nicks 
Destruction of scaffold strand, 
synthesis of double strand 
1 
Cloning into IIEV-C Pl deleted backbone, screening and 
selection 
Figure 5.1: DNA shuffling 
I)NA shuffling using RACHITT: Random chimeragenesis on transient templates, 
method first used by Stemmer et al. (1994) for retroviruses. Adapted for accelerated 
HEV-C evolution. 
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The digested fragments would then be hybridised to a uracil-containing bottom scaffold 
strand of the P1-coding region of a HEV-C. The flaps would then be digested, the gaps 
filled and the nicks ligated. Uracil-DNA-glycosylase treatment of the heterologous hybrid 
would destroy the HEV-C PI-coding region scaffold strand allowing for the synthesis of a 
double stranded mosaic recombinant fragment. The fragment would then be cloned into a 
HEV-C P 1-coding region deleted backbone and screened for viability on a variety of celI-- 
lines. An ideal cell line for PVR-tropic viruses screening is the L20B cell line. L20B cells 
are murine fibroblasts (L cells) expressing the PVR. Therefore, a virus that grows on L20B 
cells but not on L cells would be PVR-tropic. Further screening utilising neutralisation 
assays, using a cocktail of non-poliovirus REV-C specific antibodies, could be conducted. 
The method presents a few drawbacks. DNA shuffling would yield large populations of 
chimeras that would not be subjected to screening until later on in the experiment. Because 
of the sizes of the fragments composing the mosaic, a very high number of different 
combinations of sequences could result from the assay and inevitably non-viable sequences 
would be generated. However, DNA shuffling enables the dramatic acceleration of gene 
evolution. 
Other approaches to DNA shuffling such as random mutagenesis studies using ribavirin are 
possible. This assay is discussed in Chapter 2. Certain aspects of the experiment need to be 
more formally tested. Such a method combined with the use of PVR covalently-bound to 
affinity chromatography column would make the screening process more stringent and 
could increase the chances of selecting for novel tropic viruses. However, upon binding to 
PVR viral uncoating occurs and the chromatography isolation of mutated virus populations 
binding the PVR with different degrees of affinity would need to be carried out at 0-4°C. 
Elution of low-affinity PVR-bound viruses using high salt concentrations and RNA 
extraction for subsequent transfection would then be carried out. Following transfection the 
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samples would be submitted to several rounds of replication thereby enhancing the affinity 
for PVR of the isolated viruses. This method may enable isolation and study of novel 
tropic mutated viruses. 
Although the project diverged from the initial aim, the results obtained from the in vitro 
generated recombinant studies were very interesting and could be very valuable for 
poliovirus research. Further investigations could lead to the identification of a, yet to be 
determined, specific encapsidation signal and/or interactions involved in packaging of the 
viral genome. In order to investigate this result further, forced recombination in a tissue 
culture environment without predetermining the crossover sites should to be carried out. In 
vivo recombination experiments did not yield any significant data. However, there are 
alternate ways of applying selective pressure and forcing recombination between two _ ___ 
viruses in tissue culture, such as RNA interference. 
RNA interference (Fire et al., 1998) is a very useful tool for functional gene analysis, gene 
silencing and therapeutic use (Cheng et al., 2003). Small double stranded fragments of 
RNA (small interfering RNAs: siRNAs) have been shown to induce sequence specific 
degradation of RNA. In fact, binding of siRNAs to single genes leads to suppression of 
gene expression. RNA interference has been identified in many organisms such as plants, 
trypanosomes and fungi and is thought to be a means of protecting an organism against 
viral infection (reviewed Saleh et al., 2004). Recent studies indicated that 
19-23 nucleotide-long synthetic siRNA fragments could trigger strong and specific gene 
silencing (Elbashir et al., 2001). 
The use of siRNAs, in a tissue culture environment, may enable the generation of 
recombinant viruses with altered tropism, and more specifically may allow recovery of a 
PVR-tropic non-poliovirus HEV-C. An experimental assay was designed to investigate this 
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and is illustrated in figure 5.2. Recent studies have demonstrated the existence of siRNA 
escape mutants that are resistant to specific RNA degradation necessitating the use of 
multiple siRNAs for efficient silencing of the input genome (Gitlin et al., 2005). Hence, 
several siRNAs would be synthesised to bind a number of genes: CVA21 VP1, VP2, VP3 
and VP4-coding. regions. binding siRNAs and PV3 2C CRE and 3C-specific binding 
siRNA fragments. Due to the highly specific nature of RNA interference, any input 
sequence could be used and a range of genomes could be tested. Initial silencing would be 
carried out on both CVA21 and PV3 genomes in a tissue culture environment, thereby 
disabling the genomes to yield viable viruses. These two partners, when present in the 
same cellular environment, should be subjected to sufficient selective pressure to generate 
chimeras. The assay could then be extended to a wider range of different partners. 
The emergence of siRNA escape mutants, the need for high numbers of siRNAs and-the- 
off-target effects exerted by siRNAs on host cells should not be ignored (Couzin et al., 
2004). However, the method would allow a forced recombination event between different 
junctions points. Analysis, identification of crossover points, characterisation of the 
biology of potentially viable in vivo generated recombinants and comparison with the in 
vitro generated precise exchange of the P1-coding region recombinants may give an insight 
into different areas of picornavirus research such as genome cellular localisation, cis-acting 
replication and encapsidation of progeny viral genomes into newly synthesised capsids. 
CVA21 genome 
PV3 2C CRE and 3C 
silencing siRNAs 
('o-transfection in the presence of 
. iR\ \ ot'a permissive cell line 
1 InCuhation. reco\ er\ of potential 
recombinants resulting from assay 
and characterisation. 
Figure 5.2: siR\A gene silencing recombination in tissue culture 
Diagram illustrating the use of siRNAs in tissue culture as means of obtaining 
recombinants %%ithout predetermining crossover sites. 
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6 Materials and Methods 
6.1 Standard solutions and chemical suppliers 
All chemicals were supplied by Sigma-Aldrich or BDH. All enzymes were supplied by 
Invitrogen, NEB, Promega and Roche. 
Phenol: chloroform 
25 parts phenol: 25 parts chloroform: 1 part isoamyl alcohol 
lOx Grin! o 
250 mM Tris-base, 2.5 M Glycine, 35 mM Sodium Dodecyl Sulphate made up to 51 in 
dH2O 
Destain buffer 
10% (v/v) Methanol, 10% (v/v) Acetic acid and 80% (v/v) dH2O 
Crystal Violet 
0.5 g Crystal violet in 20m1 of Ethanol, 880 ml dH2O, 10% (v/v) of 37%(w/v) 
Formaldehyde and 15 mM Sodium Chloride. 
50x TAE 
2M Tris-base, 57.1 ml Glacial Acetic Acid, 10 mM EDTA (pH 8.0) made up to 11 in 
dH2O 
Mini-prep solutions 
Solubilisation: solution 1 (4°C) 
50 mM Glucose, 25 mM Tris-HC1 (pH 8.0) and 10 mM EDTA (pH 8.0) 
Cell lysis: Solution 2 (room temperature) 
200 mM Sodium Hydroxide and 1% SDS 
Neutralisation: Solution 3 (4°C) 
3M Potassium Acetate, 11.5 ml Glacial Acetic Acid and 28.5 ml dH2O 
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RNase A 
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2g RNase A (SIGMA, kept at -20°C) in 200 mis 10 mM Tris (pH 7.8) and 15 mM Sodium 
Chloride. Boiled for 15 minutes to destroy DNase and allow to cool slowly. Store at -20°C 
DEPC-treated water 
0.1% DEPC (SIGMA) to dH2O. Left at 37°C overnight and autoclaved twice. 
2x protein reducing gel loading buffer 
2 ml Glycerol, 1.5 ml 10% Sodium Dodecyl Sulphate, 0.625 ml 1M Tris (pH 6.8), 
0.375 ml dH2O, a spatula's worth of Bromophenol Blue and 50 µl Mercaptoethanol was 
added to every 1 ml of solution. 
Guanidine Hydrochloride (GuHCI)(SIGMA) 
100 mM GuHCI in dH2O 
6x DNA gel loading buffer 
7 ml dH2O, 3 ml Glycerol and a spatula's worth of Bromophenol Blue or Orange G. 
10% (w/v) Ammonium Persulfate 
20%SSC 
3M Sodium Chloride, 300 mM Sodium Citrate made up to 500 mis in dH2O. 
Hybridisation buffer 
Rapid-hyb buffer supplied by Amersham Biosciences. 
RNA denaturation buffer 
660 µl Formamide, 210 pl 37%(w/v) Formaldehyde and 130 µ1 lOx MOPS electropheresis 
buffer. 
10, MOPS 
200 mM MOPS, 80 mM Sodium Acetate, 1 mM EDTA and 100 ml of dH2O. 
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Western Blot Transfer buffer 
1% (w/v) Sodium Dodecyl Sulphate, 570 mM Glycine, 50 mM Tris-base, 
20% (v/v) Methanol and 160 ml dH2O. 
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Western Blot Blocking buffer 
5% (w/v) dried skimmed milk, 0.1% (v/v) Tween 20 in Phosphate Buffered Saline (PBS). 
Cell lysis buffer 
50 mM Tris-HC1 (pH 8.0), 1 mM EDTA (pH 8.0) and 100 mM Sodium Chloride. 
"Spiller" radiolabelling buffer 
1M Sodium Chloride, 20 mM Tris-HC1(pH 7.5) and 0.1% BSA in dH2O. 
Blue cell assay developing solution 
9.560 ml PBS, 2.500 ml 0.5M Potassium Ferrocyanide, 2.500 ml 0.5M Potassium 
Ferricyanide, 0.500 ml 1M Magnesium Chloride and 6.250 ml X-gal (1,4-O-ß-D- 
galactopyranosyl-D-glucose) (20 mg/ml). 
Plaque overlay media 
10% (v/v) l Ox EMEM: Eagle's minimum essential medium (GIBCO Life technologies), 
50% (v/v) dH2O, 1% (v/v) L- glutamine (GIBCO Life technologies), 2% (v/v) FCS (Foetal 
calf serum), 1% (v/v) Penicillin/ Streptomycin (GIBCO Life technologies), 3% (v/v) of 
7.5% Sodium bicarbonate (GIBCO Life technologies) and 30% (v/v) of 2% Bactoagar. 
Claire Blanchard Materials and Methods 
6.2 List of antibodies 
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Database 
Antibodies Dilution Usage 
reference 
Anti-PVR 280 A-AB-5H 1 in 50/ lin 200 Monoclonal antibody to PVR 
Anti-PV3 A-AA-lE 1 in 200 Rabbit polyclonal antibody to 
oliovirus type 3 
Anti-Polio A-AB-1D 1 in 200 Sheep 16- sheep polyclonal to 
type 1 oliovirus type 1 
Western blot: 1 in 1000 
Anti-VP I DAKO mouse monoclonal antibody 
DAKO Immunoflu cence: 1 in against enterovirus VP 1 400 
Anti-mouse 1 in 200 ti-mouse FITC conjugated FITC olyclonal antibody 
Anti-mouse 1 in 5000 ti-mouse HRPO conjugated HRPO olyclonal antibody 
Table 6.1: Table of Antibodies 
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6.3 List of oligonucleotide primers 
Name of 
oligonucleotide 
Database 
reference 
Nucleotide sequence 
ID6 O-AB-91 GGTGTTAGAGAAAATTGGTTTTGG 
R3D O-AD-9C GGGATATCACTCAGCATAATAATGAGTCAAGCCAAC 
GEN-3'BK'F O-AA-2F TATGAGCTCACCACWCCCGGGTTTGGSCAYCAG 
GEN-3'BK-R O-AA-7E CCYACATACATGTTGGGGTACTTACTAGTGTTC 
-F 
O-AA-7H TACGACTCACTATAGGGCG 
CA21-5'-BK-R O-AA-1 F CTTGCGCTCCCATTTGCAC 
GEN-3'BK-F-Nae O-AB-7C RASGAGCTCACCACWGCCGGCTTYGGMCACCARAAC 
GEN-3'BK-R O-AA-7E CCYACATACATGTTGGGGTACTTACTAGTGTTC 
P1-GEN-F O-AA-8E TGGGAGCTCARGTDTC 
PV3-P1-R O-AD-6D TATGTGGTCAAACCTTTCTC 
CA21-P1-R O-AC-3B AAAAGTGGTAATTGAGTCTAC 
PV3/CA21-PI-R O-AA-3F TGSCCAAATACGTAWGTGG 
Sabinl-PI-R O-AC-4B TATGTGGTCAGATCCTTG 
NT GEN 2F O-AA-9C GGAACCGACTACTTTGGG 
ENT GEN 2R O-AA-1D TCNGGNARYTTCCACCAC 
ENT PCD 6R O-AA-5E TGGTARTTRCWRATYTTG 
CAV21 FO O-AA-6G CGGTGCACACGAGAATCAAA 
CAV21 R11 O-AA-5G CGACTGGAAGTCATCAGATG 
CVA21 P1 de1DJE 1 O-AE-8E CCGGGATCTCGAGG 
CVA21 P1 delDJE2 O-AE-9E CTAGCCTCGAGATC 
Polio-End O-AA-7B TAAGTCGACTTTTTTTTTTTTTTTTTTTTTTTTCCT 
CCGAATTAAAGAAAAATTTACC 
ENT PCD 6F O-AA-6E TMACHGCHGTBGARACWGG 
ID1 O-AB-21 TTAAAACAGCTCTGGGGT 
LUCF O-AB-9I CATCTTCGACGCGGGCGT 
PV3-VP2-F O-AD-8D GCCATTCTGCCCTTATCACCG 
PV3-VP3-R O-AD-9C CATTACTAATCCACGGCAC 
PV33D-T7R 
PV3-VP3-3F 
O-AD-9D 
O-AD-7D 
GGGATATCACTCAGCATAATAATGAGTCAAGCCAAC 
GCCAATGACCAGATTGGTG 
CAV21 CAPF O-AA-1H CTTCGAGAAGCCTAGTATCG 
CB3-1F O-AB-8A TCCGGTGACCAATAGAGC 
591-SR O-AD-5C TGTCTGAAGTACAGCTTGCC 
Table 6.2: List of oligonucleotides 
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Plasmid name Description 
Simplified plasmid 
name 
pS1F 
Full length poliovirus Sabin S1F 
e1 infectious clone 
CAV21 
CVA21 full-length infectious CAV21 
clone 
Full length poliovirus type 3 
pT7FLC Leon P3/Leon/37 infectious T7FLC 
clone 
Poliovirus type 3 Leon 
T7FLC/REP3 P3/Leon/37 CAT replicon T7FLC/REP3 
derived from pT7FLC 
Backbone vector lacking the 
pT7FLC/REP3-BK complete P1-coding gene PV3BK 
derived from pT7FLC/REP3 
Backbone vector PV3BK with 
pT7REP3-BK-SL3-P1 
insertion of the complete PV3 PV3BKPV3P1 P1-coding region introduction 
derived from pT7/SL3 
Backbone vector PV3BK with 
insertion of the complete 
pT7REP3-BK-CA21-PI CVA21 P1-coding region PV3BKCVA21P1 
introduction derived from 
CAV21 
Full length poliovirus type 3 
T7/SL3 
Leon P3/Leon/37with 
T7/SL3 
mutations in the 2C CRE 
derived from pT7FLC 
Poliovirus type 3 Leon 
T7REP3-L P3/Leon/37 luciferase replicon T7REP3-L 
derived from T7FLC/REP3 
pRibol 
Vector containing a ribozyme Ribol hammerhead 
CVA21 full-length infectious 
clone introduced in a ribozyme 
pRibo-CAV21 hammerhead-containing vector Ribo-CAV21 
derived from CAV21 and 
pRibol 
CVA21 full-length infectious 
pRibo-CAV21-NaelDel clone with a deletedNae I site, Ribo-CAV21-NaelDel 
derived from pRibo-CAV21 
CVA21 backbone vector 
pRibo-CAV21-NaelDel- lacking the complete P1- 
backbone coding gene, derived from 
CVA21BK 
Ribo-C"21-Nae l Del 
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Plasmid name Description 
Simplified plasmid 
name 
CVA21 backbone vector with 
insertion of the complete 
Ribo-CAV2I-BK/CA21 P1 
CVA21 P1 -coding region, CVA21BKCVA21P1 derived from pRibo-CAV21- 
ae 1 Del-backbone and 
CAV21 
CVA21 backbone vector with 
insertion of the complete PV3 
Ribo-CAV21-BK/PV3-P1 P1-coding region, derived from CVA2IBKPV3P1 
Ribo-CAV21-Nae1Del- 
backbone and pT7/SL3 
CVA21 backbone vector with 
insertion of the complete 
Ribo-CAV2I-BK/Sabinl P1 SabinI P1-coding region, CVA21BKSabin1P1 
derived from pRibo-CAV21- 
ae 1 Del-backbone and pS 1F 
T7EV7 
Full length echovirus 7 T7EV7 infectious clone 
EV7 genome with an in-frame 
EV7AP 1 si I deletion in the P 1-coding EV7AP 1 
region, derived from pT7EV7 
CVA21 genome with an in- 
CVA21 AP 1 
frame Age I deletion in the P1- CVA21 AP 1 
coding region, derived from 
CAV21 
Table 6.3: List of plasmids 
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6.5 Cell culture and virological methods 
6.5.1 Digestion of DNA with restriction endonucleases 
Restriction digest reactions were carried out in the lx buffer recommended by the 
manufacturers in the presence of 1 unit (U) of restriction enzyme per µg of DNA. The 
reactions were made up to final volumes of 20 µ1 in the case of analytical digests or 50 Al 
in the case of preparative digests and were carried out at the temperatures recommended by 
the manufacturers for 1 to 4 hours. 
6.5.2 Plasmid DNA preparation for in vitro transcription 
5 pg of plasmid DNA, containing a T7 promoter, was linearised with the appropriate 
restriction endonuclease, phenol-chloroform extracted and ethanol precipitated. After 
washing in 70% ethanol, the DNA was pelleted, dried and resuspended in 20 p1 clean 
dH2O. 
6.5.3 In vitro transcription using T7 RNA polymerase 
1 Vg of resuspended DNA was incubated in lx transcription buffer (NEB), 1mM rNTPs, 
0.5 pl of RNAse OUT (Invitrogen), 1 pl of T7 DNA polymerase (NEB) made up to a final 
reaction volume of 25 pl with clean dH2O. The reaction was incubated at 37°C for 2 hours. 
10% of the reaction volume was checked on an agarose gel and quantified on a 
spectrophotometer. 
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6.5.4 In vitro transcription using Ribomax 
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1 µg of linearised DNA was incubated in 6 µl of 5x T7 buffer, 2.3 µl rATP, 2.3 µl rGTP, 
2.3 µl rCTP, 2.3 pl rUTP, 3 pl of T7 enzyme mix and clean dH2O (30 pl reaction mix) 
provided in the RiboMAXTh Large scale RNA Production Systems-T7, for 2 hours at 
37°C. The newly transcribed RNA reactions were then RQ1Dnase treated (1 U/µg of DNA 
transcribed) for 30 minutes at 37°C and heat inactivated at 65°C for 15 minutes. Samples 
were checked on an agarose gel and quantified in a spectrophotometer. 
6.5.5 RNA transfection of mammalian cell lines 
6.5.5.1 DEAE-dextran 
1-10 µg of T7 RNA transcripts was incubated in lxHepes-buffered saline, pH 7.1 in clean 
dH20 with 200 pg/ml DEAE-dextran and 10 pl lOx filtered glucose solution on ice for 
30 minutes. Prior to cell transfection, the pre-seeded 80% confluent 6-well dish cell 
monolayers (RD-ICAM cells, Hela cells, RD cells) were washed with Serum Free DMEM 
(SF-DMEM). To each well, 100 µ1 of the reaction mix was added and incubated at room 
temperature for 30 minutes ensuring the cell monolayers did not dry out. The transfection 
mix was then removed and 4 ml of DMEM supplemented with 10% FBS (Foetal Bovine 
Serum) were added to each well and the dishes were incubated at 37°C in a humidified 5% 
CO2 incubator. 
6.5.5.2 Electroporation 
Cells of a confluent T175 flask were resuspended using PBS-125mM EGTA and 
centrifuged at 2000 rpm for 5 minutes (Multifuge 3 S-R Heraeus). The cell pellet was 
resuspended in 500 pl PBS per reaction and transferred with 1-10 pg of T7 RNA to 4 mm 
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electroporation cuvettes for mammalian cells (CLP). The settings used for transfection 
were: 250 V, 400 12,250 µF. The cells were then added to a T25 tissue culture flask 
containing 4.5 ml of 10% DMEM and incubated at 37°C in a humidified 5% CO2 
incubator. 
6.5.5.3 Lipofectamine 2000 
10-15 pg of RNA in solution was made up to 100 p1 in OPTIMEM medium (GIBCO) and 
mixed and vortexed with a solution of 10-15 p1 of LipofectamineTm 2000 (Invitrogen) and 
90-85 pl of OPTIMEM. The mixture was incubated at room temperature for 10-15 minutes 
and a further 800 p1 of OPTIMEM was added to the mix. Before transfection the 
80%-confluent cell sheet was washed with OPTIMEM. 1 ml of the vortexed solution was 
added to each well of a 6-well dish and incubated at 37°C for 4-5 hours. The mix was 
removed and 4 ml of 10% DMEM was added to each well and incubated at 37°C. 
6.5.6 Infection of cell monolayers with virus 
80% confluent cell monolayers were pre-washed with SF-DMEM, virus was added to an 
MOI (multiplicity of infection) of 1-10 and incubated at 37°C in a humidified 5% CO2 
incubator for 30 minutes. The virus supernatant was discarded and DMEM supplemented 
with 10% FBS was added to the infected cell sheet. 
6.5.7 Purification of viral RNA 
6.5.7.1 Using Trizol1 Reagent 
Flasks of virus-infected cells were frozen and thawed twice. 750 µl Trizol® Reagent 
(Invitrogen) was added to virus-infected cells, vortexed and left at room temperature for 10 
minutes to ensure homogenisation and degradation of DNA. 200 µl of chloroform was 
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added and centrifuged for 15 minutes at 13,000 rpm (in a Biofuge pico Heraeus 
instruments) at 4°C. The upper phase was added to isopropanol and left at room 
temperature for 10 minutes before precipitation by centrifugation at 13,000 rpm for a 
further 10 minutes at 4°C (in a Biofugepico Heraeus instruments). The RNA pellet was 
washed with 75% ethanol and then the pellet was left to air-dry. The air-dried pellet was 
resuspended in 50 µl clean dH2O and incubated at 55°C for 10 minutes to ensure correct 
solubilisation of the extracted viral RNA. 
6.5.7.2 Using QIAamp® Viral RNA mini kit 
vRNA extraction was carried out using a QIAamp® Viral RNA mini kit. A volume of 
140 µl of harvested virus was added to 560 pl of prepared Buffer AVL containing carrier 
RNA in a 1.5 ml clean tube. The mixture was mixed by pulse-vortexing for 15 seconds and 
incubated at room temperature for 10 minutes. The samples were centrifuged briefly to 
remove drops from the inside of the lid and 560 pl of 100% ethanol were added to each 
tube. The mixture was mixed by pulse-vortexing for 15 seconds and centrifuged briefly. 
630 µl of the mix were carefully applied to a QIAamp spin column, which were then 
centrifuged at 8000 rpm for 1 minute (in a Biofugepico Heraeus instruments). This step 
was repeated with the remainder of the sample and using a clean collection tube. Clean 
collection tubes were used for individual steps. 500 µl of Buffer AW 1 were then added to 
each column and these were centrifuged at 8000 rpm for 1 minute (in a Biofuge pico 
Heraeus instruments). 500 µl of Buffer AW2 were added to each column and these were 
centrifuged at 13000 rpm for 3 minutes and then at 13000 rpm for 1 minute (in a Biofuge 
pico Heraeus instruments). 60 µl of Buffer AVE or elution buffer were added to each 
column in clean collection tubes, the columns were incubated at room temperature for 
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1 minute and centrifuged at 8000 rpm for 1 minutes (in a Biofuge pico Heraeus 
instruments). 
6.5.8 TCIDm 
Infectious titre of virus was routinely calculated by TCID50 (Tissue culture infectious dose 
50). One tenth of a confluent T75 tissue culture flask of cells was evenly distributed in 
100 µl volumes across a 96-well plate containing quadruplicates of 50 µl set of serial 
10-fold dilutions of virus. Three-to four days post infection crystal violet stain, 
supplemented with formaldehyde, was added to the monolayers for two to three hours. The 
non-infected cell sheets were stained and the cells, killed by infection, did not retain 
staining. The virus titre was expressed as the dilution of the virus required to infect 50% of 
the cultures (Reed & Muench, 1938). If CPE was observed in half of the wells at a dilution 
of 10'7, the titre was 107 TCID50 units in 50 µl. If all wells show CPE at 10"7 and none at 
10$, the titre is 107'5 TCID50 units in 50 µl. One well corresponds to approximately 
l0°-25TCID5o units. Titres were expressed as TCID50/ml. 
6.5.9 Plaque Assay 
RD, Hela, L20B or RD-ICAM cells as appropriate were seeded into 6-well plates and 
grown to 80% confluent monolayers. Serial 10- to 100-fold dilutions of the virus stocks 
were made in serum-free media. The cell sheets were then washed a couple of times in 
serum free media and inoculated with 200 µl of the diluted virus. The virus was allowed to 
absorb for 30-45 minutes at room temperature and the plaque overlay media was added to 
the infected monolayers. The inverted dishes were incubated for three to four days at 37°C 
in a humidified 5% CO2 incubator. Crystal violet solution was added to the dishes for two 
hours, the plaque overlays were then removed and further staining was carried out for two 
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to three hours. The plaques were counted and expressed as plaque forming units per ml 
(pfu/ml). 
6.5.10Virus neutralisation assay 
Viruses were pre-incubated with two-fold serial dilutions (50 µl) of neutralising antibody 
in serum free DMEM starting at 1: 50 for one hour at 37°C. 100 µl of cells were added to 
the wells and infection was allowed to proceed for 24-48 hours prior to crystal violet 
staining. 
6.5.11 Virus blocking assay 
Monolayers of the appropriate cell line in a 96-well plate were incubated with two-fold 
serial dilutions (50 µl) of neutralising antibody in serum free DMEM starting at 1: 50 for 
one hour at 37°C. 104 TCID50 (100 µl) of virus was added to the wells and infection was 
allowed to proceed for 24-48 hours prior to crystal violet staining. 
6.5.12 Synthesis of radiolabelled virus 
RD, RD-ICAM or Hela cells were pre-treated with Methionine-free Minimum Essential 
Medium Eagle (MEM) (Sigma) for one hour at 37°C in a humidified 5% CO2 incubator. 
The 80% confluent cell sheet of a T75 tissue-culture flask was infected with virus at an 
MOI of 10. The virus was adsorbed at room temperature for 30 minutes and the cells were 
washed and incubated with l Oml Methionine-free MEM for 2 hours. 10 ml 
Methionine-free MEM supplemented with 200 µCi [35S] methionine was added to the 
infected cells and this was incubated overnight at 37°C in a humidified 5% CO2 incubator. 
The virus was then harvested after 2 freeze-thaws and filtered through a 0.20 µm filter. The 
radiolabelled virus was partially purified by pelleting through a 12 ml linear 30% sucrose 
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gradient at 40,000 rpm (Sorvall Ultra Pro 80 centrifuge) using a TH641 rotor at 4°C for 
6 hours. The CVA21 pellet was resuspended in 300 µl Spiller buffer. All other viruses 
were resuspended in 300 µl of PBS-BSA. 
The virus was further purified by centrifugation through a 12 ml linear 10-25% sucrose 
gradient at 40,000 rpm (Sorvall Ultra Pro 80 centrifuge) using a TH641 rotor at 4°C for 
1 hour and 20 minutes to obtain infectious 160S particles. The gradient was harvested from 
the bottom in 500 µl aliquots. 5 µl of each fraction was counted in 3 ml of scintillant 
(Ecosint A scintillation fluid by National Diagnostics) by scintillation counting (Beckman 
LS5000CE machine). 160S particles, detected by a peak reading, were typically found in 
fractions 5 and 6. The sucrose was removed by washing with PBS-BSA or Spiller buffer 
and loaded into 1.5 ml Beckman Ultracentrifuge tubes in equal portions and centrifuged 
overnight at 40,000 rpm (Beckman TL-100 Ultracentrifuge) using a TLS55 rotor at 4°C. 
The 160S-pelleted particles were carefully resuspended in 100 µl of PBS-BSA and stored 
at -20°C for up to 4 weeks. 
6.5.13 Synthesis of infected cell lysates 
An 80%-confluent cell sheet was infected at an MOI of 10 for 30 minutes at room 
temperature and washed with SF-DMEM. 1 ml of 10% DMEM was added to the infected 
cells and incubated for 2 hours at 37°C in a humidified 5% CO2 incubator. Timing enabled 
viral proteases-mediated host cell shut off and insured that the proteins labelled were of 
virus origin. The washed cells were supplemented with I ml of Methionine-free MEM for 
30 minutes at 37°C in a humidified 5% CO2 incubator. The medium was removed and 1 ml 
of Methionine-free MEM supplemented with 100 µCi [35S] methionine was added and 
incubated at 37°C for 30 minutes to 1 hour. The cells were washed and resuspended in 1 ml 
PBS using cell scrapers. Cells were pelleted by centrifugation in a Biofuge pico microfuge 
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(Heraeus instruments) at 5,000 rpm for 5 minutes and resuspended in 100 µl of lx Cell 
Lysis Solution (CLS) and incubated at room temperature for 5 minutes. Cell debris were 
removed by centrifugation and the supernatant added to 100 µ12x reducing SDS-PAGE 
loading buffer. 
6.5.14Immunostaining assays 
6.5.14.1 "Blue cell" assay 
"Blue cell" assay is a rapid and sensitive method, known as CELICS (cloning by 
enzyme-linked immunocolourimetric screening (Evans et al., 1998)). 10 to 12 hours post 
RNA-transfection, the transfected cells were fixed in Methanol: Acetone (1: 1) for 
10 minutes at room temperature and washed with PBS. The cells were then incubated 
overnight in PBS-BSA (0.5%) at room temperature. The cells were washed and incubated 
with DAKO mouse anti-enterovirus VP1 antibody (diluted to 1: 400 in PBS-BSA) for 
2 hours at room temperature. The cells were washed 3 times in PBS-BSA and incubated 
for a further 2 hours at room temperature in the presence of anti-mouse ß-galactosidase 
antibody (diluted to 1: 800 in PBS-BSA). The cells were washed and incubated for 
30 minutes to 1 hour at 37°C in colour developing solution. 
6.5.14.2 Immunofluorescence assay 
6.5.14.2.1 Cell preparation 
13 mm coverslips (VWR international) were flame sterilised and put into a 24-well tissue 
culture plate. RD-ICAM cells were then seeded so as to reach 50% confluency on the day 
of infection and were incubated in 10% FCS DMEM supplemented with Penicillin: 
streptomycin at 37°C in a humidified 5% CO2 incubator. 
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6.5.14.2.2 Fixation and immunofluorescence labelling 
10 hours post RNA-transfection the transfected cells were fixed in 1 ml per well of 
Methanol: Acetone (1: 1) mix for 30 minutes at -20°C and rehydrated with 1.5 ml of PBS 
for 10 minutes. The transfected cells were then blocked in PBS + 2% FCS for 10 minutes 
on a rotating shaker. The cells were incubated with DAKO mouse anti-enterovirus VP1 
antibody (diluted to 1: 400 in PBS + 2% FCS) for 2 hours at room temperature on a rotating 
shaker. The cells were washed 3 times in PBS + 2% FCS and incubated for a further 
2 hours at room temperature in the presence of anti-mouse FITC conjugate antibody 
(diluted to 1: 400 in PBS + 2% FCS). The 24-well dish was wrapped in tin foil, as FITC is 
light sensitive. The cells were washed three times in PBS + 2% FCS and once with PBS. 
6.5.14.2.3 Analysis on the confocal microscope 
The coverslips were rinsed in dH2O and mounted onto a drop of PBS-glycerol on a glass 
slide, cells facing down. The coverslips were fixed by applying nail varnish around the 
edges of the coverslips. Slides were labelled and allowed to dry in a dark environment for 
15-30 minutes. The slides were then analysed using a confocal microscope set to detect 
FITC wavelength. The samples were photographed and analysed using LSM Meta 510. 
The figures were prepared with Adobe Illustrator 10. 
6.5.15 Packaging assays 
The trans-encapsidation assays were adapted from methods described in (Barclay et al., 
1998; Percy et al., 1992). T7 RNA transcripts were transfected into permissive cell lines 
and either co-transfected with helper T7 RNA transcript or co-infected 6 hours 
post-transfection with a helper virus. The samples were then incubated in a 37°C 
humidified 5% CO2 incubator until CPE was seen. The samples were freeze-thawed and 
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clarified. Each sample was then digested with 400 pg/ml of RNase A for 30 minutes at 
37°C. The RNAse digested samples were passaged onto a fresh cell sheet of RD-ICAM 
cells. The infected cells were incubated in a 37°C humidified 5% CO2 incubator for 8-10 
hours. The samples were harvested and screened by RT-PCR and RFLP analysis or by 
Luciferase assay. 
6.5.15.1 Luciferase assay 
The supernatants of the passaged samples were discarded and the cells were scraped off 
and resuspended in 1 ml of PBS. The cells were pelleted by centrifugation at 6000 rpm for 
5 minutes (in a Biofugepico Heraeus instruments). The supernatant was discarded and the 
cells were resuspended in lx cell lysis buffer (Promega(V). Luciferase activity was detected 
from 10 µl of the lysed samples, using a TD20/20 luminometer (Promega), after the 
addition of 100 µl of room temperature luciferase assay substrate + luciferase assay buffer 
solution (Luciferase assay system, Promega®). The Luciferase activity was measured 
using a luminometer and the data was expressed in relative light units. 
6.6 Molecular techniques 
6.6.1 Isolation of plasmid DNA 
10 ml and 100 ml overnight cultures of transformed E. coli in Luria broth with the 
appropriate antibiotic selection medium were used to perform small or medium-scale 
isolations of plasmid DNA. These were carried out following the alkaline lysis protocol 
described by Sambrook (Sambrook et al., 1989). 
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6.6.2 Restriction endonuclease digestion 
Chapter 6 143 
Restriction digests were carried out using 1 unit of the appropriate enzyme per µg of DNA 
in the buffer and at the temperature recommended by the manufacturer for one to three 
hours. Samples were visualised by electrophoresis on a 1% agarose gel in TAE buffer 
(40 mM Tris-acetate, 2 mM EDTA) containing 0.5 pg/ml ethidium bromide. The DNA 
was visualised on a UV transilluminator. The size of the DNA fragments was estimated 
using commercially available size markers, (GIBCO 1 kb ladder). 
6.6.3 Isolation of DNA fragments from an agarose gel 
DNA fragments were isolated from agarose gel using QlAquick® PCR and gel purification 
kit (QIAGEN). To an agarose slice containing the required DNA fragment in an eppendorf 
tube three volumes of Buffer QG were added and incubated at 50°C for 10 minutes to 
dissociate the agarose. The solubilised sample was then applied through a purification 
column, washed with buffer PE and eluted in 30 µl of buffer EB. A fraction of the purified 
DNA sample was then checked by visualisation on an agarose gel. 
6.6.4 Ligation of DNA fragments 
All ligation reaction were performed in 10 µl volumes at a molar ratio of insert to vector of 
3: 1 in lx ligation buffer (10 mM MgC12,200 mM Tris-HC1 pH 7.6,50 mM DTT, 1 mM 
ATp) with 1 unit of T4 DNA ligase. Reactions were incubated at 16°C for 2 hours or at 
4°C overnight. Ligation reactions were always purified by ethanol precipitation and 
resuspended in 5 µl clean dH2O for transformation. 
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6.6.5 Preparation of electro-competent Escherichia coli 
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A single colony of Escherichia coli ER2738 or DH5a was picked and inoculated in 10 ml 
of LB, containing the appropriate antibiotic selection medium, overnight at 37°C on an 
orbital shaker. The 10ml was added to 11 of LB with antibiotic and incubated at 37°C on 
an orbital shaker until the solution reached an OD600 of 0.5-0.7 before being pelleted for 
10 minutes at 3000 rpm in a Beckman bench-top centrifuge at 4°C. The bacteria were 
resuspended in 100 ml of ice-cold dH2O and centrifuged again at 3000 rpm for 10 minutes 
at 4°C (Multifuge 3 S-R Heraeus). The cells were then resuspended in 100 ml of ice-cold 
autoclaved 10% Glycerol solution and centrifuged at 2000 rpm for 20 minutes at 4°C 
(Multifuge 3 S-R Heraeus). The pellet was resuspended in 2 ml 10% Glycerol solution. 
Aliquots were snap-frozen in liquid N2 and stored at -70°C for up to three months. The 
cells were tested for their efficiency the following day by transforming 10 pg of pUC 19 
and plating it onto an LB agar plate containing ampicillin. Electro-competent cells 
routinely produced 107-108 colony forming units per µg of DNA transformed. 
6.6.6 Transformation of plasmid DNA in electrocompetent E. coli 
45 pl of thawed electro-competent E. coli cells were added to each 5 µl purified ligation 
reaction and electroporated in a1 mm electroporation cuvette (CLP) at 1600 V, 400 fl, 
25 pF with a time constant of 7-l Oms. The reaction were transferred to 500 µL of LB and 
incubated at 37°C for 45 minutes before plating on to LB agar plates containing 50 gg/ml 
ampicillin (or other appropriate antibiotic selection) and incubating at 37°C overnight. 
6.6.7 Amplification of DNA by PCR (Polymerase Chain Reaction) 
3 pg of template DNA was added to a reaction mix containing lx Thermopol buffer 
(10 mM KCI, 20 mM Tris-HC1(pH 8.8 at 25°C), 10 mM (NH4)2SO4,2 mM MgSO4, 
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0.1% Triton X-100 ), 2.5 mM dNTPs, 20 pmoles of the relevant forward and reverse 
primers and 1 unit of VentR® proof-reading DNA Polymerase (New England BioLabs 
NEB) in a 50 µl reaction volume. The DNA was preheated at 95°C for 3 minutes prior to 
adding the polymerase and amplified by 6-15 (for further cloning)-25 (analysis and 
sequencing) cycles at 95°C for 45s, 45-55°C for 45s, 73°C for 2-3 minutes (extension step 
was extended for longer products) followed by a final extension step at 73°C for 
10 minutes in a PTC-200 Peltier Thermal Cycler. The amplified DNA was analysed by gel 
electrophoresis in a 1% TAE agarose gel and purified following the isolation of DNA 
fragments from an agarose gel protocol. 
6.6.8 DNA sequencing 
200-300 ng of purified PCR products or double stranded midi plasmid DNA along with 
3.2 pM forward and reverse oligonucleotides were sent to the University of Dundee 
Sequencing Service for sequencing. Data was analysed using Bio Edit and aligned with the 
appropriate DNA sequence, from the Vector NTI database. 
6.6.9 Western immunoblotting 
6.6.9.1 Preparation of samples 
Appropriate samples were mixed in a 2x reducing SDS-PAGE gel-loading buffer. The 
samples were then heated at 99°C for a few minutes to denature proteins. 
6.6.9.2 Western blotting 
Protein samples, normalised for total amount of protein, were subjected to SDS-PAGE on 
a 10% or 12.5% polyacrylamide gel and transferred to a nitrocellulose membrane for ECL 
(Amersham Pharmacia) using a Bio-Rad Transfer Blot at 200 V for an hour. The 
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membrane was then soaked in blocking buffer at room temperature for about one hour, and 
washed three times in PBS-0.1% Tween 20. Incubation with a primary antibody diluted in 
blocking buffer to obtain a 1: 1000 dilution was carried out at room temperature for two 
hours. The membrane was washed three times in PBS-0.1% Tween 20 and incubated with 
a secondary antibody HRP, diluted to 1: 5000 in blocking buffer, at room temperature for 
two hours. A fmal three washes with PBS-0.1% Tween 20 were carried out prior to 
detection using an Amersham Biosciences ECLTM Western Blotting Detection Kit. The 
blots were exposed to a Kodak X-omat UV film and developed. 
6.6.1ODot blot replication assay 
6.6.10.1 Preparation of DNA probe 
The sequences for the probe were obtained from the pT7FLCIPV3 by amplifying the 3D 
polymerase using primers T7R3D and ID6. To 3 pg DNA was added lx Thermopol buffer 
(10 mM KCI, 20 mM Tris-HC1 (pH 8.8 at 25°C), 10 mM (NH4)2SO4,2 mM MgSO4,0.1% 
Triton X-100 ), 2.5 mM dNTPs, 20 pmoles of the relevant forward and reverse primers and 
1 unit of VentR® proof-reading DNA Polymerase (New England BioLabs NEB) in a 50 µl 
reaction volume. The PCR conditions were as follows: 95°C-3mins, 25 cycles of 95°C- 
45secs, 45°C-45secs, 73°C-2mins and a single final extension step at 73°C for 10 minutes. 
The PCR fragment was gel purified using a QIAquick® PCR and gel purification kit 
(QIAGEN) according to manufacturers instructions. 
25 ng of template DNA were mixed in dH2O to a final volume of 11 µl. The DNA was 
denatured by heating in boiling water for 10 minutes and quickly chilling on ice. 4 µl of 
High Prime, supplied by Roche, were mixed thoroughly and added to the denatured DNA 
reaction. The reaction tube was then supplemented with 5 tl (50 pCi) EasyTidesCytosine 
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5' Triphosphate (NEN [32P] a-rCTP). The solution was then mixed, briefly centrifuged and 
incubated at 37°C for 10 minutes. The reaction was stopped by heating at 65°C for 
10 minutes. The DNA probe was then purified through a Sephadex G-50 column to 
remove unbound nucleotides. 
6.6.10.2 Northern type hybridisation 
10 pl of RNA samples was added to 30 µl of RNA denaturation buffer, incubated at 65°C 
for 5 minutes and quenched on ice. A HybondTM-N Nylon membrane optimised for nucleic 
acid transfer (Amersham Pharmacia) was presoaked with dH2O before being placed on the 
BioRad Bio-DotTM microfiltration apparatus. The membrane was washed with IOxSSC 
buffer and the denatured RNA samples were added and dotted onto it by vacuum. Further 
washes with l Ox SSC buffer were carried out and the membrane was dried and samples 
were fixed by UV cross-linking at 1200 pJoules x 100 for 30 seconds in a UVStratalinker 
1800 (Stratagene). The membrane was transferred to a hybridisation chamber containing 
10 ml of Rapid-Hyb buffer (Amersham Pharmacia) and incubated at 65°C for 2 hours. 
The DNA probe mixture was added to the membrane in the hybridisation chamber and 
incubated at 65°C for 12-18 hours. The membrane was then washed with 1xSSC-0.1%SDS 
three times and with 0.5xSSC-0.1%SDS twice. The membrane was covered in cling film 
and exposed to phosphoimager screen for 30 minutes to 1 hour before visualising with 
BioRad Quantity One software. 
6.6.11Lt-vitro translation assay 
A mix of 30 µl of Hela S10 extracts, 5 µl of Flexi®Rabbit Reticulocyte Lysate System 
(Promega), 5 µl of l0xbuffer (10 mM rATP, 2.5 mM rCTP, 2.5 mM rGTP, 600 mM 
KOAc, 300 mM Creatine phosphate, 15 mM Hepes pH 7.0 made to 1 ml in dH2O) 
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supplemented with Phosphocreatine kinase (Sigma), 191 of 100 mM GuHCI, 3 µl of 
dH2O, 501Ci of [35S] Methionine and 1 gg of Ribomax prepared RNA diluted in 1 µl of 
dH2O was incubated at 30°C for 5 hours. 60 pl of 2x SDS reducing protein gel loading 
buffer was added to the reaction mix post-incubation and samples were denatured by 
incubation at 100°C for a few minutes. Samples were then run on an SDS-PAGE gel and 
visualised using Quantity One software after exposure to a phosphoimager screen for 10 to 
12 hours. 
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Appendix 1 
Viral protein sizes (in kDa) 
Poliovirus Leon Sabin poliovirus Coxsackievirus Control virus ty ty A21 
Viral proteins 
PI 95.9 97.3 97 
VPp 37.4 37.6 37.5 
VPl 32.3 33.4 33 
VP3 26.2 26.3 26.5 , .: 
VP2 29.7 30.1 29.9 
VP4 7.4 7.5 7.4 
VPI-2A 48.6 49.9 49.4 
P2 63.4 63.7 63.3 
2A 16.4 16.5 16.4 
2B 10.6 10.8 10.6 
2C 36.4 36.4 36.3 
2BC 47 47.2 46.9 
P3 82.8 83.5 82.8 
3A 9.5 9.7 9.5 
3B 2.3 2.4 2.3 
3C 20 20.2 20 
3D 51 51. 51 
3CD 71 71.4 71 
3AB 11.8 12.1 11.8 
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Table listing the viral protein sizes of PV3, Sabin 1 and CVA21 
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Plasmid name Description Published 
Full length poliovirus Sabin Provided by A. Macadam 
pS1F tvpe 1 infectious clone NIBSC, London 
CAV21 
CVA21 full-length infectious Hughes et al., 1989 clone 
Full length poliovirus type 3 
pT7FLC Leon P3/Leon/37 infectious Goodfellow et al., 2000 
clone 
Poliovirus type 3 Leon 
pT7FLC/REP3 P3/Leon/37 CAT replicon Barclay et al., 1998 
derived from pT7FLC 
Backbone vector lacking the 
pT7FLC/REP3-BK complete P1-coding gene 
derived from pT7FLC/REP3 
Backbone vector PV3BK 
with insertion of the complete 
pT7REP3-BK-SL3-P1 PV3 P1-coding region 
introduction derived from 
pT7/SL3 
Backbone vector PV3BK 
with insertion of the complete 
pT7REP3-BK-CA21-P1 CVA21 P1-coding region 
introduction derived from 
CAV21 
Full length poliovirus type 3 
pT7/SL3 
Leon P3/Leon/37with Goodfellow et al., 2000 mutations in the 2C CRE 
derived from pT7FLC 
Poliovirus type 3 Leon 
pT7REP3-L 
P3/Leon/37 luciferase Goodfellow et al., 2003 replicon derived from 
T7FLC/REP3 
pRibol 
Vector containing a ribozyme Constructed by Simmonds 
hammerhead 2001 
CVA21 full-length infectious 
clone introduced in a 
pRibo-CAV21 ribozyme hammerhead- 
containing vector derived 
from CAV21 and Ribo1 
CVA21 full-length infectious 
pRibo-CAV21-NaelDel 
clone with a deleted Nae I 
site, derived from pRibo- 
CAV21 
pRibo-CAV21- CVA21 backbone vector 
Claire Blanchard Appendices 178 
NaelDel-backbone lacking the complete P1- 
coding gene, derived from 
Ribo-CAV21-Nae 1 Del 
CVA21 backbone vector with 
insertion of the complete 
pRibo-CAV2I-BK/CA21 PI 
CVA21 P1-coding region, 
derived from pRibo-CAV21- 
ae1De1-backbone and 
CAV21 
CVA21 backbone vector with 
insertion of the complete PV3 
pRibo-CAV2I-BK/PV3-P1 
PI-coding region, derived 
from pRibo-CAV21- 
aelDel-backbone and 
pT7/SL3 
CVA21 backbone vector with 
insertion of the complete 
pRibo-CAV21-BK/Sabin1 PI Sabinl P1-coding region, 
derived from pRibo-CAV 21- 
ae 1 Del-backbone and SIF 
pT7EV7 
Full length echovirus 7 Lindberg et al., 1997 infectious clone 
EV7 genome with an in- 
EVMP 1 frame Nsi I deletion in the P1-coding region, derived 
from pT7EV7 
CVA21 genome with an in- 
CVA21AP1 frame Age I deletion in the P1-coding region, derived 
from CAV21 
Table listing plasmids used for this project 
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Appendix 4: Phylogenetic relationship based on P2, 
2A and 2B coding sequence comparison studies. 
A CAV16 
CAV19 CAV1 
ioo\ `%`--CAV22 
PV2 
PV1- 
0.1 
B 
CAV21 CAV24 
CAV21"'"/! j jooj; Z--CÄV17 CAV24" 81 I'n' CAV11 
CAV13PV3 CAV20 
CAV13 
0.1 C CAV22 
CAV1J CAV13 
PV1 
PV2-"\ / ýCAV17 
CAV11 
PV3 CAV20 I -**'`CAV24 
Phylogenetic relation ship of l1EV C based on A: P2 coding region B: 2A coding region 
and C: 2B coding region sequence analysis comparison from Brown et al. (2003). 
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Appendix 5: Phylogenetic relationship based on 
P3 and 3D coding sequence comparison studies. 
A 
t: AYIL l©ci 
CAVI CAV19 
CAV1I 
CAV17 
PV3 CAV24 
0.7 
ý1 
CAV15CAV2ýV2 
0 PV 
99 
88 
B 
CBVI 
CAV16 
CAV22 
EVlQ-""" ýo0 1°Q4-CAV1 
CAV24 loo ýA'-4L 
AV 19 
PV2 9s 
0.1 
ýý 
CAV13 11º /' 
CAV20PV3 
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Phylogenetic relation ship of HEV C based on A: 3D coding region and B: complete 
P3 coding region sequence analysis comparison from Brown et al. (2003). 
CAV21 
CAV11 
